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ABSTRACT 
The primary aim of the thesis is to contribute to demonstrating how established and emerging 
science in the regenerative medicine (RM) domain can be translated into profitable commercial 
practice, and generate clinically- and cost-effective therapies. It achieves this by exploring and 
assessing underlying economics, including investment readiness and economic assessment, 
exploring regulatory and reimbursement frameworks, developing stem cell culture systems and 
assessing fit with clinical practice. 
The thesis is the first public domain wide-ranging analysis of business trends in the production, 
manufacturing and supply segments of the RM industry. It analyses the clinical potential of the 
domain as well as the translational and commercial challenges facing the industry. The industry is 
at a turning point as big pharmaceutical companies engage with RM in order to explore 
technologies as potential therapeutics and discovery tools. This unlocks the industry by 
confirming an exit path for RM based small- and medium-sized enterprises. Translation has come 
to be recognised as a core issue in the overall space and translation of regenerative therapies into 
the clinic is presently challenging, high-risk and expensive. 
This research addresses the question “what are the mechanisms required to enable translation of 
emerging scientific knowledge into commercially viable clinical RM products?” These 
mechanisms are particularly important as their creation involves and requires major investment 
decisions, which can determine the success or failure of RM developments and indeed of the 
companies concerned. The lack of well-established business models and the complexity of the 
domain suggested a conceptual approach drawing upon relevant literature from product and 
process development, applied business and revenue models, technological evolution and capital 
market ingenuity.  
The research was carried out in two phases. The first phase was concerned with identification of 
key challenges and mapping the overall industry emergence including emergence of related 
regulations to provide a context and framework for understanding the domain. Based on the 
emergence mapping a timeline of key parallel factors was identified, and their inherent 
connections explored to identify transforming events affecting and influencing multiple factors on 
the journey to clinical success within a business environment. This creates the reference model. 
The second phase was concerned with manufacturing a stem cell based therapeutic and applying 
health economic principles to determine available headroom for investment, cost of goods and 
return on investment, taking hearing disorders as a case exemplar, and exploring the behaviour of 
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the net present value curve to identify key parameters affecting the economic positioning of this 
novel regime.  
A key output of the research is the investment readiness reference model. It integrates key RM 
business issues against reducing uncertainty and increasing value. The model argues that the 
complex nature of RM products means that the issues affecting industry emergence and 
development go well beyond the primarily scientific and technological concerns on which much 
current research focuses. The performance of RM firms ultimately hinges upon the successful 
clinical application of their developed products, the key step for creating and realising value, and 
their ability to deal with the fundamental business issues specific to the area. The framework 
deals with these business issues, which are investment & technology readiness, business models, 
organisational challenges, public policy and industry emergence. 
This thesis explores ideas that may bridge the chasm between the promise and reality of RM i.e. 
mechanisms to enable late stage translation of RM products. It links technological capability and 
business models for firms in the domain. Furthermore, it offers a unique perspective on the nature 
and characteristics of investment readiness and financial assessment, specifically identifying key 
parameters affecting economic positioning. The key contributions are therefore: 
 New insights into the key challenges involved in realising the commercial potential of 
cell based therapeutics. 
 Technology road mapping to link fundamental enabling technological capability for 
developing RM products with robust business plans integrating strategy, technology 
development and the regulatory and reimbursement framework.  
 A generic investment readiness reference model generated from the enabling technology, 
value and supply chain structures to identify key indicators and characteristics of industry 
readiness. 
 A novel experimental programme demonstrating expansion, maintenance and 
differentiation of human embryonic stem cells by manual and automated methods. 
 New insights into economic positioning by mapping net present value, and economic 
analysis by estimating available headroom, cost of goods and return on investment for a 
putative hearing therapeutic. 
 
Key Words: Regenerative Medicine, Stem Cells, Translation, Cell Therapy, Investment readiness, 
Technology Roadmapping 
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1.1 Research Background 
The healthcare sector aims to treat and manage illness, and in addition to clinically led 
activities encompasses an extensive array of product and service-driven companies. 
These companies are no strangers to risk. The business of developing therapeutics is a 
high-risk undertaking but for those who succeed, it brings high rewards. On an 
average only one in 5,000 potential products succeeds in commercial development 
and it takes upwards of USD 800 million and ten years to bring that successful 
product to market (DiMasi, Hansen et al. 2003). This high risk venture with low 
probability of success is further affected by evolving and changing trends in pricing, 
globalisation, industry maturation and competition. However, given the promise of 
the evolving fields of genomics and regenerative medicine (RM), together with the 
healthcare sector’s financial strength and substantial customer base, the overall 
industry seems relatively stable. Further, the burden of chronic diseases is increasing; 
inherent challenges ahead of developing therapeutics are mounting; manufacturing 
costs are escalating rapidly; investors desire risk profiling and confirmation of 
industry readiness; regulators seek to impact more than just safety; and payers 
demand economic assessments. These issues combined with the surfacing of an 
essentially new healthcare environment driven primarily by the principles of 
consumerism, demographic shifts, improved access and expensive novel technologies 
will impose a fundamental change on healthcare in the future (Clark 2006). 
RM is one of the fastest growing fields of biomedical science. Its objective is to create 
new therapeutics that global populations can exploit, in this post-genomic era, as 
applications that enhance human health. It is defined as an emerging multidisciplinary 
field involving biology, medicine, and engineering that is likely to revolutionize the 
ways we improve the health and quality of life for millions of people worldwide by 
restoring, maintaining, or enhancing tissue and organ function (NIH Definition). The 
success of RM to date is the result of scientific discoveries and technological 
innovation. Although an overall cost-effectiveness analysis has not yet been carried 
out, preclinical and clinical studies in specific disease areas have demonstrated the 
enormous potential of RM based therapeutics, which if exploited correctly should lead 
to reasonable net cost savings (Mason and Dunnill 2008). Advances in stem cell 
biology, functional genomics, molecular genetics, systems biology, biomaterials and 
                                                                                                          Introduction 
3 
 
tissue engineering, transplantation medicine, nano-medicine and medical imaging 
have resulted in improved outcomes from the application of RM based therapeutics. 
These advancements leading to improved outcomes will ultimately benefit the overall 
healthcare system in terms of significant reduction in mortality rates, improved patient 
quality of life, and reduced frequency and length of hospitalization, leading to reduced 
social and economic costs, thereby revolutionizing diagnosis, treatment, and 
rehabilitation.  
These are exciting times for the RM industry, real hope is associated with this 
emerging field (McKay 2000). In addition to creating a new generation of 
therapeutics for some of the most important and intractable chronic conditions, the 
development of cell-based therapies also offers disease models for drug discovery.  
Recently, there has been a significant level of investment in the industry together with 
increased attention from big pharmaceutical industries. Building on genuine medical 
advances and major scientific breakthroughs, many governments are trying to build a 
more permissive regulatory environment for both the study and use of stem cells as 
therapeutics (U.S. Department of Health and Human Services. Washington 2005). 
However, there are still major challenges to overcome before stem cells can be 
developed as safe and efficacious therapies (Spar 2004). The regulatory landscape 
remains difficult and critical questions surround RM business models and 
reimbursement strategies.  
The definitions and explanation of all the technical terms and key words used in this 
research thesis can be found in the publically available specification (PAS) document 
developed by the Department of Trade and Industry (DTI) together with the British 
Standards Institution (BSI) (PAS83:2006). 
 
1.2 Research Aims 
Over recent years, translation has come to be recognised as a core issue for RM and 
the task of getting regenerative therapies into the clinic is presently challenging, high-
risk and capital-intensive. The demands from potential investors and stakeholders to 
predict behaviour, optimise performance, reduce risk and accelerate time to market 
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can become a constraint to a firm’s pursuit of economic goals. This is largely due to 
the longer time durations associated with ultimate product performance, value-
creation, consolidating share in existing markets or new market creation where whole-
life costs are modelled and understood. Therefore, early design and accurate 
evaluation of business offerings is particularly significant in the RM domain, as the 
initial stage of development activities tends to be centred in small start-up firms rather 
than large, well-funded organisations. The initial exploratory work and literature 
review undertaken, as outlined in Chapters two and three, reveal that there is a 
knowledge gap in understanding how firms can structure their activities to increase 
technology- and investment-readiness and operate viable business models. Hence, this 
research attempts to tackle the following question: 
“What are the mechanisms required to enable translation of emerging scientific 
knowledge into commercially viable clinical RM products?” 
The objectives of this research are: 
 To understand RM industry emergence and the characteristics of product 
development. 
 To characterise the industry investment readiness process by which new 
therapies are first taken into clinical markets. 
 To understand the mechanisms of knowledge translation between science and 
business in the RM domain, the importance of regulatory oversight and 
economic assessment. 
Therefore, the main aim of the thesis is to contribute to the understanding of how 
emerging and established science in the RM domain can be translated into profitable 
commercial practice to generate clinical- and cost-effective therapies. This requires an 
assessment of underlying economics and investment readiness together with 
regulatory and reimbursement strategies. 
This research adopted an approach of conceptualisation and theory building, the 
discovery of a reference model from data, through analysis and deductive reasoning. 
The approach has been taken as a result of: 
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 The absence of a priori frameworks and formal theories in the 
literature/practice that can be used to answer the research questions 
 The aim of generating knowledge that will be accessible to RM product 
developers and usable in clinically- and cost-effective therapeutic applications 
 The lack of knowledge of the commercialisation process within the RM 
domain 
 
 
1.3 Research Process 
The research was carried out in two phases. During the first phase, key challenges 
were identified and the overall industry emergence including the emergence of related 
regulations was mapped. These maps provided a framework for an in depth 
understanding of the domain. The first phase ended with the development of a 
reference model in the form of a parallel timeline including key indicators, providing 
preliminary answers to the research questions. The second phase was focussed on a 
case example, taking hearing disorders as the exemplar, manufacturing a stem cell 
based therapeutic for hearing loss and applying health economic principles to 
determine available headroom for investment, cost of goods and return on investment, 
and then exploring the net present value curve to identify key parameters affecting 
economic positioning of such a novel therapeutic.  
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1.4 Thesis Structure 
 
The research is presented in eight chapters (see Figure 1-1). An outline of each 
chapter is provided in the following section. The thesis is structured as follows: 
 
 Background 
 Research aims 
 Thesis structure 
 
 Identification of key therapeutic areas 
 Clinical and commercial conditions for success 
 
 Systematic review 
 Key challenges in translation 
 Discussion & conclusion 
 
 Hype curve and technology road mapping 
 Reference model for investment readiness 
 Key indicators 
 
 Regulatory emergence 
 Impact on product developers  
 
 
 Cell population manufacture 
 Scale up protocols 
 Differentiation towards otic progenitor cells 
 
 Exploring net present value 
 Headroom, cost of goods & revenue estimation 
 Qualitative assessment 
 
 Summary of research findings 
 Implications of research for theory and practice 
 Research contributions and limitations 
   Further research 
 
Figure 1-1 Thesis Structure 
 
 
 
 
 
Chapter 1 
Introduction 
Chapter 2 
Clinical Review 
Chapter 3 
Systematic Review 
Chapter 4 
Investment Readiness 
Chapter 5 
Emergence of Regulations  
Chapter 6 
Stem cell therapeutic 
Chapter 7 
Economic Assessment 
              Chapter 8 
Conclusion 
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1.4.1 Chapter 2: Clinical Review 
Chapter two presents the core clinical literature relevant to the research. The approach 
taken in this chapter is to narrow down the research agenda from a clinical perspective 
to a defined research gap. The aim is to establish the clinical foundation on which the 
research is based. It takes the form of a clinical review from a translational 
perspective summarising current knowledge regarding the clinical use of stem cells as 
cellular therapies. It has a particular focus in identifying the translational requirements 
to realise real clinical stem cell treatments for three of the major disease groups - 
neurological and cardiac disorders, and diabetes mellitus. The chapter begins with 
presenting the nature and characteristics of the overall RM industry, with specific 
focus on industry growth and RM product development and production. The next 
section focuses on identifying cell-based therapeutics in different stages of 
development for unmet clinical needs within the three disease groups. Thereafter, the 
literature on the commercial activity within the domain is presented which provides 
the basis for narrowing the scope of the research to commercialisation aspects of RM 
based products. The final section brings together insights from the overall review, and 
defines research questions which are based on knowledge gaps in both practice and 
theory. 
 
1.4.2 Chapter 3: Qualitative Systematic Review 
Chapter three presents a case example that has been used through the work to ground 
the research in a practical example. The detailed and focussed case exemplar is based 
on hearing disorders. The chapter introduces the disease and its epidemiological 
statistics. This is followed by a description of the present incumbent technologies with 
their market structure and size. Thereafter, the challenges involved in realising the 
commercial potential of a cell based therapeutic for hearing loss are presented under 
the scientific, translational and commercial headings. In this chapter, a systematic 
review of literature, based on the protocol set by the Health Technology Assessment 
(HTA) programme was undertaken to organize, evaluate and integrate the research 
evidence from the medical and health care literature. Such a systematic review 
process gives guidance for further research and helps in efficiently integrating valid 
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information to provide a basis for rational decision making. The exemplar illustrates 
challenges at both scientific and commercial levels. The objectives of this chapter are 
to contextualise key aspects of RM product and process development, the challenges 
and demands of translating promising science to profitable commercial products, and 
the significance and roles of developers from the early stages of product development. 
The chapter concludes that, while the basic work in fundamental science and 
knowledge is strong and strengthening, there is a compelling requirement to create 
simultaneously in a timely way the enabling clinical and commercial infrastructure for 
the ultimate realisation of cellular products.  
 
1.4.3 Chapter 4: Investment Readiness 
Chapter four describes the process of developing the “Investment Readiness” 
reference model. The purpose of this part of research was to focus on the 
requirements for the “bench to bedside” translation by examining key indicators from 
both technical and business contexts. The chapter describes the industry evolution 
using Gartners’ hype-cycle, and the Cambridge technology road-mapping framework 
to map the emergence of overall RM industry. These high level strategic tools assisted 
in identifying specific indicators of investment readiness which were integrated to 
form an RM industry investment readiness model. Together they can be used as a 
strategic technology management tool to capture the industry landscape, and 
associated uncertainties and opportunities for potential stakeholders. The chapter 
concludes by presenting six key factors of the industry that must be considered in 
order to successfully reach its high growth potential. The factors reflect the new 
perspective offered by the reference model in relation to current knowledge and the 
research gap highlighted in chapter two. 
 
1.4.4 Chapter 5: Emergence of Regulations 
Chapter five focuses on the emergence of regulations for advanced therapy medicinal 
products (ATMPs) particularly in Europe. This chapter explores the impact of 
regulation on RM product definition and the consequent complex interactions 
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between regulatory requirements and product and process design, product 
development and manufacture, and ultimately business risk. The current critical gaps 
in European regulation are identified by assessing the latest provisions of these 
recently framed regulations and also certain mandates, which are anticipated to have 
significant impacts on developers, are discussed. The chapter also explores some of 
the potential shortfalls within specific product categories of the mandate with regard 
to current and future research and development activities for advanced therapies. The 
chapter closes with a discussion of the implications of the research findings and 
means by which the gaps can be closed. 
 
1.4.5 Chapter 6: Stem Cell Therapeutic 
Chapter six includes the results of a novel experimental programme that shows the 
development of human embryonic stem cell culture systems appropriate for 
commercial applications. The experimental programme illustrates the expansion of 
human embryonic stem cells to create cell banks and further demonstrates their 
expansion and maintenance on an automated cell culture platform. Further, the results 
of a novel method to differentiate the above cell populations into otic (hearing related) 
progenitor cells using a scalable, translational friendly cell-culture protocol are 
presented. This demonstrator experimental programme allows the determination of 
key experimental costs to evaluate approximate cost of goods for input into the 
economic assessment exercise presented in chapter seven. 
 
1.4.6 Chapter 7: Economic Assessment 
Chapter seven presents a study to determine the economic positioning, including 
qualitative evaluation, of a cellular therapeutic for hearing disorders at early/initial 
stages of its development.  The chapter demonstrates the significance of economic 
positioning by mapping net present value and financial analysis by calculating 
available headroom, cost of goods and revenue to give insight into the budgetary 
impact of including a new intervention within healthcare practice. The cost 
effectiveness and potential profitability of the cell based hearing therapy presented 
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were established from the cost of goods determined from the work on stem cell 
manufacturing presented in chapter six. In the final section, the parameters affecting 
return on investment are discussed, which are particularly sensitive to rate of adoption 
including the reimbursement decisions of healthcare providers; competition; cost of 
product development; effectiveness; and final pricing. Further, the consequences of 
these parameters on net present value are discussed. 
 
1.4.7 Chapter 8: Conclusion 
Chapter eight revisits the research objective and questions, brings together the 
findings from the research, and discusses the implications of the findings for theory 
and practice. The key findings of this research, i.e. challenges of product 
development, the reference model for investment readiness and the economic 
assessment of a novel cellular product, are discussed. The chapter concludes with a 
summary of research contributions, the limitation of this research and suggestions for 
further research.  
 
1.5 Research Scope 
The definition of RM adopted here is “regenerative medicine is an emerging 
multidisciplinary field involving biology, medicine, and engineering that is likely to 
revolutionize the ways we improve the health and quality of life for millions of people 
worldwide by restoring, maintaining, or enhancing tissue and organ function” (NIH 
Definition). In addition to a therapeutic application, where processed cells are 
transplanted to enhance tissue function, RM technologies can have diagnostic 
applications where cells in vitro can be used for testing drug metabolism and uptake, 
toxicity, and pathogenicity. 
The reference model developed will enhance understanding of where and how value 
will be created in the RM value chain, and will assist businesses to best capture that 
value. To fulfil the potential of the overall field, a number of key challenges need to 
be overcome so that companies can successfully exploit promising discoveries. RM 
companies are operating in an emerging business sector in an international 
                                                                                                          Introduction 
11 
 
environment, where the delivery of RM could take a number of different approaches 
as the products and services are developed and affected by factors outside the 
boundaries of individual businesses or specific value chains. The thesis supports these 
businesses in configuring their activities to extract the most value, both for themselves 
and their customers. It integrates key RM business issues, particularly technology, 
regulation, market and reimbursement together with the coupling of business and 
investment financial strategy, and will consequentially assist research-based 
technology-intensive RM firms as they move closer to market. The work further 
identifies areas in public policy that would enable RM businesses to realise value 
more effectively. 
Although methods of assessing investment readiness and cost effectiveness for the 
early evaluation of a cellular therapeutic are presented using hearing disorders as an 
exemplar, this analysis forms a model that can be applied in other therapeutic areas. 
This research deals with the mechanisms required to enable translation of emerging 
scientific knowledge into commercially viable clinical RM products. The thesis was 
generated through studies of key challenges and parameters defining new RM 
products and firms, and as such will assist their organisational development and 
structure of business models for seamless transition of therapeutics from bench top to 
bedside with the ultimate goal of providing excellence in clinical care. 
 
1.6 Research Method 
The overall methodology adopted in this thesis is shown in Figure 1-2. The first phase 
in the research methodology aims to understand the context of the research question. 
The core clinical literature relevant to the research was used to narrow down the 
research agenda and formulate the detailed research question as presented in Chapter 
two, and thereafter, key challenges faced by RM were identified as discussed in 
chapter three. Further, as a potential practice-driven solution to the research question, 
an “investment readiness” reference model in the form of a parallel timeline of key 
indicators affecting translation of emerging and established science in the RM domain 
was formulated. The model arose from industry observation, an RM emergence map, 
and RM positioning on Gartners’ hype cycle.  
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Generating a clinical- and cost-effective therapy for a profitable business needs 
assessment of underlying economics, and regulatory and reimbursement strategies. 
Therefore, in the second phase of the thesis, realisation of a stem cell based 
therapeutic for hearing loss was demonstrated using a scalable automated protocol. 
Health economic principles were then applied to determine available headroom for 
investment, cost of goods and return on investment based on the experimental 
procedure. Finally, the net present value curve was explored to identify key 
parameters affecting economic positioning and further rate of adoption of such a 
novel therapeutic. 
 
 
 
Figure 1-2: Research Methodology adopted in this thesis/research 
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2.1 Introduction 
This chapter reviews the core theoretical perspectives that are relevant to the research 
agenda that emerged in chapter one. The review allowed narrowing of the research 
agenda to a defined research gap. 
Section 2.2 reviews the nature and characteristics of the overall RM industry, with 
specific focus on industry growth and RM product development and production. The 
sub-sections provide the industry backdrop of this research and a basis for narrowing 
the scope of the research to investment readiness and economic aspects of products. 
Section 2.3 reviews literature related to clinical needs for which RM based products 
are in various stages of development. In this section, three key disease application 
areas are examined which formed the basis for narrowing down the case example to 
hearing disorders, which is presented in chapter three. Section 2.4 examines the 
literature on commercial activity within the domain, which provides further basis for 
narrowing the scope of the research to commercialisation aspects of products. Finally 
section 2.5 brings together the insights gained from the literature review, and defines 
a research gap relevant to practice. 
 
2.2 Overview of the Regenerative Medicine Industry 
2.2.1 Present size and structure of the industry 
The RM industry, mainly comprising SMEs, is presently trying to establish itself 
firmly in the overall biotechnology sector. Primary firms are working on promising 
underlying science, but at the same time have not had the commercial success they 
would have anticipated in the beginning. The overall size of the industry has increased 
significantly in the past five years (Lysaght and Reyes 2001; Lysaght, Jaklenec et al. 
2008). At the start of 2009, 138 primary firms and 49 secondary firms were recorded, 
and 71% of the primary firms were working on stem cells (Martin, Hawksley et al. 
2009). Primary RM firms are involved in producing commercial therapeutic products 
based on cell therapy, including stem cell therapy, tissue engineering and gene 
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therapy. Secondary firms are working upon biocompatible scaffolds and matrices to 
support tissue repair (Martin, Hawksley et al. 2009). Even though many firms have 
been in existence for over a decade and have developed new products, the overall 
industry mainly comprises SMEs. This industry structure suggests a lack of resources, 
mainly from comparatively low product sales and restricted access to capital together 
with limited support from large pharmaceutical and, other healthcare companies.  
 
2.2.2 Industry consolidation and collaboration 
Lately, corporate activity in terms of mergers and alliances has increased within the 
RM domain, though it is not comparable to other parts of the pharmaceutical or 
biotechnology industry (Danzon, Epstein et al. 2004; Ilic 2006). Alliances and 
partnerships with large companies involve exchange of knowledge, and also provide 
early stage small start-up firms access to capital and complementary resources 
essential for late stage product development and marketing (Danzon, Nicholson et al. 
2005). The collaborations formed by companies primarily centre on research and 
licensing, which is characteristic of an early-stage technology where the conception 
and exchange of novel ideas and knowledge is the primary activity (Martin, Hawksley 
et al. 2009). However, commercialisation collaborations as well as mergers and 
acquisition deals are also taking place which reflect the presence of products in the 
future product pipeline of various companies. 
There is gradual investment from large pharmaceutical and biotechnology companies, 
though they appear to be “watching and waiting” as underlying stem cell technologies 
mature and become more established. In addition large medical device companies and 
major life science tool firms have also invested in RM product developers in 
accordance with technological and operational synergies, creating mainly 
manufacturing collaborations (Lysaght and Hazlehurst 2004). 
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2.2.3 Products and Technology 
Product developers work on different types of cells, however, adult stem cell-based 
products predominate the commercial activity and clinical development programs 
(Giordano, Galderisi et al. 2007). Within the primary product category, allogeneic 
products in the market outweigh autologous products. This suggests that the more 
conventional manufacturing and supply chain model is working in the favour of 
allogeneic products. Autologous products presently in the market mainly focus on 
structural tissues i.e. cartilage, skin and bone. They have a small market with low 
volumes and therefore little growth (Bock, Ibarreta et al. 2003). In contrast, allogeneic 
products primarily used in the active treatment of chronic skin wounds have an 
established market with commercially attractive sales (Becker). Though the focus of 
product developers is increasingly shifting towards metabolic products, there are no 
products in the market at present. 
There are also products in different phases of clinical development both targeting 
structural and metabolic tissues together with an increasing emphasis on cosmetic 
indications. Within stem cell based products, autologous are predominant as 
embryonic stem cell products are yet to reach the clinical development stage. A 
significant number of companies are directing their efforts towards developing 
embryonic stem cell based products (Jeffrey 2009). However, at present, the majority 
of clinical trials are based on bone marrow or cord blood derived stem cells 
(Giordano, Galderisi et al. 2007). 
In contrast to conventional drug therapies (10-15 years), time to market for RM 
products appears shorter; some firms have launched their products within 5-10 years 
of their inception (Petit-Zeman 2001). However, it is not clear how RM products 
presently on the market have navigated through the different phases of clinical trials 
and regulations. 
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2.2.4 Disease Focus 
The global ageing population, plagued with various age-related chronic diseases and 
cell dysfunctions, provides a ready market for novel therapies based on RM. In this 
regard nearly 200 companies seek to tap the potential in the RM space for providing 
novel treatment therapies for currently untreatable diseases including coronary artery 
disease, diabetes mellitus, Parkinson’s, Alzheimer’s and spinal cord injury, among 
others. The most common disease application areas worked on by RM product 
developers are cardiovascular conditions, followed by classical structural tissues i.e. 
skin, bone and cartilage, and metabolic disorders (Martin, Hawksley et al. 2009). 
Also, there is a large amount of clinical activity being undertaken in neurological 
disorders and very recently the U.S. Food and Drug Administration (FDA) has 
granted clearance to an Investigational New Drug (IND) application for the clinical 
trial of GRNOPC1 (oligodendrocyte progenitor cells derived from hESCs) in patients 
with acute spinal cord injury (Jeffrey 2009).  
The initial products have been primarily used as skin substitutes or for cartilage 
repair, however, as this up and coming industry continues to evolve the focus is 
beginning to move towards a broader range of invasive and complicated product 
categories mainly for metabolic disorders. Further, from a public health perspective, 
there is a substantial opportunity in addressing chronic disorders and organ 
replacement due to the increasing disparity between patient need and donor 
availability. 
 
2.2.5 RM Product Development 
The inter-operational capabilities and processes required for RM product development 
processes are represented in figure 2-1. This figure shows the series of stages through 
which a potential product must pass in order to gain marketing approval from the 
relevant regulatory authorities. The processes are distinctly divided between basic 
research activities and product development processes. 
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Figure 2-1 Inter-operational Capabilities for developing a RM based product 
 
During the initial research phase, a number of stem cell types with the underlying 
technology for their isolation, processing and maintenance, are employed for the 
discovery of a new therapeutic. The cells can be sourced from various tissue types at 
different stages of development, and different technologies can be employed for their 
processing in accordance with the ultimate function required. Once a potential new 
cell population is manufactured, it is then subjected to a range of tests, typically in 
vitro and in vivo, to validate specified end points and further test physiologic function. 
These processes generally characterise the product in terms of its safety and 
effectiveness in treating a diseased state. These processes are referred to as pre-
clinical development. Results from pre-clinical development are submitted to the 
regulatory authority to gain approval for performing clinical trials in humans as 
“investigational products” (Lee, Arcidiacono et al. 2009). The regulatory review 
process is based on understanding the inherent science of the product and ideally 
should parallel critical product development. The assessment is dependant on product 
characteristics, results from preclinical studies designed to support product use and 
proposed clinical trial design. The objective of the clinical trials is to prove product 
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safety and efficacy on administration to human patients. Upon successful completion 
of clinical trials, developers submit an application to the regulatory authority in the 
form of a biological licence application (BLA) or investigational new drug (IND) 
application, depending on the nature of the product, for market approval and ultimate 
clinical use. 
 
2.2.6 RM Product Development cost, time and risk 
The total time for an RM product development includes the time required to bring the 
product to regulatory submission stage and the time the product application spends 
under the regulatory review by relevant authorities (Ashton 2001). The development 
process is complex, expensive and can take years to complete (Tyebjee and Hardin 
2004). In theory it takes several hundred million dollars to discover, develop and gain 
regulatory approval (Tyebjee and Hardin 2004). The cost of conducting clinical trials 
alone can be a developer’s biggest investment and have maximum failure rate (Fox 
2001; Stewart, Allison et al. 2001). With passage of time, the complexity and size of 
the different phases of trials increase in terms of product quantity and the related 
process requirements for product manufacture (Poe 2003). All post phase II studies 
and multi-site clinical research trials have to be conducted in strict accordance with 
GMP standards, although preclinical and phase I studies can have GLP-grade 
material. The associated uncertainty of clinical development implies that RM product 
development is extremely complex and risky. In addition, the development demands 
enormous front-end investment (Giebel 2005). If the product fails at any of the trial 
phases the financial implications for the developer are significant. The production 
costs of these products could be up to 50% of sales value and therefore, failure to 
formulate a commercially feasible process could lead to unprofitable manufacturing 
processes and further, inability to capture the full value of a firm’s initial discovery  
(Karri, Davies et al. 2001; Parson 2008). 
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2.2.7 Production Costs 
Successful clinical development activities eventually lead to new products which need 
to be produced on a scale sufficient to cater to the market needs. Thus, production and 
its associated process together with analytical characterisation are critical to the 
success of commercialisation and timely development of products. As the process 
becomes locked in during the overall development process, the configuration and the 
economics of the ultimate production are a consequence of initial choices made 
during process improvement and development. 
The production of a new RM product is not a simple undertaking, as these are 
biologically complex and inadequately characterised in comparison to conventional 
low molecular weight drugs (Carpenter, Frey-Vasconcells et al. 2009). Therefore, in 
contrast to the traditional production processes which are essentially standard 
comprehensive assembly processes, production related to RM products is unique, 
highly complex and specialised thereby, requiring exclusive facilities with superior 
quality standards in controlled environments (Archer and Williams 2005). As a result, 
production facilities are expensive to assemble (Kemp 2006). Further, RM products 
have a short shelf life and they cannot be mass produced. For that reason the industry 
needs to reconsider the pharmaceutical manufacturing philosophy that centres on 
economies of scale (Kemp 2006). This suggests prior attention and investment should 
embrace issues related to quality control and setting up well-organised logistics in 
terms of transport, storage and delivery. This requires significant initial investment 
which coupled with stringent regulations on production results in a high entry barrier 
for developers as well as potential stakeholders.  
 
2.2.8 Discussion 
RM is a fast growing sector in the global economy, especially as the products can be 
employed as therapeutics as well as in drug testing. However, converting an initial 
discovery into a commercially viable product is challenging and complex. For a RM 
product to enter the market, pre-clinical and clinical development is conducted to gain 
approval. Pre-clinical development, clinical trials and product launch require huge 
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capital. Depending on the product, the scale of trials and the size of the market, 
developers have to adopt a well informed strategy to secure sufficient capital. In short, 
the clinical development involves parallel decisions on other key investment 
indicators which must be synchronised with regulatory and reimbursement 
requirements. 
The investment decisions depend upon the underlying technology and the overall 
product development strategy. Both these are complex and multidimensional which 
brings in a level of uncertainty. The uncertainty related to technology and investment 
decisions implies that RM product development for disease applications is not only 
highly complex but high-risk too. The ability to plan for such inherent uncertainties is 
important for companies to commercialise potential technologies with finite resources 
for each development project. The remainder of this research will focus on the 
commercialisation aspect of the overall translation process. 
The following section reviews the primary disease application areas in which firms 
could engage and invest their resources in product development activities. 
 
2.3 Regenerative Medicine disease target areas 
2.3.1 Introduction 
This section presents three key disease application areas that were reviewed at the 
beginning of the research in order to explore the science and clinical need behind the 
development of new RM products. The disease application areas illustrate unmet 
clinical needs and the underlying scientific and technological opportunity. The section 
summarizes current knowledge, and the challenges and advantages of the clinical use 
of RM applications, specifically focussing on stem cell based products. It also states 
some of the key ongoing clinical trials for demonstrating safety and efficacy of cell 
based therapies in humans. The section further integrates the common requirements of 
the three principle disease application opportunities reviewed, neurological and 
cardiac disorders and diabetes mellitus, to establish generic requirements for the 
translation of such products to clinical reality. 
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2.3.2 Rationale for developing RM products 
There is a continuous increase in demand for novel treatment strategies to treat tissue 
or organ damage due to the rise in the mean life expectancy coupled with severe 
shortage of donor organs and the limitations of conventional treatment regimes. 
Allogeneic transplants, autografts, xenografts and medical devices all have their 
inherent shortcomings, replacing the diseased tissue or organ imperfectly or number 
limitations in the case of transplants, as well as requiring immunosuppressive 
treatment. Researchers globally regard stem cell therapies as a treatment option with 
the potential to alter the face of contemporary medicine, and ultimately give a new 
and effective dimension to medical therapeutics. Recent work in RM has proved the 
proof of principle for cell based replacement for a number of structures, (Mooney and 
Mikos 1999; Stock and Vacanti 2001) ranging from skin (Lee, Lee et al. 2006), 
musculoskeletal (Davies and Grounds 2006; Yu, Zhang et al. 2007) and neuronal 
tissue (El-Badri, Hakki et al. 2006; Lee, Al Shamy et al. 2007; Lee, Al Shamy et al. 
2007) to osteo-chondral grafts (Gillogly, Myers et al. 2006; Gooding, Bartlett et al. 
2006) and complex organs such as the kidney (Bates and Lin 2005; Hishikawa and 
Fujita 2006) or liver, (Aurich, Mueller et al. 2007; Oh, Witek et al. 2007), which may 
supplant more conventional therapeutics to revolutionise current medical practice.  
 
2.3.3 Characteristics of cell based RM products 
The proliferation capacity of many adult organ-specific cells can be low, and long 
term in vitro cultivation in particular reduces their functional ability (Alison, Poulsom 
et al. 2002). Cells for therapies should be phenotypically stable with no loss of pluri- 
or multi-potency on culture, non immunogenic, easy to isolate, highly responsive to 
distinct environmental cues and survive implantation together with functionally 
integrating into the host tissue to provide long term therapeutic benefit. In addition to 
satisfying these characteristics, the multi-lineage differentiation potential and self 
renewal make stem cells promising candidates as cell based therapies for RM. 
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2.3.4 Disease application area I - Neurological Disorders 
2. 3.4.1 Overview 
Neuronal disorders exhibit substantial challenges for cell-based therapies due to 
complexities of the cellular organization of the nervous system and the precision with 
which the cellular components interact spatially as well as temporally. However, a 
number of diseases are relevant for cell-based strategies for repair, particularly those 
characterised by exclusive single phenotype cell loss and in which restoration of 
direction specific links are not solely a necessity for functional therapeutic benefit 
(Koch, Kokaia et al. 2009). The most compelling include: neurodegenerative diseases, 
myelin disorders and traumatic brain and spinal cord injuries.  
The potential of stem cells for the treatment of these disorders has been triggered by 
the observation that the adult central nervous system (CNS) is developed from multi-
potential stem cells and that neural stem cells are retained in the adult brain. (Colucci-
D'Amato, Bonavita et al. 2006; Rietze and Reynolds 2006). This is reinforced by 
recent evidence indicating endogenous neuro- and gliogenesis (processes by which 
new neurons and glial cells, respectively, are generated) occurring following neural 
insult (Minger, Ekonomou et al. 2007; Sgubin, Aztiria et al. 2007).  
 
2.3.4.2 Neurodegenerative diseases  
These disorders are characterized by progressive and gradual irreversible loss of 
physiologically active neurons over a period of several years ultimately leading to 
significant morbidity and mortality (Steiner, Wolf et al. 2006). The two most common 
age-related neurodegenerative disorders are Parkinson’s and Alzheimer’s disease 
(Jenner and Olanow 1998). More than 1 and 4 million people are affected by these 
disorders respectively in the United States, the prevalence rising with age, 
exponentially in the case of Alzheimer’s (Lang and Lozano 1998; Lang and Lozano 
1998; Martin 1999). Both genetic and environmental factors have been implicated in 
the etiology of these disorders as a result of point mutations and oxidative stress, 
respectively (Klein and Schlossmacher 2006; Ding, Dimayuga et al. 2007). The 
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pharmacotherapy of these neurodegenerative diseases can only provide modest 
cognitive or disease modifying benefits. Hence, the urgency to identify individuals at 
high risk along with developing therapies (Sadan, Melamed et al.) which are capable 
of halting the progression before irreversible damage ensues. 
 
2.3.4.2.1 Parkinson’s disease 
For Parkinson’s, the need may be ameliorated by transplant of human dopaminergic 
neurons obtained from defined dopaminergic specific neuronal progenitors. Previous 
attempts using foetal tissue as a cell source had limited success (Hagell, Piccini et al. 
2002; Kriks and Studer 2009) due to the relative scarcity of dopaminergic neurons in 
the foetal midbrain cells, and the presence of other heterogeneous cell types (Freed, 
Greene et al. 2001; Olanow, Freeman et al. 2001; Redmond, Sladek et al. 2001). 
Further, a lack of pertinent afferent control and inhomogeneous tissue distribution of 
the engrafted cells led to variability in functional outcome (Piccini, Pavese et al. 
2005). Alternative more mainstream neurosurgical procedures such as deep brain 
stimulation and stereotactic leisoning are effective in patients with advanced disease 
but aim to compensate for damaged neuronal circuits rather to repair and enhance 
normal brain function (Vilela Filho, Silva et al. 2001; Piasecki and Jefferson 2004; 
Anderson and Lenz 2006).  
Significant therapeutic improvements have been demonstrated with dopaminergic 
grafts (Freed, Greene et al. 2001; Bjorklund, Sanchez-Pernaute et al. 2002; Isacson 
2002). The dopamine neurons in such intra-striatal grafts of embryonic mesencephalic 
tissue exhibit many of the morphological and functional characteristics of native 
dopamine neurons. Piccini et al. have assessed dopamine release at ten years 
postoperatively in a patient (Piccini, Brooks et al. 1999), showing marked quantified 
symptomatic improvement. Also, grafted cells have been reported to survive up to ten 
years post-transplantation and no case of immunological rejection was reported in any 
patient even several years after withdrawal of immuno-suppressants (Freed, Breeze et 
al. 1992; Lindvall, Sawle et al. 1994).  
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To overcome the shortcomings of foetal/embryonic tissues as sources for neural grafts 
and invasive surgical procedures, embryonic stem cells (Ho and Li 2006), neural stem 
cells derived from foetal or adult brain (Sanberg 2007) and other tissue stem cells 
derived either from bone marrow (Lu, Zhao et al. 2005) or umbilical cord blood 
(Sanberg, Willing et al. 2005) have been experimentally applied to generate 
dopaminergic neurons. Such cells will help to provide a clinically competent and 
effective therapeutic regime without the need for further interventions.  
Stem cells graft strategies are: in vitro pre-differentiation to dopaminergic neurons 
prior to transplantation or in vivo differentiation of stem cells after implantation into 
the striatum or substantia niagra. The most important clinical issue is the ability to 
generate functional dopamine neurons and establish the role of other cell types, such 
as glial cells present in the mesencephalic foetal grafts, in the differentiation and 
function of these neurons. Site-specific integration in to the brain parenchyma is 
essential to replace dopamine in a physiologically natural fashion. This requires 
transplanting a cell population with a high percentage of live cells, secreting a 
consistent amount of dopamine, that are capable of interlinking with the host cells to 
replace damaged neuronal circuitry without immune rejection. Importantly the loss of 
single phenotype of cells together with the uniform pathology that characterises 
Parkinson’s disease suggests treatment regimes based on the substitution of the single 
lost neuronal cell type. 
 
2.3.4.2.2 Alzheimer’s disease 
Alzheimer’s is the most common type of degenerative dementia globally (Marin, 
Sewell et al. 2002). The symptoms occur as a consequence of reduction in the number 
of cholinergic neurons in the forebrain cholinergic projection system. (Auld, 
Kornecook et al. 2002). Neural stem cell grafts have the potential to be utilised as a 
therapeutic neuro-replacement strategy (Sugaya 2005; Wang, Matsumoto et al. 2006; 
Blurton-Jones, Kitazawa et al. 2009). Wang et al. have shown the effect of 
transplanted neurospheres, generated from mouse embryonic stem cells, on the 
striking alleviation of dementia in a mouse model having a lesion in the nucleus 
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basalis of Meynert, the primary site of degeneration in Alzheimer’s (Wang, 
Matsumoto et al. 2006).  
 
2.3.4.3 Spinal cord injury 
The spinal cord has also been a primary objective for cell based therapies as no 
current treatment can aid regeneration after spinal cord injury. New understanding of 
axonal regeneration in the injured cord has highlighted the potential of stem cells in 
this nascent area (Johansson 2007). There is loss of neurons, astrocytes and glial cells 
which usually occurs due to trauma, iatrogenic occlusion or spinal cord ischemic 
events. Attempts to promote functional recovery post spinal cord injury have focussed 
on generating new neurons, axonal re-growth, providing neurotrophic factors and 
suppression of the self perpetuating ongoing disease pathology.  
Cell based treatment should therefore supply cells which have the potency to 
differentiate into the three requisite cell types, be capable of engraftment and survival 
as transplants, and cause axonal regeneration and directional synaptogenesis, thereby 
inducing simultaneous morphological and functional modulation of cells and the 
disease environment (Wallenquist, Brannvall et al. 2009). The engrafted cells 
contribute to functional restoration by providing neurons for processing and 
transmitting signals, oligodendrocytes for re-myelination, and neurotrophic factors to 
defend the existing host cells (Becker, Sadowsky et al. 2003; Borgens 2003).  
Cell based therapies for spinal cord injuries have, so far, been predicated with the 
premise that local signals will drive differentiation to the specific phenotype of cells, 
required at the diseased site. This assumption has been validated by Ogawa et al. who 
saw behavioural improvement in rats with spinal cord injury transplanted with neural 
stem cells when compared to non transplanted controls (Ogawa, Sawamoto et al. 
2002) and Keirstad et al. who reported locomotor improvement by grafting embryonic 
stem cells pre-differentiated towards the neuronal lineage into rats with traumatically 
injured spinal cords (Keirstead, Nistor et al. 2005). Phenotypically confined stem cells 
are likely to have a more predictable and reliable behaviour upon host engraftment. 
Recently, Tarasenko and colleagues grafted human neural stem cells into the injury 
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site in adult rats following spinal cord contusion and showed their differentiation into 
neurons and oligodendrocytes to promote functional recovery (Tarasenko, Gao et al. 
2007). They also confirmed the significance of timing of transplantation for graft 
survival. 
 
2.3.4.4 Demyelinating disorders 
A number of research groups address the potential of cell-based re-myelination 
strategies for CNS diseases characterized
 
by myelin deficiency as a result of trauma, 
congenital anomalies
 
or diseases. The loss of a single homogenous cell type, 
oligodendrocytes, means that the success of a cell based approach is more likely 
which is further advantaged by the abundance and committed nature of glial 
progenitors towards the oligodendrocyte phenotype (Scolding, Franklin et al. 1998; 
Siatskas and Bernard 2009). For instance Eftekharpour et al. transplanted adult 
neuronal
 
stem cells derived from the brain of adult transgenic mice
 
into the spinal 
cords of adult Shiverer mice, which were genetically deficient in myelin basic protein. 
The
 
transplanted cells expressed oligodendrocyte markers, migrated extensively along 
the white matter tracts, formed myelin which ensheathed the axons and
 
established 
paranodal junctional complexes leading to the formation of nodes of Ranvier, thereby, 
enhancing
 
axonal conduction (Eftekharpour, Karimi-Abdolrezaee et al. 2007). In 
addition to neuronal progenitors, the findings of McKenzie et al. indicated that skin 
derived progenitor cells can also differentiate into Schwann cells (analogues of the 
CNS oligodendrocytes) when provided with suitable cues (neuregulins), which are 
capable of myelinating injured peripheral nerves and demyelinated brain and spinal 
cord (McKenzie, Biernaskie et al. 2006). These findings give substantial support for 
the concept that human progenitors represent a clinically useful source of 
oligodendrocytes which can be used for a variety of demyelinating disorders from 
paediatric leucodystrophies to multiple sclerosis.  
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2.3.4.5 Clinical Trials 
Presently, clinical trials for these disorders are underway at multiple centres. Slight 
functional improvement and varying clinical results were demonstrated by two NIH-
sponsored double-blind clinical trials for Parkinson’s disease, along with occurrence 
of dyskinesias (Freed, Greene et al. 2001; Olanow, Goetz et al. 2003). These early 
trials suggest graft-induced amelioration of symptoms but accentuate the requirement 
to address several significant issues, from transplantation procedure to patient and 
tissue selection.  
An initial phase I clinical trial for Alzheimer’s with genetically modified fibroblasts 
expressing nerve growth factor demonstrated beneficial effects on injecting the cells 
in the nucleus basalis of Meynert (Tuszynski, Thal et al. 2005). In another ongoing 
trial, Cox and co-workers are infusing autologous bone-marrow derived mononuclear 
cells intravenously in paediatric patients with traumatic brain injury to establish safety 
and efficacy of cell therapy for such injuries.  
Such trials are improving and refining cell transplantation procedures and patient 
selection criteria which are necessary steps to give substantial validated evidence for 
cell based therapies as safe and efficacious restorative treatment regimes for 
neurological disorders. While such trials progress, the research community is trying to 
address methods of delivering sufficient cells, and at the same time increasing their 
understanding of mechanism of differentiation of cells in the local milieu (Suarez-
Monteagudo, Hernandez-Ramirez et al. 2009). 
 
2.3.5 Disease application area II - Cardiac Disorders 
2.3.5.1 Overview 
Nearly 80 million adults in the United States suffer from cardiovascular diseases, the 
cause of around 40% of total deaths in 2004 (American Heart Association, 2007). 
This clearly indicates the gravid nature of the problem and the limitations of current 
therapeutics. For instance, present therapies improve the prognosis of patients 
suffering from acute myocardial infarction but none address the fundamental cause of 
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the remodelling process or substitute myocardial scar with functioning contractile 
tissue post infarction. 
Recent clinical and pre-clinical reports have shown improvement in cardiac function 
post-infarction using a number of progenitor cells, from embryonic stem cells to 
skeletal myoblasts (Retuerto, Beckmann et al. 2007; Gersh, Simari et al. 2009) (Table 
2-1). Due to the limitations of each progenitor cell type, many have used 
unfractionated bone marrow cells which include haematopoietic and mesenchymal 
stem cells with endothelial progenitor cells (Jackson, Majka et al. 2001; Orlic, 
Kajstura et al. 2001; Fernandez-Aviles, San Roman et al. 2004; Kuethe, Richartz et al. 
2004; Wollert, Meyer et al. 2004; Chen, Liu et al. 2006). Also resident and circulating 
endothelial progenitors can incorporate into the damaged myocardium and restore 
cardiac function (Shintani, Murohara et al. 2001; Massa, Rosti et al. 2005; Lyngbaek, 
Schneider et al. 2007; Liu, Sluijter et al. 2009). Likewise endogenous cardiac repair 
mechanisms have also been reported (Schmidt-Lucke, Rossig et al. 2005; Oyama, 
Nagai et al. 2007). 
 
2.3.5.2 Proposed Mechanism of action 
The process by which transplanted cells capture the function of resident 
cardiomyocytes is not yet fully elucidated but the two main processes identified to 
date are transdifferentiation and/or fusion (Alvarez-Dolado, Pardal et al. 2003; Yeh, 
Zhang et al. 2003; Nygren, Jovinge et al. 2004; Alvarez-Dolado 2007). Transplanted 
progenitors not only have the ability to induce proliferation of endogenous 
cardiomyocytes to take up the function of those lost, but also protect them from 
apoptotic cell death. By this they maintain the contractile function and minimize 
scarring (Kocher, Schuster et al. 2001). Such cells also stimulate revascularization of 
the infarcted area by enhancing angiogenesis and restoring regional capillarization 
and collateral circulation (Mazhari and Hare 2007). Therefore, the transplanted cells 
have a favourable impact on myocardial perfusion and enhance left ventricular 
contractility to ameliorate coronary failure symptoms. Hence, cell therapy may offer 
exciting therapeutic options for cardiac disorders. 
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Table 2-1: Studies by different research groups of stem cell based therapies for 
cardiac disorders 
Cell Source Disease Result/Outcome Reference 
Study 
Murine 
embryonic 
stem cell lines 
Myocardial infarction 
model in mice 
Transplanted cells survived and 
differentiated to cardiomyocytes 
in the ischemic zones 
 
(Nelson, Ge 
et al. 2006) 
 
Bone marrow 
mononuclear 
cells 
Chronic ischemic 
heart disease 
Increased left ventricular 
ejection fraction and perfusion of 
the infarcted myocardium 
 
(Stamm, 
Kleine et al. 
2007) 
 
Bone marrow 
mesenchymal 
stem cells 
Acute myocardial 
infarction 
Improved left ventricular 
function with increased wall 
movement, left ventricular 
ejection fraction and decreased 
perfusion defects 
 
(Chen, Fang 
et al. 2004) 
 
Peripheral 
blood 
mononuclear 
cells 
Congestive heart 
failure 
Significantly viable transplanted 
cells in infarct zones and 
improved left ventricular 
ejection fraction 
 
(Ozbaran, 
Omay et al. 
2004) 
 
Endothelial 
progenitor cells 
Myocarditis induced 
dilated 
cardiomyopathy rat 
model 
Reduced scar tissue and 
thickened ventricular wall with 
functional improvement in 
cardiac performance 
 
(Werner, 
Deutsch et 
al. 2005) 
Human 
umbilical cord 
blood-CD 133
+
 
cells 
Myocardial infarction Prevented scar thinning and left 
ventricular dilatation together 
with functional recovery 
 
(Leor, Guetta 
et al. 2006) 
Skeletal 
myoblasts 
Ischemic heart failure Increased left ventricular 
ejection fraction and functional 
improvement 
 
(Ince, 
Petzsch et al. 
2004) 
 
Adipose tissue 
derived stem 
cells 
Myocardial infarction Decreased trans-mural scar size, 
increased capillary density in the 
infarct region and improved 
ventricular ejection fraction, 
end-diastolic pressure 
(Zhang, Gai 
et al. 2007) 
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 2.3.5.3 Disease Target - Coronary Artery Disease 
Recent experimental studies, such as that of Hou et al., to determine the fate of 
mesenchymal stem cells in patients with coronary artery disease, assessed their 
functional effect post-transplantation into infarcted myocardium in a rat model (Hou, 
Yang et al. 2007). Their results suggested the progenitors proliferate, differentiate to 
diverse cell types including cardiomyocytes and endothelial cells, and show a 
beneficial therapeutic effect. Zhang et al. compared the regenerative capacity of 
distinct cell populations to distinguish a single non-haematopoietic mesenchymal 
stem cell subpopulation which conserved the homogenous appearance and cardiac 
specific cell surface markers both in vitro as well as in vivo (Zhang, Ge et al. 2006). 
This stem cell subpopulation was isolated from human bone marrow, clonally purified 
and grafted into the infarcted hearts of rats to preserve left ventricular function and 
suppress infarct expansion thereby arresting imminent heart failure. Further, Wu et al. 
reported a statistically significant improvement of cardiac function with human 
umbilical cord blood derived stem cells in a rat myocardial infarction model (Wu, 
Zhou et al. 2007). The transplanted cells survived and expressed markers specific for 
cardiac phenotype suggesting regeneration of damaged myocardium. The increase in 
capillary and arteriole density, and decrease in the number of apoptotic cells also 
suggested myocardial regeneration. The effect of cardio-protective cytokines is being 
evaluated both as an independent treatment regime and as an adjunct to cell therapy 
by different groups (Prunier, Pfister et al. 2007; Zhang, Zhang et al. 2007). 
 
2.3.5.4 Clinical Trials 
Trials have been initiated to test the feasibility and safety of stem cell therapy in 
patients with acute myocardial infarction. For instance, the feasibility of bone marrow 
derived stem cells has been evaluated as an adjunct therapy to surgical intervention 
for myocardial infarction. Stamm et al. injected CD133
+
 cells intra-myocardially with 
coronary artery bypass grafting (CABG). They concluded that CABG plus 
intramyocardial delivery of CD133
+
 cells is not only safe but also improves 
contractile function of the heart in comparison to CABG alone (Stamm, Kleine et al. 
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2007). Further, to show the efficacy of stem cell transplantation as a singular 
procedure Klien et al., in their current phase 1 clinical study, transplanted autologous 
bone marrow CD133
+ 
enriched stem cells and assessed the cardiac function in terms 
of ventricular ejection fraction (Klein, Ghodsizad et al. 2007). No surgical procedure 
was performed simultaneously which has been the case in most clinical studies. Their 
results showed the safety and feasibility of this individual procedure and delivered 
improved cardiac function. Therefore, this approach may be a promising alternative 
for patients unsuitable for conventional surgical revascularization procedures.  
 
2.3.5.5 Approaches for cell delivery 
To transplant an adequate number of cells in the diseased region of the heart, trans-
vascular as well as direct injection access has been used (Thompson, Nasseri et al. 
2003; Tse, Kwong et al. 2003; Tse, Siu et al. 2007). The trans-vascular approach is 
more suitable for treating freshly infarcted myocardium whereas direct injection of 
cells is favoured for patients presenting late (Perin and Lopez 2006). These 
approaches are suitable for the target diseased population as they fall under the high 
risk category for both operative procedures and general anaesthesia.  
A large proportion of a variety of progenitor cell populations can be delivered at the 
infarct site via intracoronary artery infusion (Assmus, Walter et al. 2006; Kang, Kim 
et al. 2007; Qian, Yang et al. 2007). This route allows cells to move directly into 
myocardial areas with preserved oxygen supply and blood flow, guaranteeing 
favourable surroundings for their survival, this is associated with lasting and 
substantial melioration of symptoms related to left ventricular contractile dysfunction 
(Assmus, Honold et al. 2006).  
Stem cells from a number of sources, when administered intravenously, are able to 
engraft at the injured site and limit infarct size (Min, Huang et al. 2006; Krause, 
Harter et al. 2007). However, homing of cells to other organs and migration out of the 
vessel into the surrounding tissue restrains the clinical application of such a systemic 
approach (Barbash, Chouraqui et al. 2003). 
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Another viable alternative approach is direct intramyocardial injection of the relevant 
cell population (Amado, Saliaris et al. 2005; Archundia, Aceves et al. 2005; Losordo, 
Schatz et al. 2007). The risk of ventricular perforation does limit the use of this 
technique. Also, progenitor cells directly injected into necrotic tissue will not receive 
the necessary local cues or be in an environment which assists favourable engraftment 
and differentiation. This necessitates the use of imaging and mapping to identify areas 
of viable and/or hibernating myocardium to precisely locate the preferred regions for 
direct injection (Frangioni and Hajjar 2004; Graham, Lederman et al. 2006; San 
Roman and Fernandez-Aviles 2006; Beeres, Bengel et al. 2007).  
Defining a specific route of delivery for a particular patient will therefore depend on 
the individual patient patho-physiological profile. 
 
2.3.5.6 Engineered cells for cardiac repair 
The use of engineered or augmented donor cells is also possible to supplement the 
function of an infarcted heart. Askari et al. have examined the effect of adenoviral 
vascular endothelial growth factor (AdVEGF) transfected skeletal myoblasts in a 
model of ischemic cardiomyopathy post myocardial infarction (Askari, Unzek et al. 
2004). They demonstrated enhanced efficacy of the combined approach of gene 
transfer and cell transplantation in comparison to direct injection of AdVEGF or 
autologous cell transplantation. Similarly, to overcome the problem of poor cell 
viability post-transplantation, Mangi et al. showed genetically augmented 
mesenchymal stem cells, with an anti-apoptotic gene Akt, halted remodelling and 
restored both systolic and diastolic cardiac function (Mangi, Noiseux et al. 2003).  
 
2.3.5.7 Implications for cardiac repair 
Conventional palliative medical interventions for treating cardiovascular disorders do 
not rectify the fundamental defect, the decrease in the number of cardiomyocytes due 
to their ischemic death, and, aggressive interventions like orthotopic organ 
transplantation, CABG and left ventricular assist devices are not only invasive but 
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have limited efficacy and life-span (Park, Tector et al. 2005; Leshnower, Gleason et 
al. 2006; Thomas, Flet et al. 2007). In contrast, stem cell therapies may permit the 
regeneration of necrosed myocardium (Lee, Thorne et al. 2005; Cho, Lee et al. 2006; 
Puceat 2006). Moreover, their role in cellular cardiomyogenesis, neovascularisation, 
cytoprotection and remodelling reduction has increased the level of activity in this 
therapeutic area which emphasises the importance of the ability to translate these 
primarily single cell therapies into clinical reality. 
 
2.3.6 Disease application area III - Diabetes Mellitus: 
2.3.6.1 Overview 
Diabetes mellitus is a chronic metabolic disorder with distorted glucose homeostasis, 
a consequence of progressive failure of functional β-cells, contributed by both genetic 
predisposition and environmental factors. Type I diabetes (insulin-dependant), caused 
by selective immune-mediated destruction of the insulin-secreting β-cells, is an 
appropriate target for cell based therapies as there is loss of a single phenotype of cell 
(Gepts and Lecompte 1981; American Diabetes Association, 2004). Type II diabetes 
mellitus has a more complex patho-physiology.  
An estimated 171 million cases of diabetes were reported worldwide in the year 2000. 
This number is predicted to be doubled by the year 2030 (Wild, Roglic et al. 2004), as 
a number of people have the pre-diabetic condition of high blood sugar, placing them 
in the high risk category of developing the full blown disease in future. In another 
estimate from the American Diabetes Association, the cost of diabetes inclusive of 
secondary disability payments, chronic complications and lost days at work was $132 
billion in 2002 in United States alone (Hogan, Dall et al. 2003). 
 
2.3.6.2 Conventional therapeutic regimes 
At present, there are diverse alternatives, some well entrenched, available for 
symptomatic relief of diabetes (DeFronzo RA 2004). These are pharmacotherapy 
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(Sicat and Morgan 2007), artificial insulin delivery systems (Shalitin and Phillip 
2006), gene therapy (Samson and Chan 2006) and pancreatic transplantation (Ito, 
Shimada et al. 2007). 
Insulin therapy gives a precise glucose control but holds the risk of hypoglycaemic 
episodes which can accelerate diabetic systemic complications and lead to permanent 
neurological sequel (Vanhorebeek, Langouche et al. 2007).The gene therapy approach 
requires complex gene transfer manipulations and reconstruction of a regulated 
insulin secretion mechanism in non β- cells customised to the needs of individual 
patients.  
The Edmonton Islet Transplantation protocol has significantly altered the likelihood 
of productive and successful islet transplantation, as a result of improved islet 
isolation techniques and new immunosuppressive regimes. However, the dearth of 
donor tissue, uncertainty concerning the long term endurance and function of islet 
grafts, and life long immunosuppresion remain hurdles (Shapiro, Lakey et al. 2000; 
Ryan, Lakey et al. 2001). 
These shortcomings reinforce the requirement to establish an alternative inexhaustible 
source of insulin-producing pancreatic islets that can be used for clinical 
transplantation.  
 
2.3.6.3 Stem cell based therapeutics 
Stem cells offer exciting opportunities to restore β-cell function and glycaemic control 
(Mayhew and Wells 2009). Several groups have differentiated stem cells from a 
number of initial cell types into insulin producing cells (Lumelsky, Blondel et al. 
2001; Oh, Muzzonigro et al. 2004; Chang, Kao et al. 2007). The endpoint requires not 
only the presence of insulin in the differentiated cell population but an appropriate 
glucose sensing machinery within the cells to reverse the condition in transplant 
recipients and acquire exemption from exogenous insulin. 
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2.3.6.3.1 Embryonic stem cells 
Embryonic stem cells, both human and murine, can generate embryoid bodies (EBs) 
which bear cells with a β-cell like phenotype in vitro showing spontaneous expression 
of insulin in EBs (Soria, Skoudy et al. 2001). A number of groups have reported 
increase in the number of insulin producing cells, either by over-expressing 
transcriptional factors like Pax-4 and Pdx1 which are implicated in pancreatic 
development or by using differentiation factors such as nicotinamide during in vitro 
differentiation, and lowered blood glucose levels with differentiated embryonic stem 
cells (Blyszczuk, Czyz et al. 2003; Miyazaki, Yamato et al. 2004; Segev, Fishman et 
al. 2004). 
Segev et al. have reported similarities between normal development of the pancreas 
and in vitro differentiation of embryonic stem cells by showing their organisation into 
islet-like clusters, similar to immature pancreatic β-cells, and insulin secretion in the 
differentiated cells (Segev, Fishman et al. 2004). However, Sipione et al. reported that 
insulin content in culture of embryonic stem cells is in fact derived from insulin 
uptake from the culture medium, added as part of the differentiation protocol or 
present in serum rather than endogenous synthesis (Sipione, Eshpeter et al. 2004). 
This was further supported by experiments, by Rajagopal and colleagues, in which the 
insulin positive cells exhibit condensed nuclear DNA and positive TUNEL assays, 
signs associated with cells undergoing apoptosis (Rajagopal, Anderson et al. 2003). 
Further, it was also demonstrated that C-peptide, part of the pro-insulin molecule, was 
not released together with insulin in an equi-molar amount indicating the presence of 
insulin in these cells was not a consequence of insulin biosynthesis (Hansson, 
Tonning et al. 2004). These reports were challenged by the observation that 
transplantation of insulin producing cells derived from embryonic stem cells could 
revert diabetes in rodents, showing their capacity to synthesise and release insulin 
(Soria, Roche et al. 2000; Jiang, Shi et al. 2007). Moreover Blyszcuk et al. have 
described an efficient design for in vitro differentiation of embryonic stem cells into 
both C-peptide and insulin positive islet like clusters which release insulin in response 
to high glucose concentration (Blyszczuk and Wobus 2006).  
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The studies from Brolen et al. introduced another method for inducing such 
differentiation of human embryonic stem cells using signals from embryonic mouse 
pancreas. These cells had common features with normal β-cells in terms of not only 
insulin biosynthesis and processing but also nuclear localization of cardinal β- cell 
transcription factors (Brolen, Heins et al. 2005). With further improvement in our 
understanding of embryonic stem cell differentiation, it should be possible to generate 
sufficient β-cells in vitro to serve the current limited supply of insulin producing cells. 
 
2.3.6.3.2 Neural stem cells 
The constitutional similarities between pancreatic β-cells and neural cells highlight 
the possibility that stem cells of neural origin may offer a useful starting point to 
generate insulin producing cells, since they share the molecular machinery necessary 
for insulin secretion (Hori, Gu et al. 2005; Eberhardt, Salmon et al. 2006). Some 
research groups have generated insulin producing cells from neural stem cells, which 
express phenotypical markers and functional responses characteristic of pancreatic β-
cells (Burns, Minger et al. 2005; Hori, Gu et al. 2005). Nestin, a marker for neural 
precursor cells, expressed by mesenchymal cells derived from islets and endothelial 
cells of islet vasculature is one such candidate phenotype marker. 
 
2.3.6.3.3 Other stem cell types 
Progenitor cells from various adult tissues can differentiate into islet cells and 
therefore could serve as an alternative (Sahu, Tosh et al. 2009). While adult stem cells 
have a restricted proliferation capacity and are committed to specific cell types, they 
offer the advantage of autologous transplantation avoiding immune rejection issues 
and recent studies have confirmed their plasticity (Pittenger, Mackay et al. 1999; 
Jackson, Jones et al. 2007). Consequently, adult stem cells are good candidates to 
generate cells of pancreatic endocrine phenotype. Human bone marrow derived 
mesenchymal stem cells have been shown to reach pancreatic islets in diabetic mice 
and reverse hyperglycaemia with increasing blood levels of mouse insulin (Lee, Seo 
et al. 2006).  
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Recently, placenta derived multipotent stem cells (Chang, Kao et al. 2007), cord 
blood mononuclear cells (Pessina, Eletti et al. 2004), human adipose tissue derived 
mesenchymal stem cells (Timper, Seboek et al. 2006), hepatocytes (Cao, Tang et al. 
2004; Yang 2006), splenocytes (Kodama, Davis et al. 2005) and intestinal stem cells 
(Fujita, Cheung et al. 2004) have been reported to differentiate into insulin producing 
cells. 
 
2.3.6.4 Clinical Trials 
On the basis of such available preclinical data, Haller et al. have initiated an 
experimental pilot study with autologous cord blood infusion in type 1 diabetics to 
analyse the safety and potential efficacy of cord blood infusion to preserve β-cell 
function. Though they report encouraging results with no adverse events, they signal 
the requirement for further follow-up, more randomized controlled trials and 
exploration of other therapeutic avenues (Haller, Viener et al. 2008). This is necessary 
to narrow down to a specific procedure to reverse the condition permanently. 
 
2.3.6.5 Research Implications 
To establish the clinical application of stem cells into a practical realistic alternative 
for the treatment of diseased endocrine pancreas will require increased understanding 
of the fundamental biological processes and careful selection of the fraction of 
physiologically functional β-cells with dynamic biphasic insulin release to regulate 
glucose levels from any differentiated cell sample. An exact piecewise sequential 
analysis of the expression pattern of the transcription factors involved is required to 
describe the sequence of events ensuing β-cell development which can be then 
replicated on the bench for stem cell differentiation towards functional insulin 
producing cells. These cells should have the ability to regulate blood glucose levels by 
active phasic insulin release without any untoward features of senescence or tumour 
formation.  
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Clearly there is great promise for the use of cellular therapies in the treatment of 
diabetes; however work in this area must recognise that there is a well established and 
well accepted conventional therapy, insulin, and that this therapy has resisted 
challenges from improved variants. 
 
2.3.7 Discussion 
A major force for the development of stem cell based therapies in the past decade has 
been the demand from clinicians to go beyond simple regeneration of cells and/or 
tissues at a laboratory bench scale to the generation of clinically relevant numbers of 
cells capable of establishing themselves in tissues to give functional recovery upon 
transplantation.  
 
2.3.7.1 Identification of disease targets with appropriate end points 
A key issue is the requirement to identify key disease targets, coupled with the 
implications of their respective patho-physiological profile, for cell based 
regeneration therapies. Initially diseases with loss of single phenotype of cells should 
be targeted so that an individual and consistent batch of stem cells can be used to 
replace the diseased or degenerated cells, diseases with multiple cell type loss should 
then follow. The use of a single cell type dramatically reduces the complexity of the 
cell culture process and therefore, GMP compliant manufacturing.  
The consequences of the disease process on the local milieu also need to be 
considered as this may have some untoward effect on the transplanted cells in terms 
of their viability, differentiation and integration with the host tissue.  
Furthermore, due to the dynamic nature of the disease process, the treatment regime 
for a particular disease phase can not be generalised to the overall disease or 
apparently identical diseases. This is important for the timing of any intervention as 
favourable events following cell transplantation occur only during specific periods 
subsequent to onset of the disease process as a consequence to the inherent 
differences between acute, sub-acute and chronic stages of the disease. Thus it is also 
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necessary to define the time windows for transplanting cells at the appropriate stage 
of the disease. 
 
2.3.7.2 Cell type, dosage and delivery issues 
Another issue in clinical stem cell administration is the determination of their type, 
dose and delivery method. To harvest a sufficient quantity of a particular cell type for 
an effective dose, the technology of cell selection and further expansion has to be 
precise and accurate that isolates and expands the exact type and fraction of required 
cells. The efficacy of a cell therapy depends upon the adequate engraftment, survival 
and function of the applied cells at the injury site (Liechty, MacKenzie et al. 2000). 
This is controlled by the molecular mechanisms involved in their homing. A low ratio 
of transplanted cells has been detected in some investigations raising concerns of long 
term engraftment and homing. This necessitates the devising of molecular strategies 
and precise cell delivery tools to increase engraftment (Robey, Saiget et al. 2008). 
Therefore, data from preclinical studies has to be intelligently interpreted in 
accordance with individual patient needs to establish cell types with defined dosage 
and delivery method for each disease and patient.  
 
2.3.7.3 Move to Clinical Trials 
The majority of stem cell investigators have used animal models because of their ease 
of handling and optimal biological characterisation with the expectation that 
discoveries made in these model organisms will provide significant insight into their 
behaviour in humans (Sanchez Alvarado and Tsonis 2006; Steindler 2007). Therefore 
the next step, based on the success of these preliminary studies on model organisms, 
is to test the safety and feasibility of stem cell therapies on humans in clinical trials 
that bring them closer to successful clinical protocols. This will require careful 
elucidation of the key issues associated with the move to trials from animal models to 
humans and clearer definition of the most favoured clinical targets with respect to 
both the interventional limitations of this new range of therapeutics and the practical 
issues associated with eventual recovery of development and trials costs. 
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Clinical trials design is thus, a challenge that must be addressed in order to reap 
maximum benefit from these new therapies in a timely way. In particular, resolution 
is required in the choice of valid clinical end points that provide useful analogues for 
clinical benefit. The design and execution of such clinical trials should ultimately 
demonstrate either prolongation of life
 
or improved quality of life for patients, with 
extended follow-up to oversee any undesirable long term effects. 
 
2.3.7.4 End points for Clinical Trials 
The largest number of clinical trials is ongoing for cardiac disorders. A range of 
dosages have been used, determined according to the cell processing conditions and 
type (Losordo, Schatz et al. 2007; Lunde, Solheim et al. 2007; Ripa, Haack-Sorensen 
et al. 2007). On the basis of encouraging results from several authors demonstrating 
functional myocardial recovery using the injection of populations of single stem cell 
types, clinical end points have been defined to assess and validate the efficacy of 
these therapies. For cardiac disorders, enhanced myocardial contractility and left 
ventricular ejection fraction in accordance to normal limits constitute valid endpoints.  
Similarly, as there is a wide spectrum of neurological disorders likely to be suitable 
for stem cell therapies; objective assessments that precisely indicate spontaneous 
functional recuperation need to be determined. Such assessments should not be 
restricted to clinical examinations, constant neuro-physiological scoring together with 
the study of local and systemic effects will be crucial to reliably monitor the 
therapeutic effect on disease progression. Therefore, symptom amelioration and 
functional improvement according to the disease-stage are affirmative though flexible 
patient specific end points.  
Furthermore, for diabetes the end points will have to be patient specific according to 
the age and stage at which the disease is diagnosed. Also, due consideration will have 
to be given to any complications which have set in affecting any of the organ systems 
in the course of the disease. 
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Human trials must necessarily furnish the information to unravel the complex biology 
and other clinical factors that can not be sufficiently replicated in experimental model 
organisms.  
 
2.4 Dynamics of Regenerative Medicine industry 
Since its inception, the RM domain has encountered changes in business conditions. 
This requires agile flexibility to reconfigure scientific, business and financing 
strategies. Consequently, businesses have used different approaches to secure 
investments and strategic alliances to fulfil the long-term goal of building a 
mechanism for sales and profits. As well as demonstrating the clinical value, safety 
and efficacy of RM based therapies to the clinician, the patient and the regulator, 
businesses need to establish methods to repeatably realise these therapies at an 
acceptable cost. Acceptable cost forms a key part of the case for potential 
stakeholders; repeatability of process is a key requirement of the regulator.  
 
2.4.1 Commercial Activity in the RM domain 
The pharmaceutical and biotechnology industry has initiated a pragmatic but cautious 
approach towards stem cell based therapies. The pharmaceutical industry sees stem 
cells as useful tools for drug discovery as they can be used as an in vitro model 
system, for instance in toxicity testing, thereby assisting effective translation of 
experimental small molecules into clinical drugs (Harding, Ali et al. 2007; Reppel, 
Igelmund et al. 2007). RM firms on the other hand are combining both clinical and, 
less strictly regulated, aesthetic medicine products in their portfolio (Mason and 
Manzotti 2009). 
However, exploitation of stem cell therapies will challenge a pharmaceutically 
focussed business model, because they will for sure, initially in autologous 
approaches, require individual customized treatments with case by case understanding 
of individual disease pathology. The notion that stem cell science could produce a 
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variety of customized treatments tailored to individual patient needs is paving the path 
for various stem cell start up companies and spin outs from academic institutions and 
opportunities for the acquisition of academic intellectual property. Collaboration with 
academic research teams gives business a blend of applied and blue sky research. The 
dependence on quality academic research for the conception of commercially viable 
spin outs will assist in bridging the gap between bench-top science and the patient bed 
side.  
RM businesses have employed different business models to build value. In the initial 
stages these businesses typically have limited resources and therefore have to 
ascertain how they can best develop their science and intellectual property assets in 
order to provide the best opportunity for business success. Further, due to the 
heterogeneous nature of the overall domain, the business models employed have 
become more complex and therefore, more uncertain. Likely candidate business 
models at present either provide a service to individual patients, or businesses are 
identifying specific patient populations and working on a therapeutic around the 
specified populations (Plagnol, Rowley et al. 2009). There are various risks and 
market challenges due to the level of scientific innovation and business uncertainties 
associated with emerging RM based therapeutics. The initial risk involved can be 
compensated if a marketable product is formulated successfully to give a good 
financial return, and lessons are learned from some of the early business failures.  
 
2.4.2 Challenges in RM domain 
Recently there has been a step in the pace of growth of spin outs, these firms are 
becoming a part of the high technology medical device manufacturing industry 
(Lysaght and Hazlehurst 2003; Shastri 2006). Much of the onus for growth of this 
industry lies in the hands of the entrepreneurial academics with the energy to kick off 
new companies (Lysaght and Reyes 2001). University commercialisation activities 
are nurturing entrepreneurial activity in this promising area of science. However, 
there are many challenges in front of these start-up businesses including cost control, 
scaling up of usually a laboratory level manufacturing process and preservation and 
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transport of live-cell products so they can be available “off-the-shelf”. Legal and 
ethical issues are legion. To overcome these challenges the academic research 
community, commercial sector and government will have to work together to 
transform the promise of the laboratory bench-work into commercially viable medical 
products. 
Realising this revolutionary impact on conventional therapeutics will also require 
continued basic and applied academic research. Well controlled differentiation is the 
primary prerequisite for producing specific cell types capable of use in any kind of 
therapeutic strategy. This progressive increase in the understanding of stem cell 
differentiation mechanisms to clinically relevant types and numbers is essential to 
facilitate the development of this innovative and modern industry (Kemp 2006; 
Shastri 2006).  
Demonstrating the application of designed experiments to establish process conditions 
and optimisation protocols for the volume processing of human mesenchymal, 
progenitor or embryonic stem cell populations will be significant in initial proof of 
concept studies, and later at pilot and trial scales to be ultimately manufactured for 
therapeutic use at commercial scale (Archer and Williams 2005; Thomas, Chandra et 
al. 2007). Process design and continuous improvement techniques as part of the 
overall translation process will have to be applied to give scalable, well characterised 
stable bioprocess output and improve the resource effectiveness in the compliant 
manufacture of cell populations. 
Further to exploit the underlying science and execute the corresponding business 
model successfully in RM, sizeable financing is necessary because of the large 
amount of capital and time required for a relatively high-risk opportunity at building a 
profitable company and obtaining a financial return.  
 
2.4.3 Discussion 
Stem cell research is still in its relatively early days and many challenges remain to be 
surmounted. In spite of their unmatched capability to address several unmet medical 
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conditions, practical, legal and ethical issues are constraining the current development 
of stem cell based therapies. The legal and ethical issues centre on the source of stem 
cells whereas practical difficulties revolve primarily around process development and 
business issues. It is not within the scope of this thesis to address the legal and ethical 
issues; therefore this research will focus on the practical aspects concerned with 
commercialisation of the overall translation process. Systematic, robust and efficient 
processing and characterisation methods to assert the final product are at the core of 
the process development. Platforms and more effective standard protocols for cell 
cultivation and expansion in culture and the genetic alteration of cells, if required, will 
make significant contributions in establishing the conditions for application of stem 
cells as cell therapies, in RM and in the development of new drugs (Archer and 
Williams 2005; Williams 2006). The remaining principal challenge is to successfully 
navigate the business issues and, ultimately introduce commercially feasible RM 
products in the market.  
Chapter three presents these challenges as the commercial exploitation of new therapy 
platforms holds many scientific, technological and business issues for the science 
based businesses that are generating them. The chapter takes a case exemplar, of 
hearing loss, and places the issues under scientific, translational and commercial 
headings. Identification and resolution of these issues is important as the current pace 
of stem cell research is creating a platform for their use in an array of applications 
spanning cell therapy based RM to drug discovery and toxicology. Therefore, 
bringing forth these challenges in front of developers and businesses will assist them 
in making well informed decisions at important time points. 
 
2.5 A Research Gap 
The literature review reveals that the overall RM industry is fraught with challenges 
and risks. The highly regulated environment, complicated science, long and expensive 
product development and uncertain business models are some of the factors that 
contribute to the challenges of the RM domain. The businesses that contribute to 
addressing unmet clinical needs will thrive, which emphasises that the final 
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application(s) of a product is central to the survival and success of a RM business. 
Investors are constantly looking at the product pipeline of companies as an indication 
of its potential returns (Ahn and Meeks 2008). Consequently, companies are under 
tremendous pressure to push products down the development pipeline. The translation 
of RM products is a bridge for products to move from bench to market. Development 
of these products is complex and production demands, especially in the early stages, 
are intense both investment and technology-wise (Pisano 1997). Despite the 
expensive and risky nature of the RM business, it holds the potential to offer 
tremendous returns for companies, if ultimately successful. In short, the driver of both 
opportunity and risk in RM businesses is translation of bench side science into 
commercially profitable applications. 
The review acknowledges that companies need to address unmet clinical needs and 
provide new and better products which will improve and sustain their competitive 
position. It has shown that there are multiple scientific strategies in different disease 
application areas with as yet, in many cases, no clear front runner for a therapy. 
Necessarily, further preclinical and clinical trials with well defined and clinically 
recognised end points that take account of other components of disease will be 
required to resolve this. Further, this demands constant refinement of the underlying 
technology and careful navigation through the key RM specific business parameters 
to fit a given firm’s strategic context. Successful innovation requires a definitive 
translational route that balances the requirements of the new product and its 
manufacturing processes, the market needs, and the need to maintain a robust business 
model that can continue to support all these activities effectively. However, the ways 
in which companies in the RM domain might do that are not addressed in the current 
literature. The approaches to the translation process are complex and the requirements 
for success vary greatly from case to case. Thus, an understanding of the nature and 
characteristics of translational requirements in RM in the context of the business 
strategies employed is needed. 
The following knowledge gap is identified from the literature survey: an 
understanding of how firms can structure their technical, business and financing 
strategies so that they can realise the benefits of scientific innovation and yet still 
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operate within the context of the employed economic model. Bringing together 
perspectives from theory, a research question is defined to address a practice-driven 
knowledge gap. 
 
2.5.1 Research Questions and Objectives 
Having identified a research gap, a research question is defined as follows: 
“What are the mechanisms required to enable translation of emerging scientific 
knowledge into commercially viable clinical RM products?” 
To tackle the research question above, a list of sub-questions is also defined as 
follows: 
 What are the key scientific, translational and commercialisation challenges 
facing successful realisation of RM products? 
 What are the principal indicators effecting commercialisation of RM and how 
can they be considered in an integrated manner? 
 How can economic assessment of potential technologies help RM businesses? 
Consistent with the research questions, the following are the objectives of this 
research: 
To understand RM industry emergence and the underlying challenges facing 
successful realisation of RM products. 
To characterise the industry investment readiness process by taking into account 
key enabling indicators that assist new therapies to be first taken into clinical markets. 
To understand mechanisms for economic assessment of a potential RM technology 
within the wider business context. 
The research question is formulated to tackle the fundamental knowledge gap that 
needs to be addressed. How can the emerging RM science be transformed into a 
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successful business? What are the key indicators to maximise returns on investment 
within the RM domain? It may be that, for a successful RM venture, emerging and 
established science is the most important underlying parameter. However, formulation 
of a business strategy by which the science can be translated into profitable 
commercial practice to generate cost-effective therapies is equally important. This can 
be undertaken by assessing underlying economics and investment readiness together 
with the regulatory and reimbursement strategies of the overall business. 
 
2.6 Conclusion 
This chapter outlines the core literature that is relevant to the research. The literature 
selection was guided by an initial research agenda which emerged from exploratory 
work. The approach taken in this chapter is to highlight the relevant theoretical 
clinical and business perspectives that shaped the process of narrowing down the 
research agenda to a defined research gap. The three areas of literature reviewed and 
discussed in this chapter are: the nature and characteristics of the RM domain, key 
disease application areas for RM, and dynamics of the RM domain. 
Commercialisation strategies are critical in the overall translation of RM products. 
Despite its importance, there is an inadequate understanding of how 
commercialisation capability is linked to overall translation in the RM domain. 
Furthermore, existing literature has a number of weaknesses; for example, there is 
lack of research in understanding how commercialisation activities in the RM domain 
could be approached at both scientific and product development levels, how 
companies could benefit from initial economic assessments before embarking on 
developing a particular technology to meet their development and business goals, and 
how business models could be best designed to enhance value capture especially in 
the area of gaining investment, and public policy i.e. regulation and reimbursement. 
This chapter concludes by synthesising the current perspectives in the literature and 
the need for knowledge in practice as outlined in the Chapter one. Following that, a 
research gap was identified and the corresponding research question together with 
sub-questions defined to address the knowledge gap in both theory and practice. 
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3 CHALLENGES FACING REGENERATIVE MEDICINE 
BASED PRODUCTS 
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3.1 Introduction 
In contrast to conventional pharmaceuticals, live cell based therapies have unique, 
dynamic and extensive pharmacological characteristics. They can affect the target 
tissue with mechanisms ranging from delivery of therapeutic factors to trans-
differentiation to the native cell population. Their mechanism of action is not yet fully 
clear as for instance they can deliver a number of bioactive molecules in not readily 
predictable quantities along with varying in vivo effects (Caplan 2007). Also, their 
manufacture and supply requires distinctive bioprocesses from cell harvesting, 
processing, storage, transport to ultimate implantation (Mason and Hoare 2007). 
Determining which of these cellular products can be delivered to the clinic in a 
commercially viable manner remains problematic (Singh and Williams 2008). 
Therefore, a range of challenges must be addressed (Baker 2005) before such cellular 
products become reality. Their target or disease specific composition, mechanism of 
action, pharmacokinetics and pharmacodynamics, toxicity and efficacy assessment 
represent scientific challenges that must be resolved in the context of product 
complexity and the regulatory environment, as such multiple challenges have not been 
faced by medicine in the past. A pressing requirement for the routine use of cell 
therapies in the clinic is the development of product quality controls for safety and 
efficacy based on clinically relevant potency assays, with ultimate validation in 
phased human clinical trials (Giordano, Galderisi et al. 2007).  
This chapter will focus on steps for resolution of these issues of potential cellular 
products taking the case example of sensori-neural hearing loss (SNHL) (Kozak and 
Grundfast 2009). A cellular product for SNHL is used as an exemplar to explore 
challenges facing the application of this high risk and ultimately high return RM 
based technology in the clinic. Both SNHL specific issues and those that can be 
extrapolated to other generic cell-based approaches are discussed.  
The chapter in section 3.2 introduces the systematic review methodology undertaken 
in this chapter to organize, evaluate and integrate the research evidence in the 
following sections from the medical and health care literature. Section 3.4 presents the 
disease, SNHL, along with its background, epidemiology, cell therapeutic rationale 
and approach. This section ends with a description of the present incumbent 
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technologies used in the treatment of SNHL, together with their market structure and 
size. Section 3.5 presents generic factors affecting willingness to pay for a novel cell 
therapeutic. Sections 3.6 to 3.8 identify and discuss the challenges involved in 
realising the commercial potential of a cell based therapeutic for hearing loss under 
scientific, translational and commercial headings. Section 3.9 presents how a cellular 
therapeutic for SNHL can integrate within the Porter care delivery value chain for a 
therapy. Section 3.10 discusses the overall findings and defines an initial practice-
driven research agenda which is discussed in section 3.11 before concluding in 
section 3.12. 
 
3.2 Methodology 
This section reports the method employed to gain insights from the literature studied. 
The objective was to understand the key challenges facing commercialisation of RM 
based cellular therapies in the context of the research question defined in chapter two. 
A systematic review of literature is considered the least biased, and most rational 
fundamental scientific activity to organize, evaluate and integrate research evidence 
from amongst the expanding medical and health care literature (Needleman 2002). 
Being a formulized and thorough method of investigation, it assists in integrating 
valid information to provide a basis for rational decision making. It also improves the 
reliability and accuracy of recommendations (Needleman 2002). The basic 
components of a systematic review are shown in Table 3-1. This chapter presents a 
qualitative systematic review which adheres to the standards for gathering, analyzing 
and reporting evidence. These are discussed more fully later in the section. 
This systematic review served the following purposes: 
 It reduced a large amount of information to a manageable size in order to 
identify different challenges associated with commercialising a novel cellular 
therapeutic, in particular for SNHL. 
 It helped in determining the consistency of challenges quoted in different 
publications to further extrapolate the key issues for SNHL. 
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 It enabled the combination of information from individual publications with a 
broader perspective in comparison to a single analysis before refining the 
research question and objectives of this thesis, as identified in Chapter two. 
 
Components Systematic reviews 
Formulation of the 
question 
Address key challenges facing translation of cellular 
products 
Methods section Defined pre-stated criteria about publications 
included  
Search strategy to identify 
studies 
Search strategy was exhaustive, reproducible and less 
prone to selective citation as multiple databases used 
Quality assessment of 
identified studies 
Only publications using pre-stated criteria included 
Data extraction & 
synthesis 
Titles and abstracts of studies were independently 
assessed and full text versions were obtained for 
assessment 
Heterogeneity Pre-stated inclusion criteria to reduce heterogeneity 
Interpreting results No bias or personal opinion, as a formulised and 
thorough method of investigation followed 
 
Table 3-1 - Components of the systematic review undertaken 
 
3.2.1 Search Strategy 
Electronic database searches formed the basis of the literature search and therefore, 
the following databases were searched with appropriate keywords and their 
combinations as enlisted in Table 3-2 
 Pubmed 
 Medline 
 Science direct 
 ISI web of science 
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 Cochrane library 
 ISI Science Citation Index 
The results of electronic literature searches were collected and duplicates were 
deleted. Thereafter references were selected on the basis of title and abstract for 
potential inclusion, following which a search was carried out to identify authors who 
were cited two or more times from the retained references. An electronic author 
search was then run on the databases to extract any further applicable studies by these 
authors. The reference lists of all included publications were scanned during data 
abstraction for any additional papers meeting the inclusion criteria. 
 
Regenerative Medicine Scientific challenges 
Cell Therapies Translational challenges 
 Commercial challenges 
  
SNHL Epidemiology 
 Etiology 
 Therapeutics 
 Stem Cells 
 Clinical effect of cell based therapies 
 
Table 3-2 - Keywords used during the systematic review process (Words in 
column one were searched singularly and in combination with corresponding 
words in column two) 
 
Initially over 500 electronic abstracts and book
 
titles were scanned, out of which 75 
full-text books or papers were selected for further
 
analysis. After appraising all these 
for quality and relevance, 55 (of which 41 were empirical studies and 14 were 
narrative reviews) have been cited in this chapter. The titles and the abstracts of 
studies identified by the search strategy were individually assessed and full text 
versions were obtained for assessment.  
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A standard method of gathering, analyzing and reporting evidence has been employed 
for conducting this qualitative review to compare the conceptual and theoretical 
approaches for synthesising empirical evidence towards the overall research objective. 
 
3.2.2 Inclusion and exclusion criteria for publications 
Publications were included if they fell under the specific section headings or 
identified key challenges facing commercialisation of RM, in particular directed 
towards hearing loss. Generic translation reviews and studies were integrated 
provided relevant issues were discussed and inferences of value could be drawn with 
respect to cell-based hearing therapies. Generic reviews focussing on scientific and 
commercial issues facing RM were also included to enable identification of 
challenges which might relate to hearing loss at present or in the future as therapies 
get closer to reality. 
 
3.2.3 Quality assessment 
Only publications using the above criteria in section 3.2.2 were included, 
consequently contributing to enhancing understanding of key challenges facing 
translation of cellular products. 
 
3.2.4 Data extraction 
Excerpts were extracted from the publications regarding the different challenges 
facing RM, particularly issues relevant to translation of therapies. The challenges 
were categorised into scientific, translational and commercial headings.  
 
3.3 Hearing Loss 
Hearing loss (HL) is full or partial diminution in the ability to perceive or understand 
sound. It is a clinically heterogeneous disorder, with variations in etiology, age of 
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onset, severity of the disease and site of lesion (Nadol 1993). HL can be categorized 
into three basic types according to the site of auditory system damaged: conductive 
hearing loss (CHL), sensory neural hearing loss (SNHL) and mixed hearing loss. CHL 
occurs when sound is not conducted efficiently through the external auditory canal to 
the tympanic membrane and ossicles of the middle ear. It is generally secondary to 
lesions in this pathway from external auditory meatus to the middle ear. SNHL 
develops due to loss of cochlear hair cells or their associated neurons. Lost hair cells 
are neither replaced by cell division nor regeneration from endogenous cells present in 
the inner ear epithelium, rendering SNHL an irreversible condition. There is little 
mortality risk factor associated with SNHL, a non-fatal disease, but there is a very 
high disability factor (Culbertson and Gilbert 1986; Bess, Dodd-Murphy et al. 1998), 
which makes this disorder a good potential candidate for a novel RM based 
therapeutic modality. 
 
3.4 Sensori-neural Hearing Loss  
3.4.1 Background 
SNHL cannot be compensated by endogenous repair mechanisms and may eventually 
lead to permanent deafness. It is an increasingly significant health problem with wide 
psychosocial (Gilhome Herbst, Meredith et al. 1990) and economic (Schroeder, 
Petrou et al. 2006; Kotby, Tawfik et al. 2008) implications. Current technology based 
treatment regimes neither replicate the complex native biological system nor furnish a 
full, permanent solution (Kelsay and Tyler 1996; Counter 2008). This opportunity has 
driven the development of potential cell therapies with the promise to replace 
degenerated inner hair cells in SNHL and ultimately reverse the natural progression of 
the disease (Dazert, Aletsee et al. 2003).  
In the early 90’s it was demonstrated by research groups that the avian cochlear hair 
cells, receptors for auditory perception, undergo structural and functional regeneration 
following noise induced damage or amino glycoside treatment (Cotanche, Lee et al. 
1994; Cotanche 1999). Such events lead to apoptosis of the hair cells, loss of cochlear 
ganglion cells and structural damage to the tectorial membrane thereby disrupting 
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normal auditory input. The dying hair cells induce the neighbouring supporting cells 
to undergo regeneration to substitute the lost hair cells in the avian model either by 
their direct trans-differentiation or mitotic proliferation. Concurrently, some of the 
supporting cells synthesise new tectorial membrane and the peripheral cochlear nerve 
processes detach from the basal surfaces of the dying hair cells awaiting the 
differentiation of new hair cells to reinstate synaptic contacts (Stone and Rubel 2000; 
Stone and Cotanche 2007). Further, recent studies have identified stem cells in the 
inner ear of mice. They have demonstrated cell survival and differentiation, and also 
shown positive expression of characteristic markers when exogenous stem cells were 
transplanted in experimental animal models (Li, Liu et al. 2003; Li, Roblin et al. 
2003). Although mammalian cochlear hair cells undergo apoptosis in response to 
ageing, noise damage and/or ototoxic medication, the supporting cells do not possess 
the ability to undergo regeneration, unlike the avian model. Such permanent loss of 
hair cells extends to variable level of spiral ganglion cell loss, which can also impact 
the success of therapeutic electronic devices such as cochlear implants. 
As the regenerative biology of the auditory system is being unfolded, the time is ripe 
to be attentive to the problems of repeatably realising therapeutic cell populations 
under robust bioprocesses which can be ultimately employed under good 
manufacturing practice (GMP) compliant conditions suitable for cost effective mass 
treatment (Archer and Williams 2005). This together with a suitable delivery 
technique (Swan, Mescher et al. 2008) to implant the cells in the inner ear is a key 
step in translating this promising therapy into the clinic and subsequently to the 
broader patient population. In parallel with such work in fundamental and applied 
science there is also a requirement to create in a timely way the enabling clinical and 
necessarily, commercial infrastructure that will further allow the realisation of these 
therapies (Pangarkar and Hutmacher 2003). Establishing viable business models for 
the components of this infrastructure will be another major challenge (Pangarkar and 
Hutmacher 2003). 
Therefore, building upon the current developments in stem cell research for SNHL, 
this chapter attempts to capture the most significant challenges that must be addressed 
to deliver a cost effective clinical treatment regime. While the challenges are 
presented under scientific, technological & commercial headings they must be 
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examined concurrently. Individual problems with their solutions are integrated to 
reveal how these challenges can be met to allow the realisation of such a therapy. 
 
3.4.2 Epidemiology 
Hearing impairment is the most common chronic disabling sensory disorder in 
humans (Davis 1990). Severe to profound HL affects 1 in 1000 newborns, another 17 
in 1000 children before they reach adulthood, and 50% of people older than 75 years 
will manifest a HL of at least 25 decibels (dB) (Abutan, Hoes et al. 1993; Factsheet 
2007). Due to increased life expectancy and the resultant increment in ageing 
population, the prevalence of acquired hearing loss is rising. Hearing impairment, 
both acquired and congenital, in most cases is a direct consequence of loss and/or 
damage to cochlear hair-cells or their connected neurons. SNHL, which affects the 
inner hair cells and the sensory epithelia in the organ of Corti of the inner ear, is the 
most common form of HL. Approximately 60% of HL has a genetic basis and a 
substantial proportion of it is non-syndromic, the majority of which is inherited in an 
autosomal recessive mode (Schrijver 2004; Schrijver and Gardner 2006). 
 
3.4.3 Approach 
All hearing sensation is derived from the output of a surprisingly small number of 
sensory cells - fewer than 15,000 per inner ear. SNHL is mainly attributed to the loss 
of these cells; therefore, a biological approach encompassing replacement of damaged 
cells by a functioning cell population holds tremendous potential. Hence, the premise 
of a cell based therapy will be to replace the dead or diseased cells, both hair cells and 
their supporting cells, with a functioning cell type which would integrate into the 
damaged auditory epithelium to re-establish the neuronal pathways and restore 
hearing. The potential of this approach is reinforced by the progress accomplished in 
the repair of nervous and visual sensory systems by the restoration of diseased cells 
(Iguchi, Nakagawa et al. 2003; Tateya, Nakagawa et al. 2003; Limb, Daniels et al. 
2006).  
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3.4.4 Rationale 
The recent detection of progenitor cells in the mammalian adult inner ear having the 
capacity to differentiate into hair cells as well as the finding that murine embryonic 
(Li, Roblin et al. 2003), adult inner-ear (Li, Liu et al. 2003) and neural stem cells 
(Tateya, Nakagawa et al. 2003) can be differentiated into hair cells further 
consolidates the potential of such a therapy. The inner-ear progenitors generated from 
murine embryonic stem cells express hair cell specific genetic makers and on further 
differentiation, the cells express characteristic transcription regulators involved in the 
generation and maturation of hair cells, Math1 and Brn3.1, along with structural hair 
cell proteins, myosin VIIA, parvalbumin 3 and espin, thereby demonstrating hair cell 
phenotype. Further, the genetically labelled selectively enriched murine inner ear 
progenitors express hair-cell specific markers in the developing sensory epithelium of 
the otic vesicle when grafted into the inner ear of chick embryos (Li, Roblin et al. 
2003). This establishes that the murine progenitor cell derivatives respond to local 
cues that ensure avian hair cell growth and differentiation. Also, a number of cell 
therapy studies have successfully demonstrated delivery and survival of cells in the 
damaged inner ear. These transplanted cells preserved existing hearing function by 
replacing primarily degenerated/lost sensory hair cells, and spiral ganglion cells (Ito, 
Kojima et al. 2001; Sakamoto, Nakagawa et al. 2004; Corrales, Pan et al. 2006). 
 
3.4.5 The Incumbent Technologies 
3.4.5.1 Hearing aid 
The hearing aid is an electro-acoustic device. A microphone converts the external 
acoustic signals into electrical energy which is received by an amplifier to increase its 
amplitude and then transmits to the receiver. The receiver converts the modified 
electrical signal back into acoustic signal that is directed towards the inner ear. The 
hearing aid industry currently turns over USD 8 billion, with the unit cost of a device 
ranging from USD 1500 – 8000 with additional fees for professional services, testing, 
and fitting (Vio and Holme 2005). Globally, most of these devices are not covered by 
private and government health insurance and only certain hearing tests and services 
are covered under Medicare, a U.S. federal government program of health assistance 
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for people aged 65 and older in the United States. Some reimbursement is available in 
Europe in the public medical service sector, though accompanied with long waiting 
lists. Likewise, in Japan, hearing impaired people may receive public support for the 
purchase of hearing aids through the local welfare office on a special handicap 
identity card. In spite of the substantial scale of the industry and user base, there is 
low compliance amongst users as only one in five patients who needs a hearing aid, 
actually uses one (Meister, Walger et al. 2008).  
 
3.4.5.2 Cochlear Implant 
The cochlear implant industry is worth USD 410 million at present with average 
single procedure cost, including evaluation, surgery, device and rehabilitation, 
standing at approximately USD 40,000 (Vio and Holme 2005). Though the procedure 
is reimbursable, it requires patient adaptation time of between 18-24 months as the 
implants restore hearing by a non-biological mechanism. This further deters the 
patients from undergoing the procedure (Copeland and Pillsbury 2004). The implant 
is surgically embedded and provides a sense of sound, picked up by a microphone, by 
stimulating the nerve fibres in the scala tympani (Connell and Balkany 2006). The 
receiver and stimulator secured in bone beneath the skin convert the sound signals 
received through the speech processor into electric impulses. These impulses are 
relayed through an internal wire to multiple electrodes which send the impulses to 
nerve fibres in the scala tympani (Klinke and Hartmann 1997). The signals are then 
directed to the brain through the auditory nerve system. Rehabilitative therapy post-
implantation is vital to ensure success (Fu, Galvin et al. 2004). Further, patient 
variables for instance hearing history, age of onset, age at implantation, linguistic 
abilities, and availability of oral language development support impact the overall 
benefit provided by these implants (Niparko and Blankenhorn 2003). 
 
3.5 Willingness to pay for a novel therapeutic 
The low compliance associated with electronic devices does not discourage their huge 
market, which suggests a novel cell based therapy as a therapeutic addition or 
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substitution is likely to have a place as a therapy. To secure a place as part of routine 
healthcare therapeutics, an unencumbered reimbursement plan for cellular products 
may help and guarantee product income and adoption by patients and clinicians. Cost 
effectiveness remains a critical factor along with appropriate medical evidence. For 
this, the willingness to pay (WTP) measure will give a fair idea of the patient base and 
the gatekeepers involved in adoption of a cellular product for treating hearing loss, in 
comparison to the incumbent (Figure 3-1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-Fig 1: Factors effecting Willingness to Pay for a new Hearing 
Therapy- 
 
 
1. Key Challenges 
 
 
 
Figure 3-1- Willingness to Pay for a new Hearing Therapy 
 
WTP is necessary to estimate demand for such a cellular product in terms of its 
market potential and the related cost-benefit analysis. As it is the maximum amount of 
money that may be contributed by an individual and/or a payer to adopt a therapeutic 
change, they must be able to identify the associated benefits. This would be 
established by going through the background information available, clinical trial data 
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and the comparative efficacy of incumbent technologies. Approval by regulators and 
adoption by gatekeepers will add to the confidence and thereby increase the 
associated WTP. On the other hand for patients with relevant past medical history of 
risk factors for developing SNHL together with positive screening/diagnostic tests 
will encourage patients to undergo the procedure. Due to the socioeconomic impact of 
SNHL on patients, if the therapy delivers cost-effective quality adjusted life years 
(QALYs) with a robust reimbursement procedure in place, it would not only be 
beneficial to patients but also economically efficient. 
In the United States alone, the individual lifetime costs for severe to profound hearing 
loss are approximately USD 297,000 and in adults aged more than 60 years the 
corresponding figures were approximated to be on average USD 43,000 (Mohr, 
Feldman et al. 2000). A major proportion of these losses are due to decreased 
productivity at work and requirement of additional special education resources, 
mainly amongst children. Further, lifetime costs for those with pre-lingual onset 
exceed a million US dollars (Downs 1995). Disability levels amongst hearing 
impaired patients vary widely, and the patients suitable for a cell therapy will be 
younger than average and will have a better quality of life post treatment. Therefore, 
restoration of hearing loss and its removal of resulting disabling conditions through 
development of improved treatment methods must remain a priority. 
 
3.6 Scientific Challenges 
Current research has established differentiation of stem cell populations towards inner 
hair cell lineage using otic inducers and environmental cues that reflect the aboriginal 
hair cell development pathway. These cell populations are capable of replacing 
diseased cells (Li, Liu et al. 2003). Therefore, to transform a progenitor cell 
population into a viable replacement cellular product, it is imperative that the 
progenitor cell expansion and differentiation processes are robust and reproducible 
without batch to batch variation (Phinney 2002) and yield a clinically relevant number 
of (Caplan and Bruder 2001) functional and genetically stable inner ear hair cells 
(Figure 3-2). 
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3.6.1 Cell sourcing, differentiation and characterisation 
Currently there is no well defined or preferred cell source and differentiation protocol 
to facilitate the development of an appropriate cell based therapy for SNHL (Dazert, 
Aletsee et al. 2003). Lack of definitive criteria for the measurement of functional 
performance and appropriate cell sources that can be differentiated and expanded to 
clinically relevant numbers expressing validated biological markers (Boyle, Schulman 
et al. 2006; Smart and Riley 2008) are the initial hurdles to be crossed before 
realisation of a classic cell based therapy for hearing loss. Further, integration and 
engraftment of the grafted cells post transplantation at the native site without 
immunological rejection (Boyle, Schulman et al. 2006) has to be taken into account.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cell culture and population expansion are critical steps of bio-processing required to 
generate sufficient cells for the therapy. Continued and sequential passaging can have 
detrimental effects on cells including loss of “stemness” which is dependent on cell 
 
 
Figure 3-2- Scientific challenges for a new cell based hearing therapy 
 
•Isolation, expansion & controlled differentiation of 
applicable progenitor cell types
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culture platform
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processing
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Functional 
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source, culture duration, and culture and differentiation processes (Hayflick and 
Moorhead 1961; Cristofalo and Pignolo 1993; Douay 2001) and the number of cells 
ultimately required for a therapeutic intervention. Therefore, it will be necessary to 
design capable processes producing stable cell populations thereby resulting in 
improved survival and function of cells both in vitro and in vivo (Joannides, Fiore-
Heriche et al. 2006). In this direction, automation of the cell culture process can 
improve process capability by removing the operator and reducing or eliminating 
other sources of variation and further allowing scale up and/or out (Thomas, 
Anderson et al. 2008). This will be instrumental in providing a surrogate population 
capable of taking over the function of resident degenerated/diseased inner hair cells. 
Directing the efforts towards such systems is a significant step; however, a prior 
crucial step is to distinguish and delineate cytokine and growth factor 
supplementation strategies, to encourage development of consistent and stable inner 
ear hair cell populations at laboratory bench scale. Further, electrophysiological 
profiling of differentiated cells will assist fundamental understanding of function 
(Sundelacruz, Levin et al. 2008), their characterisation and differentiation process 
validation.  
 
3.6.2 Cell Delivery 
Another challenge relates to the petite space in the scala media (the whole cochlea is 
35 mm long spiralled about 2.7 times upon itself) where the cells have to be 
transplanted. It requires development of novel surgical delivery techniques before 
such a therapy can be translated from a promising experimental modality to clinical 
reality (Douglas, Corlette et al. ; Coleman, Hardman et al. 2006). A minimally 
invasive transplantation procedure to access inner ear necessitates direct 
microsurgical access to deliver cell populations (Backhouse, Coleman et al. 2008). 
The efficacy of such a delivery technique depends upon the adequate engraftment, 
survival and functioning of the applied cells at the target site. This is controlled by the 
molecular mechanisms involved in their homing and the balance between mass 
transfer and metabolic demand at the graft site (Swan, Mescher et al. 2008). This 
means that molecular and genetic strategies together with precise cell delivery tools 
have to be devised to enhance engraftment. Direct delivery to the inner ear via the 
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endolymphatic sac, the non-sensory component of the endolymph filled membranous 
labyrinth, has significant potential therapeutic advantage due to the presence of 
blood–labyrinth barrier which is anatomically and functionally similar to the blood–
brain barrier (Salt and Plontke 2005; Plontke, Siedow et al. 2007). Here the 
transplanted cells will have ready access to the target tissue in the inner ear (the hair 
cells) and their synaptic regions, but will be prevented from migrating to other areas. 
Also, no variation in pressure has been noted between the endolymph and perilymph 
after injection of up to 2 µl of artificial endolymph as evidenced by mechanical 
compliance examination of the endolymphatic compartments (Takeuchi, Takeda et al. 
1991). In fact, a 0.5 µL of cell injection in the scala media depicted no significant 
morphological damage (Kakigi and Takeda 1998). 
 
3.6.3 Measuring efficacy 
Such a therapy must also necessarily be evaluated by comparison with the incumbent 
treatment regimes and standard of care available. In terms of SNHL, there is a 
possibility that the terminal therapeutic strategy might be a combination product of 
cell and gene therapy coupled with a pharmaceutic and/or an electronic device 
depending upon the efficacy of individual regimes. Therefore, logical and statistically 
significant animal and clinical studies with valid endpoints replicating the clinical 
problem and demonstrating efficacy and cost effectiveness with respect to the 
incumbent technologies need to be detailed. Also, data from such trials has to be 
carefully interpreted by using clinically valid assessment criteria in the form of 
audiometric testing to reflect individual patient needs and applying cell types with a 
defined dose and delivery method. 
 
3.6.4 Cell Imaging 
Direct assessment of cell engraftment, survival and integration into the host ear 
requires precise and specific non invasive imaging techniques (Ahrens, Flores et al. 
2005) with high spatial resolution to establish whether cells engraft (Srinivas, Morel 
et al. 2007) at their target. Such imaging tools will allow improvement of implantation 
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techniques as well as assessment of the patient (follow up) to determine both cellular 
viability and function with time (Baumjohann and Lutz 2006; Walczak and Bulte 
2007). Nuclear imaging techniques, such as direct cellular radio-labelling (PET and 
SPECT) and reporter genes, give high sensitivity with quantification and visualisation 
of cellular function at particular locations. Magnetic resonance imaging gives good 
spatial resolution, and optical techniques allow tracking of cells (de Vries, Lesterhuis 
et al. 2005; Gebel 2006). Therefore, the ultimate objective of complete functional 
monitoring of the repair process will require a combinatorial approach with multiple 
imaging modalities and output integration to monitor inner ear hair cell engraftment. 
 
3.7 Translational Challenges 
The transition of proof of concept studies for cellular products derived from insights 
in the laboratory to enabling technologies for scale up and/or out is a complex issue. 
These include characteristic biomarker validation for stability and potency, design of 
phased clinical trials for safety and efficacy, release tests of the final formulation for 
adequacy, decision algorithms for clinical assessment and multivariate statistical 
analysis for functional assays, and cellular profiling to ultimately produce pure, safe 
and efficacious high volume clinical products that satisfy the regulatory framework. 
 
3.7.1 Cell Processing 
A cell based therapy for SNHL may offer a one off physiologically complementary 
therapeutic intervention. To achieve such a cellular product requires the solution of 
the underlying translational challenges. It is frequently argued in biopharmaceuticals 
that the “product is the process” (Mason and Hoare 2007). Therefore, a generic 
fundamental challenge is to create an enabling process technology which in this case 
would be a capable cGMP compliant production unit to prepare a consistent stable 
cell population that meets regulatory requirements at an economically viable scale 
along with requisite validation (Burger 2000).  
Automated cell culture and population expansion is fundamental for the transition 
from mainly laboratory-centred, labour intensive manual processes that require highly 
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skilled personnel to perform meticulous aseptic manipulations over many days or 
even weeks (Thomas, Chandra et al. 2007). For most therapeutic applications, these 
manual processes lack the standardisation and reproducibility required for scaled, 
robust and cost effective commercial and regulatory compliant production (Mason 
and Hoare 2007). By eliminating the manual operator associated variability 
automation improves the reproducibility of process steps (Kempner and Felder 2002) 
and will consistently follow GMP processes (Gastens, Goltry et al. 2007; Thomson 
2007). It gives cost-effective scalability of cellular product manufacture with minimal 
time constraints and does not require training with operator turnover (Kempner and 
Felder 2002; Terstegge, Laufenberg et al. 2007). Although cost prohibitive for most 
start-up or small SMEs, in the long run some form of automated cell processing 
platform is likely to form the core of a cell therapeutic production system. Latest 
developments in robot platforms and sensor technology are now making it possible to 
automate production processes for scale-up/-out to expand cell populations 
reproducibly and on a scale suitable with autologous or allogeneic therapies (Kino-
Oka, Ogawa et al. 2005; Joannides, Fiore-Heriche et al. 2006; Terstegge, Laufenberg 
et al. 2007; Thomas, Chandra et al. 2007). With such technology platforms emerging, 
establishing their match with particular therapeutic requirements and cost-effective 
business models is important. 
 
3.7.2 Process Design and Improvement 
With growing expectations from regulatory agencies, better process understanding 
and control are likely to be key drivers in the manufacture of these cellular products. 
This will help in minimising product quality variation, non-conformance and prevent 
delays in product approval. Product quality and performance will be achieved and 
assured by the translation of bench based prototype processes to efficient and 
effective manufacturing processes on established technology platforms. Systematic 
process design and improvement strategies (Figure 3-3) will need to be aimed at 
translating features that are critical to quality from both the perspective of end-users 
and the manufacturing process (Mason and Dunnill 2008).  
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The increased process understanding from theoretical, analytical and statistical 
models will provide opportunities for further process improvement by accurately 
identifying process variables together with user specifications, and therefore, lead to 
risk mitigation. It will further allow a framework to establish process design including 
defined critical unit control parameters to consistently produce a cellular product with 
desired specification of the clinical requirement. 
 
3.7.3 Quality control and efficacy testing 
The application of effective product release and quality assurance systems in a 
controlled environment requires parallel emphasis on process design and quality 
control for product consistency, efficacy and stability (Mayhew, Williams et al. 1998; 
Mason and Hoare 2007).  This is particularly important for cellular products as 
characterisation will be defined by the process as well. An adequately controlled cell 
 
 
 
Figure 3-3- A systematic approach for process design 
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storage system, consisting of stable master and working cell banks permits 
appropriate storage, maximum recovery and consistent supply of sterile cells without 
any modification to their final characteristics (Cobo, Stacey et al. 2005). Phenotypic 
and genotypic profiles of the live cell preparations should be characterised in terms of 
requisite marker expression distinctive to the functionality of the desirable final 
product. A normal karyotype and expression of validated biomarkers to confirm the 
biological and functional activities for both progenitor and differentiated inner ear 
hair cells are valid efficacy and quality control measures. In vitro characterisation of 
inner ear hair cells can also be pursued using non-destructive spectroscopic 
techniques which do not involve cellular labelling. These could include Raman micro 
(Notingher, Jell et al. 2005) and optical waveguide light-mode spectroscopy (Hug, 
Prenosil et al. 2002). Such non invasive techniques allow in vitro studies of individual 
living cells by providing biochemical information regarding differentiation and 
quantitative monitoring of cell proliferation. 
Further, final homogenous cell populations should be certified to be free of 
contaminating agents or other cell types and stored under controlled conditions to 
ensure viability and sterility (Baron, Turbachova et al. 2006). Both donor pre-
screening and product testing for transmission of high-risk communicable pathogens 
including human immuno deficiency virus (HIV-1 & 2), Hepatitis B & C, human T-
lymphocyte virus (HTLV-1 & 2), cytomegalovirus (CMV) and Treponema Pallidum 
will be essential due to their contagious nature (Ustun, Koc et al. 1997; Preti 2005). 
This necessitates active participation of practicing clinicians, the key gatekeepers, in 
the conception, development, evaluation and informed use of such novel therapeutic 
regimes. 
 
3.7.4 Clinical trials 
The move to human clinical trials is a complex step and in the case of SNHL, efficacy 
testing through direct or surrogate markers only adds to the complexity. Therefore, 
screening and phased trials for evaluating safety and efficacy of the administered cells 
in an adequate dosage range (15,000 inner ear hair cells in each normal ear); 
identification and monitoring of side-effects to compare with incumbent therapeutic 
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electronic devices; and defining post marketing studies are important steps to realise 
such a product. Decisions regarding appropriate intervention time during the course of 
the disease and inclusion of sham procedures in the control group are further 
challenges during the trial design. Further, process and batch control with data 
management is required (Kourti 2006). Computer aided automated methods for the 
controlled scale-up and GMP-manufacture of cell populations for trials can be a 
possibility, but have inherent challenges in terms of complexity and costs (Schroeder, 
Niebruegge et al. 2005). The methods for measuring the performance of a cellular 
product could be based upon its characterisation which therefore can be used as 
release tests. Also, employing the early stage science (characterisation markers) and 
clinical trial end-points together with these methods will lend clinical and commercial 
solidity to the product in its journey from bench top science towards a commercial 
entity (Figure 3-4) (Tran, Burton et al. 2007). 
 
3.7.5 Logistics 
Distribution of live cellular products under strictly controlled conditions drives 
requirement of specialised sales and service teams, and distribution networks. This is 
significant as the manufacturing procedures will be supported in limited centres, and 
off-the-shelf availability of these products in every point of care institution is far from 
reality. In terms of logistics, maintenance of adequate records and labelling to 
facilitate traceability and setting up of appropriate protocols for packaging, storage 
and transportation of source cells and final therapeutic cell population with regular 
quality audits and review, are important procedures. The final lot release testing for 
batch consistency and relevant functional release criteria such as a formalized potency 
assay measuring bioactivity for stability, cell typing and shelf-life evaluation will 
further contribute to product safety and efficacy (Baron, Turbachova et al. 2006). The 
specifications of such assays will have to be established from prior production 
experience and proof of concept experimental data to ascertain product quality, 
integrity and stability. The sensitivity to transit time of both initial raw materials and 
final formulation calls for immaculate coordination with clinical schedules. 
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Figure 3-4: A generic roadmap for the development of cellular products 
    
 
3.8 Commercial Challenges 
It is now appropriate to turn from the discussion on the scientific, technological and 
translational issues to focus on the ultimate application and delivery of these novel 
therapeutic regimes as economically viable products. Analysts anticipate that the 
global market for RM therapies may be worth in excess of USD 30 billion in the 
coming 10 years (Lysaght, Jaklenec et al. 2008). Achieving this promise from the 
science will give significant commercial challenges to both the healthcare giants and 
the start-ups that feed them. In particular, there is a requirement for the creation of 
dynamic business models capable of recovering the costs of product development 
with satisfactory profit margins and sufficient revenues to provide impetus for the 
future product pipeline. 
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3.8.1 Role of clinicians 
Cellular products are likely to enhance many aspects of conventional clinical practice 
by creating novel curative and/or interventional regimes to accelerate therapeutic 
outcome (Singh and Williams 2008). In this direction potential strategies to 
implement research based therapeutic evidence by medical practitioners are required 
including incentives for them to induce the necessary change. Assessment of the 
clinician’s perspective on such emerging therapies for unmet needs (Chien 2004), 
extensive promotion of innovation with supporting value addition to create interest 
and parallel operational training (Mason and Dunnill 2008), if required, would be the 
initial measures towards this step-change across the therapeutic landscape. Practicing 
clinicians tend to be pessimistic about the potential of new therapeutic agents 
(Mahabir 1974) which can be a potential barrier to the adoption of novel cellular 
products. The antidote for this hurdle is creating realistic expectations within the 
medical community of what a new therapeutic can potentially deliver with more 
accurate forecasts and projections based on preliminary evidence of efficacy (Mason 
and Dunnill 2008).  
In case of SNHL, an appropriate surgical implantation procedure to reach scala media 
is necessary which will require the engagement of both the manufacturer and the ENT 
surgeon. The interventional procedure is exclusively to implant cells and any risk 
must therefore be relative to the potential benefit. The therapeutic procedure would 
entail stereotactic cell transplantation through a minimally invasive microsurgical 
access in an interventional imaging suite (Bogaerts, Douglas et al. 2008). Robotic 
assistance could also be used in such a format of cell provision (Marohn and Hanly 
2004). Further, clinicians need to address facilitation of recovery of the patient and 
success of the product. As the cell numbers required for SNHL are relatively low, no 
cell manipulation would be required at the implantation site and in the case of an 
allogeneic therapy; vials with requisite cell numbers might be available on demand.  
 
3.8.2 Funding 
To develop a concept to market and ultimately realise the business model requires 
significant investment over a period of time (Parson 2006) (Figure 3-5). Funding is 
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required for research, product development and manufacturing and for logistics 
infrastructure investment. This represents a high risk opportunity for investors but has 
the prospect of high returns for both patients and businesses. The emerging RM 
industry players need to be creative in attracting investment at key stages in product 
development keeping in view the dynamics of the economic environment (Bonfiglio 
2007; 2008). Multiple players from high net worth individuals and venture capitalists 
to government and charity grants will play an important role in funding the initial 
phase of young start-ups and their products. Alliances with major healthcare 
companies may allow late stage development to be self sustaining when products have 
reached the early stages of human clinical testing, and if the growth of a 
manufacturing and production infrastructure is realised (Parson 2006; Regalado April 
2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.8.3 Exit Strategy 
The fundamental ideas and science behind a commercialisable cell based therapy for 
hearing loss have real substance (Dazert, Aletsee et al. 2003) but keeping in mind the 
present scenario of adverse investor sentiments towards the industry (Giebel 2005) 
 
 
Figure 3-5 - Cellular product timeline with approximate investment and players involved 
(Bonfiglio 2007) 
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and the high requirements for basic science, early-stage businesses will have to be 
flexible in the inception stages (Mason and Dunnill 2008). Setting up trade sales to 
increasingly hungry pharma giants or out licensing to contract manufacturers are 
some of the options to raise capital and revenue at post-development stages, or are 
credible exit strategies for investors (Ilic 2009).  
 
3.8.4 Collaboration and IP monetization 
Historically, pharmaceutical companies have stayed away from cell therapy (Herrera 
2005) largely due to its unsuccessful commercial history, and ethical and political 
incertitude exacerbated by a murky IP position, but recent equity investments through 
their investment arms reflect their newly found interest in this high profile exciting 
science (Regalado 2005; May 2005). Further, contract manufacturers are expanding 
their capacity and service offerings to focus on advanced-stage projects of start-ups. 
This collaboration not only lends added value to high-end research but also speeds up 
the process (by improving hit-to-lead conversion and early identification of therapies 
that maybe difficult to realise and manufacture), improves efficiency and reduces cost 
burden (Mason and Hoare 2006). Management of such collaboration requires a clearly 
defined scope of work and clarity of deliverables in well scrutinized technical 
agreements with excellent two-way communication (eg.: set fee for service model to 
risk sharing model). Issues related to outsourcing such as loss of control, intellectual 
property and confidentiality concerns could be resolved through strategic 
partnerships, robust business models, appropriate legal protection and integrated 
knowledge-management systems.  
In terms of a cellular therapeutic for hearing loss, the non clinical development will be 
challenging. Establishing a well protected differentiation protocol for progenitor cells 
and patents of markers for in vitro and in vivo survival (myosin VIIA, espin, 
parvalbumin 3), inner ear hair cell specific cyto-morphological differentiation 
(presence of F-actin rich hair bundles) (Li, Roblin et al. 2003) and characteristic 
functionality (via audiograms) are paramount, as are both safety and efficacy 
evaluations. These studies will show functionality of the transplanted cell populations 
and that they survive, migrate and integrate in the lesion site within the inner ear and 
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lead to significant hearing improvement in the patient subjects. Generating and 
executing a comprehensive manufacturing strategy around these scientific principles 
is a major challenge in the clinical development stages. The manufacturing process 
and scale coupled with available infrastructure are the key deciding factors for 
whether to partner with contract manufacturing organisations (CMOs) or establish in 
house manufacturing capabilities (Mason and Hoare 2006). The current presence of a 
number of CMOs (Fox 2005) gives an opportunity to start ups to partner with them in 
order to mitigate the financial risk of prematurely constituting in-house 
manufacturing. The use of stem cells as the primary raw material also presents a 
chance to the manufacturer to serve as a CMO and utilise excess capacity, as these 
cells can be used as disease models for toxicity assessment of small molecules/drugs. 
Further, the fact that a single cellular product might not be able to provide a definitive 
answer for addressing SNHL, and as the terminal therapeutic modality may require a 
combination of cell and gene therapy conjugated with drug treatment and/or an 
electronic device, there lies a possibility of early collaborations with industries 
presently supplying such products. Therefore, another approach which might benefit 
companies developing cell based hearing therapies is the liaison with large medical 
device companies as these potential therapies may require special sophisticated 
localised delivery and support systems.  
 
3.8.5 Tapping the market potential 
Study of the incumbent technologies for treating hearing loss reveals a large market 
with two major segments (Table 3-3). In this market, application of cellular products 
for hearing remains uncharted territory.  
As a consequence of increased neonatal and elderly screening for hearing impairment 
by improved tests and early specialist referral the number of people diagnosed is 
increasing (Bogardus, Yueh et al. 2003). Further, as our population ages there will be 
increasing demand for more and better therapeutics at a price affordable by the 
healthcare provider/payer. This emphasises the importance of controlling the cost of 
goods for developing, and clinical services for delivering the therapy. Increased 
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demand for such a therapeutic will also be influenced by the physiological approach it 
takes towards restoring the healthy state (Strauer and Kornowski 2003). 
 
Hearing aid industry 
Cochlear implant industry 
$8 billion, at present $410 million, at present 
$1.5-8K, per unit cost $40K, average cost including evaluation, 
surgery, device, rehabilitation 
Most not covered by private insurance/ 
No Medicare/Medicaid reimbursement 
Reimbursable 
Low compliance amongst users Require patient adaptation time 
 
Table 3-3 - Market segmentation of incumbent medical devices for hearing 
ailments 
 
3.8.6 Overall business model 
A business model that generates significant value for the user, clinician, business and 
investor is critical for ultimate adoption of any cellular product (Figure 3-6). Such a 
model must demonstrate the key components of the product value proposition by 
elucidating clear advantages over the gold standard treatment regime. Further, having 
a credible intellectual property strategy which imparts enough freedom of activity 
through approved patents will not only attract investors but will also give additional 
credibility to the potential therapy (Bergman and Graff 2007). Depending on the 
scope and security of the patent filed to protect the therapy development or the stage 
at which the products are in human clinical testing, businesses can opt for either a 
stage payment of exit by trade sale model, a product/service model or a vertically 
integrated (manufacture and supply) business model. Presently, it is anticipated that 
early therapies will be autologous and consequently it is critical that these 
technologies are acceptable both to clinicians and others working at the point of care 
delivering such services (Giordano, Galderisi et al. 2007; Mason and Hoare 2007). 
Later allogeneic therapies may have a more conventional manufacturing and supply 
chain model with definitive donor eligibility criteria in place. 
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Further, apart from efficacy and patent positioning, market forces will also drive the 
mergers and acquisition of start ups with/by well established pharmaceutical, 
biotechnology or medical device companies. The introduction of such a therapy in the 
market will require both a strong therapeutic case and a strong business case to unlock 
the level of investment required to allow further development. Determining the 
appropriate mechanism for reimbursement forms a critical step in establishing the 
value proposition and proving the benefits of these products to the medical 
community and the regulators. 
 
•User group
•Clinical
•Manufacture
•Financial
•Capital
•Infrastructure
•Organisational
•Technological
•Product distribution
•Expert personnel
•Cell sourcing, 
expansion & supply
•Quality control,                     
rcharacterisation &
• delivery
•Vertically Integrated
•Out-licensing
•Product  or 
Platform/Service
•Hybrid
•Early Exit Alternative 
Economic 
Model
Process
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Resources
 
Figure 3-6 - An overall integrated business model identifying key constituents 
 
Systematic Review 
79 
 
3.9 Integration within Porters’ Care Delivery Value Chain 
The care delivery value chain (CDVC) allows a systematic approach for value 
creation. It allows care delivery process identification and subsequent analysis, from 
prevention and diagnosis to intervention and management for a particular disease state 
(Porter and Teisberg 2006). Integration within the care delivery value chain presents 
another challenge for a novel cell based therapeutic. Such systematic processes for 
knowledge development support continuous improvements in care delivery.  
The CDVC looks at care as an overall system and not at separate interventions. 
However, it takes into account the separate activities necessary to deliver care and 
simultaneously illustrates their sequence, organization and contribution towards value 
addition to the patient. Therefore, value is measured as a product of the entire care 
cycle as clinical care involves various mutually dependent activities. Using this 
potential cell based hearing therapy as an exemplar, CDVC was used to identify 
changes in the value chain consequent on the introduction of an alternative 
intervention (Figure 3-7).  This not only highlighted the key features of the product 
value proposition (Table 3-4) but also the changes in discrete activities before and 
after the new therapy in the value chain. It allowed analysis of the care delivery 
process for SNHL in order to configure the process to augment value for patients as 
individual activities within the cycle contribute value but do so in relation to other 
activities. Thus the value of a new intervention can only be understood by considering 
its relation to other activities within the CDVC. Further, comparison with the 
incumbent technology allowed identification of both clinical and economic 
components of the value proposition and cost targets for the profitable economic 
model necessary for commercialisation as will be presented in Chapter seven.  
The changes in intervention consequent upon a novel RM based cell therapy imply 
significant procedural modifications in both patient preparation, and subsequent 
recovery and management plans. Further, when RM products come into mainstream 
clinical practice, systematic knowledge would be developed at the medical condition 
level which might lead to superior improvement in the care delivery methods 
throughout the care cycle. By delineating the activities and their interrelations in the 
care cycle (Figure 3-7), issues such as their alignment and coordination can be 
addressed across the care cycle to enhance value for patients. 
Systematic Review 
80 
 
 
 User group  - More efficacious and potentially a one off intervention  
- Natural sound  
- A potential cure  
Clinical  - Clinically significant results from research groups available  
- Physiological approach to restore healthy state  
- Increased compliance & manageable long-term follow up  
Manufacture  - Regulatory approval 
- Cost effective optimised process capable of meeting demand 
- Established distribution system  
Financial  - Reimbursable at an appropriate level  
- High potential for take up as low risk to surgeons & health 
services  
 
Table 3-4: Attributes of an effective value proposition for a RM based hearing 
therapy 
 
A business model generating significant value is consequently required to drive 
adoption. The value proposition for the implemented model includes user group, 
clinical, manufacturing, and supply and financial components mainly those required 
to satisfy the regulator and reimburser (Table 3-4). Comparison with the incumbent 
technology allowed identification of both clinical and economic components of the 
value proposition and cost targets for the profitable economic model necessary for 
commercialisation. 
The CDVC maps the activities associated with SNHL care delivery in order to 
elucidate effective linkage and coordination of the activities. The framework allows 
knowledge development for the overall system of care delivery and provides a 
framework for improving it. The framework can also be used by hospitals or 
practitioners to improve SNHL care delivery. 
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Figure 3-7 – Application of Porters' care delivery value chain (CDVC) to SNHL
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3.10 Practice- and Implementation-Driven Research 
This work confirms the importance of identifying and working towards overcoming 
the key challenges faced by RM industry, especially for commercialisation of cellular 
products. At both a scientific and an industry level, there is recognition that resolution 
of these challenges will assist the sustainable growth and competitiveness of the 
emerging RM industry. This chapter focuses on the significance of addressing these 
issues during early stage development. Consistent with this, many product developers 
recognise the importance of early-stage process development and translation (product 
is the process). Based on insights gained from reviewing publications and studies in 
this exploratory work, the following questions are raised: 
 How will identifying and addressing translational and commercialisation 
challenges in early stages of product development affect the performance of 
both products and companies developing them? 
 What is the best practice to resolve these challenges to support product 
development and commercialisation activities? 
 If these issues are critical path activities, how best should product developers 
and stakeholders organise assessment activities to derive benefits from cellular 
products? 
With these initial questions in mind, the next chapters devise a reference model and 
explore key indicators involved in enabling late-stage translation of RM products. 
 
3.11 Conclusion 
The recent discovery of endogenous inner ear stem cells and generation of hair cells 
from embryonic and adult stem cells have signposted an exciting new opportunity for 
the development of strategies to treat hearing loss using these cells. As these cell 
populations are being considered for therapeutic application to restore hearing, the 
time is right to review the translational and commercial challenges that must be met to 
enable the launch of relevant cellular products into the commercial arena successfully 
and profitably. It is also important to recognise that such a cell based therapy alone 
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may not substitute the current therapeutics to address hearing loss, and the final 
therapeutic regime might be a combination of cell and gene therapy coupled with drug 
treatment and the latest electronic devices. 
Recent advances in stem cell biology have resulted in specific and targeted strategies 
aimed at functional restoration of a number of organ systems. Stem cell viability and 
plasticity in the inner ear has signalled a new therapeutic paradigm for inner ear hair 
cell replacement and repair. Despite this promise significant gaps remain in our 
knowledge regarding the functional restoration of the auditory system together with 
certain practical considerations that must be addressed. While these gaps are filled, 
there is enough time to examine the challenges associated with forming a cell based 
regime into a profitable commercial entity. Therefore, as the basic work in 
fundamental science and knowledge is strengthening there is a compelling 
requirement to create simultaneously, in a timely way, the enabling clinical and 
commercial infrastructure before envisaging the realisation of such cellular medicines.  
The requirement of suitable in vitro surrogates for assessing the functional viability 
and potency of therapeutic cell populations is a key step in transforming cells into a 
therapeutic cellular medicine. These surrogates are required from acceptance testing 
of incoming raw materials to serving as process controls for in-process and release 
testing. The complexity associated with the characterisation of these cellular 
formulations brings in the need to have sophisticated potency and validation assays to 
rigorously control the manufacturing process and product consistency. 
While working on the specific challenges from a hearing loss perspective, it is clear 
that apart from the initial enabling science involved in the discovery of a particular 
cellular therapeutic, both translational and commercial issues can be extrapolated to 
other generic cell-based approaches. Therefore, overcoming such challenges will 
allow for an infrastructure to harvest, manufacture, test and deliver an altogether 
novel class of cellular products which have the potential to transform the practice of 
clinical medicine. 
This chapter presents the results of work to explore commercialisation issues in the 
form of a qualitative systematic review. This demonstrates the importance of 
identifying and working towards the solution of challenges faced by RM during the 
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commercialisation of cellular products. The chapter uses past publications and 
reviews to provide an introduction to the issues and challenges faced by RM taking 
the case example of SNHL to ground the work and indicate the corresponding steps 
required for resolution of these issues. It identifies and discusses the key challenges 
and complexities of scientific, translational and commercial issues inherent in the 
process of translation of basic scientific methods into profitable cellular products. 
Although challenging and complex, these issues are critical-path activities, ultimately 
enabling new discoveries to be produced in a commercially viable manner. Consistent 
with this, product developers will appreciate the importance of working through these 
challenges, as appropriate for their business model and value proposition. The next 
chapter takes this knowledge and background and devises an “investment readiness” 
reference model. 
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4.1 Introduction 
The chapter presents the industry “investment readiness” reference model by considering 
issues surrounding the translation of emerging RM science to address the research question 
and objectives identified in chapter two. The model illustrates industry analysis across six 
broad indicators to identify strengths and weaknesses in specific characteristics, and enables a 
balanced assessment of the principal risks and opportunities associated with the investment. 
The model is centred on understanding the reduction of uncertainty, as reduced uncertainty 
ultimately equals investment readiness. 
The chapter is structured as follows. This introduction is followed by a short description of 
investment readiness in section 4.2 and the methodology/approach used to identify 
investment readiness of the RM industry in section 4.3. In section 4.3 as part of the 
methodology, the RM industry is mapped on the Gartner’s hype cycle and a technology 
roadmap of the overall RM industry is drawn. This is followed by identifying the key 
indicators of investment readiness in section 4.4, which are further integrated into a 
“reference model” in section 4.5 and described individually in section 4.6. Before concluding 
the chapter in section 4.8, six important factors of the industry that must be considered in 
order to successfully reach its high growth potential are presented in section 4.7. 
 
4.2 Investment Readiness 
Healthcare markets and healthcare delivery systems will undergo tremendous changes in the 
coming years and this change will be on a global basis (Coye 2001; McNamara 2006). The 
demands in the global healthcare market reflect powerful demographic and lifestyle trends 
which require new preventive, therapeutic and diagnostic systems and technologies. New 
innovative RM technologies will foster a paradigm shift in disease management and 
preventive medicine (Rosenthal 2003). The aim of a positive and sustainable change has 
prompted investors to concentrate not only on financial performance but also on operational 
strength and clinical quality in firming up their capital investment agenda (Mason and 
Dunnill 2008). Also, healthcare providers continuously confront changes that directly affect 
their operational and financial performance. Therefore, due diligence for these new 
therapeutics should focus on identifying risks and opportunities beyond those for 
conventional businesses.  
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Investment-readiness is the outcome of the process of supplying adequate data, credibility 
and confidence to potential investors to motivate them to invest in a proposition. The terminal 
decision, i.e. whether or not an organisation/technology is 'investment-ready', is that of the 
investor. The balance between their individual perspective on the business opportunity, 
together with the degree of risk they are willing to accept, forms the basis of their decision 
making process. Clearly, the background work required to prepare for investment varies 
according to the business sector, investment required, state of readiness of the technology 
proposition and probability of commercial success (Giebel 2005; Wilan, Scott et al. 2005). As 
well as people and strategic investment decisions, a successful business venture depends on 
other elements, including quantification of historical and projected financial results, access to 
technical concepts and innovation via strategic alliances and a market structure fitting the 
business model. 
This chapter describes the process of preparing the form of an investment readiness reference 
model to address the research question posed in chapter two. Starting points were Gartner’s 
hype cycle, adapted for RM, and a technology roadmapping exercise. Both methodologies 
were exploratory and the research scope at this stage was broad. With the exploration, a 
reference model of key indicators in the form of a parallel timeline emerged and from it 
individual trajectories were developed. The main aim of this chapter is to present and build 
into the overall model how its parallel trajectories could best be managed in different 
technical and business contexts. 
 
4.3 Method/Approach: Is RM as an industry, Investment Ready? 
The theoretical potential of RM to be applied in significant healthcare markets addressing 
almost every diseased tissue/organ in the body suggests it is a viable business proposition 
(Singh and Williams 2008). Resolving whether the hope and hype is realistic from a holistic 
commercial point of view in order to establish whether the field is really investment ready is 
the key underlying question. As an answer to this challenging question, in this chapter the 
RM industry was first mapped on the Gartner’s hype cycle (Figure 4-2) and then its 
emergence was analysed in a technology roadmapping based framework (Figure 4-3). The 
specific context of healthcare i.e. safety, regulatory standards and the corresponding 
reimbursement issues were monitored closely before arriving at an investment readiness 
Industry Investment Readiness Model 
 
88 
 
reference model that recognised the past and present dynamics of the RM industry. These 
specific issues mean that the commercialisation of RM products may be significantly 
different to that of other science based innovative technologies. 
 
4.3.1 Mapping RM on Gartner’s’ hype curve 
Gartner’s hype cycle (Figure 4-1) was utilized and data-validated to identify the investment 
readiness of RM in comparison to other technologies which also had similar associated hype 
and subsequent disillusionment. This hype cycle for emerging technologies has been 
demonstrated to follow a regular pattern described by Gartner Inc. (Fenn and Raskino 2008). 
The typical pattern of hype associated with an innovation as it diffuses through the economy 
was captured for RM technologies (Figure 4-2). The hype cycle provided an industry 
perspective on the state of technology and trends that RM investors should consider while 
investing in RM technology portfolios to exploit the associated impact. It offers an intelligent 
way to sort through the hype and choose the right innovative technologies at the right time 
(Fenn and Raskino 2008). This further helps as, retrospectively, the pattern of the cycle holds 
the potential to alter conventional business models by defining the speed of product 
development, and relationship with core research and empowered consumers. The cycle 
characterizes the typical progression of an emerging technology, from over-enthusiasm 
through a period of disillusionment to the ultimate understanding of the technology's 
application and role in a market or domain. It further ascertains the technology levels 
essential to accomplish corporate objectives as each phase is characterized by distinct 
indicators of market, investment and adoption activities. Such a hype cycle for RM can be 
used as a predictive tool for prioritizing emerging RM technologies by investors as well as 
stakeholders to assess technology opportunities in terms of their relative impact and reducing 
uncertainty. They can focus on the potential benefit of the technology, and better determine 
the importance and timing of potential investments based on benefit rather than hype. 
Gartner's hype cycle for RM shows the maturity of the overall industry, adoption rates and 
development stages of its various applications across the clinical spectrum (Figure 4-2). 
RM, in its “tissue engineering” era, has already experienced a boom cycle subsequently 
followed by a slow down period. Considerable media hype was generated during the boom 
phase resulting in unrealistic expectations. Also, the majority of initial funding, USD 3.5 
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billion between 1990 to 2000, came from the private sector (Lysaght and Reyes 2001) which 
constrained the time period under which results had to be delivered as investors anticipated 
significant and early return on the capital they provided as early-stage investment. Similarly, 
in the 70’s and 80’s genetic engineering and monoclonal antibodies in the biopharmaceutical 
space suffered from early hype and over expectation together with resistance from the large 
pharmaceutical industry (Clark 2005). However, biopharmaceutical SMEs were ultimately 
successful in moving their candidates through the developmental pipeline to take on the 
unmet needs of the healthcare market (Gudiksen, Fleming et al. 2008) (Box1). Similarly, at 
present, the RM industry appears to be emerging from the initial economic crisis and is 
steadily maturing (Mason and Dunnill 2008). 
 
 
Figure 4-1: Gartner Incs' Hype Curve for Emerging Technologies 
 
Gartner’s hype cycle is a useful framework which characterises the typical progression of an 
emerging technology from its emergence to its eventual understanding and applicability in 
the commercial sector (Linden and Fenn 2003). The cycle has been used in the past as a 
means to understand emerging technologies and related research and business issues together 
with comparing different technologies at similar stages in the cycle. Similarly, investment 
firms and stakeholders in the RM space can use the hype cycle to manage their funds. Proteus 
Venture Partners have further confirmed that RM has emerged out of the trough of 
disillusionment and is heading onto the slope of enlightenment (Bonfiglio 2007). 
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The present position of RM on the hype curve marks its relative maturity and the associated 
risk, and is driving a number of investment related questions by showing different 
development opportunities, thereby having an impact on the overall field.  The technologies 
which have been previously mapped, like biometrics, artificial intelligence, cell phones, 
information systems (Linden and Fenn 2003; O'Leary 2008) etc, on this curve differ 
considerably from RM based technologies. Early smart phones, for instance, slid into the 
“trough” as they were expensive and therefore not widely adopted. However, the introduction 
of more affordable devices increased the rate of adoption to less than two years. Similarly, 
GPS services are climbing the slope with the introduction of network and device support 
from which they have gained acceptance as a viable tracking tool. 
 
The characteristics of industry emergence for RM are inherently different from these sectors 
and have not yet been addressed. Firstly, RM products, unlike such hi-tech electronic devices, 
have to surmount stringent regulatory and challenging reimbursement hurdles. Secondly, RM 
is too early in its life cycle to observe stable patterns of performance. Despite these additional 
hurdles and the emerging nature of the RM industry, RM products have followed the hype 
curve, and as present businesses increase their understanding of the practical applications, 
commercially viable products have started to emerge (Kemp 2006). Further, it is now 
understood that unlike the product life cycle for mobile and wireless technologies, which is 
Box 1. Early biopharmaceutical companies engaging the Big Pharma 
 
In 2004 Astrazeneca, the second biggest British pharmaceutical company acquired 20% of 
Cambridge Antibody Technology (CAT) for £75m ($130m) before buying the entire 
biological therapeutics enterprise in 2006, for £702 million, nearly 67% above its market 
value (according to trading of shares, CAT was worth £420 million at that time). Founded 
in 1989 to harness the potential of antibody engineering, CAT was a company at the 
forefront of developing novel drugs on the basis of their proprietary technologies and 
capabilities in human monoclonal antibodies (2002). Prior to this, CAT licensed intellectual 
property related to the use of antibodies from other biotechnology firms and also had a 
strategic alliance with Genzyme. AstraZeneca also acquired a US based biotech company in 
June 2007, MedImmune, in an all-cash transaction at a total company value of $15.2 billion 
to boost its biologics and vaccines capability (AstraZeneca 2007). CAT was re-named 
MedImmune in Cambridge, in which the resources and expertise of CAT, the pre-existent 
MedImmune and former biologics activities within the AstraZeneca Group merged. With 
similar objectives, Merck acquired GlycoFi and Abmaxis to build critical mass in biologics 
capabilities. 
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Figure 4-2: Tracing RM technologies and the underlying enabling science on Gartners' Hype Curve. Adapted from (Bonfiglio 2007)
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typically under two years, RM products have a highly complex, risky, costly and longer 
product life cycle where products can take anywhere between 5-15 years just to get to the 
market. There are numerous steps including preclinical evaluation, process and product 
development, analytical procedures, safety studies and clinical trials. Also before the product 
can be finally marketed, it should be reimbursable and able to be manufactured on an 
appropriate scale to obtain marketing authorisation as granted by the regulatory bodies 
concerned (Halme and Kessler 2006). The identification of these complex steps has led to in 
depth due diligence by businesses and investors to understand how to smoothly navigate the 
steps, and their corresponding approaches will decide RM technology’s time to plateau 
(Archer and Williams 2005; Kaplan, Moon et al. 2005). This is a consequence of present 
expectations from the field being now more based on engineering and business progress 
rather than those earlier based on excitement and aspiration. 
  
The hype cycle also establishes a measure of risk and uncertainty (Linden and Fenn 2003). In 
the inception stages investors had little idea about the high risk of early stage RM ventures 
and were therefore not able to make well-informed decisions (Bouchie 2002). However, the 
current positioning of RM on the curve suggests reduced uncertainty with increased know-
how and relatively reduced risk amongst enterprises and therefore, investors are in a position 
to make more intelligent decisions.  
The timing and height of the plateau of productivity will be based upon the ultimate product 
application. In the case of allogeneic therapies, there will be increased visibility as a result of 
a broad patient base (Bradley, Bolton et al. 2002). The plateau will move downwards if the 
ultimate therapies, for instance are autologous and benefit a niche market as part of 
personalised medicine (Caplan and Bruder 2001; Fenn and Raskino 2008). Also, the area 
under the plateau will reflect the amount of ongoing activity and hence be a direct measure of 
investment and technology readiness for the entire field (Penn and Raskino 2008). The hype 
cycle only assists us to conceptualise the growth of the industry, the final pattern of the curve 
for RM will be decided by the cost- and clinical-effectiveness of its future applications.  
Therefore, now is the time to learn from the past and manage the emerging RM technologies 
associated with unreasonable hype and expectations. This requires far greater technology 
understanding together with robust business models for investors to readily make these 
technologies part of their investment portfolio. Hence, knowing the position of RM on the 
hype cycle is a valuable predictive tool to manage and pursue the realisation of safe and 
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profitable RM technologies. Thus, the cycle is a simple tool to understand the trends of 
excitement and disillusionment that surround emerging technologies. The present emergence 
of RM out of the trough of disillusionment implies better strategic fit of the technology with 
the overall business opportunities, which will allow stakeholders to engage in this innovative 
emerging industry. The reduced risk and decreasing uncertainty as reflected in the cycle 
further assist the decision making process to invest in RM technologies. 
 
4.3.2 Technology roadmapping to understand RM industry emergence 
As RM products are moving towards practical applications in healthcare they are bringing a 
new industry sector to global prominence. In a retrospective scan of RM technology and 
industry, a technology roadmapping based framework was used to understand its dynamics 
and the characteristics of emergence (Farrukh, Phaal et al. 2003). Such frameworks help to 
organise and present the key technology-planning information and system requirements to 
make appropriate technology investment decisions and to leverage those investments. They 
can also be used to explore and communicate the dynamic link between technology 
resources, organizational strategies and the changing environment. Therefore, the RM 
technology roadmap provides an insight into the dynamics of emerging RM products and 
enhances the ability to define and exploit the scientific and technological capabilities 
associated with these products by charting their course through the past and present economic 
environments. 
The framework employed is part of the Navigating Transitions project at the Institute for 
Manufacturing, Cambridge University, in which roadmapping based frameworks are used to 
undertake rapid scans of historical technology based industrial emergence (Phaal and 
O'Sullivan 2008). These maps assist in understanding the dynamics and characteristics of 
emergence and further support the navigation of future emergence and associated transitions 
(Phaal, Farrukh et al. 2004). The roadmap presented in this thesis was desk research based 
building on industry observation, published literature and information available on the World 
Wide Web on product developers and firms developing applications and technologies in the 
RM domain. The information on underlying enabling science was gathered from published 
patents and scientific papers. The mapping technique applied here for the RM industry clearly  
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Figure 4-3: Technology Roadmap for emerging technologies and underlying enabling science in the RM domain 
Industry Investment Readiness Model 
 
95 
 
illustrates the phases and transitions (Phaal and O'Sullivan 2008) associated with its 
emergence, characterising events, enablers, regulatory standards and products in the market 
or in the process of reaching the market (Figure 4-3). This technology roadmap provides a 
graphical framework to explore strategic emergence of the RM industry. It is a superimposed, 
time-based chart linking enabling technologies with their associated applications and 
regulatory criteria, and products with their corresponding markets. The map can be used as a 
key technology management tool to link underlying enabling technological capability to RM 
product development through robust business plans keeping strategy and technology 
development together. It further allows identification of technological and commercial gaps. 
The RM industry traces its origin back to transplantation medicine, which has a relatively 
long history though real positive results came to fruition only in the middle of the 20
th
 
century. The first reasonable account is of a skin autograft performed by an Indian surgeon, 
Sushruta, in the second century BC (Veith 1961). Centuries after this an Italian surgeon, 
Gasparo Tagliacozzi, performed successful skin autografts (Webster 1969), but failed 
consistently with allografts and offered the first suggestion of the rejection phenomenon. The 
first successful human corneal transplant was performed in 1905. Pioneering work with 
transplantation and anastomosis of arteries by French surgeon Carrel won him the 1912 
Nobel prize in Physiology/Medicine. The main advances in skin grafting occurred during 
World War I led by Harold Gillies when he used tubed pedicle grafts which were further 
applied to battlefield injuries during World War II as part of reconstructive surgical 
techniques. In 1962, a severed limb was reattached successfully. The first successful 
transplant, in 1954, was a kidney transplant between identical twins due to lack of immune 
rejection amongst identical twins. In the 50’s Peter Medawar had suggested the use of 
immunosuppressive drugs (Medawar 1956), though it was not until the discovery of 
cyclosporine and prednisone that transplant surgery found an adequate immunosuppressive 
(Starzl, Klintmalm et al. 1981). Such initial success led to a successful deceased-donor lung 
transplant in 1963 and liver (Starzl, Marchioro et al. 1963) and heart transplant in 1967 
(Barnard 1968; Barnard 1968). The advent of cyclosporine as an immunosuppressive, further 
allowed transplant surgeries as life-saving treatments for various organ failures and thereafter 
such transplants were performed on a more regular basis. 
While transplant medicine was making strides, organ shortages led to the exploration of other 
areas. This led to the identification of different cell types and their in vitro growth as single 
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cells and organotypic cultures (Medawar 1948). Tissue engineering emerged in 1985, when 
these cells were used in conjunction with scaffolds to replace restore, maintain or improve 
tissue function or a whole organ (Langer and Vacanti 1993). Several products were proposed, 
some of which were approved by regulatory authorities and some of which are presently in 
the preclinical or clinical development stage as seen in the retrospective technology roadmap 
of RM industry emergence (Figure 4-3).  
This retrospective analysis that forms the basis of the technology roadmap clearly depicts that 
RM as an industry did not take long to initially emerge from the science base of tissue 
engineering, bearing in mind the long product development lifecycle of current RM based 
products in a more demanding regulatory and reimbursement environment. Companies like 
Biosurface Technology (later taken over by the Genzyme Corporation) emerged within ten 
years from the discovery of their corresponding technologies (Green, Rheinwald et al. 1977).  
However, it took nearly two decades before skin substitutes generated revenues with positive 
cash flow (Figure 4-4). Within this time there were casualties. Massachusetts-based 
Organogenesis and California-based Advanced Tissue Sciences, both of which had FDA-
approved artificially engineered skin substitutes, filed for bankruptcy in 2002 due to their 
poor sales which were unable to cover operating costs due to high manufacturing cost of 
goods together with a small addressable market (Bouchie 2002). Another Massachusetts-
based company, Curis, with an initial mission of engineering cell and tissue based therapies 
for the musculoskeletal system had to change its focus and develop molecular factors that 
stimulate regeneration of tissues or organs. However, there are companies like Aastrom 
Biosciences which did weather the storm and have managed to stay in business as they 
developed their proprietary technology while simultaneously exploring different applications 
within the space (Wilan, Scott et al. 2005).  
The earliest instances of intellectual property in RM came mainly from academic institutions 
as initially the single most significant geographical and institutional locus of tissue 
engineering research had been the Boston area in the US, centred on the Massachusetts 
Institute of Technology (MIT) in Cambridge and the Harvard Medical School (HMS) in 
Boston. Further, the premise that university licensing stimulates investment and promotes 
jobs even before sales of licensed products (Pressman, Guterman et al. 1995) coupled with 
well established processes available in institutions such as MIT for exploitation of intellectual 
property led to patent publication and the subsequent emergence of initial RM companies  
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Figure 4-4 Technology Roadmap showing the key strategic stages in the emergence of RM industry
Industry Investment Readiness Model 
 
98 
 
from their academic labs. Also recognising that commercial rewards from success in the 
market place may take 10 to 20 years it is likely that the original intellectual property, 
typically issued in the early phases of product development, might expire by the time 
products ultimately get to the market (McAllister, Dusserre et al. 2008). 
The seminal lines of research on substitutes for human skin had clinical promise and some of 
them ultimately emerged as approved medical products that are available in the market at 
present (Kemp 2006). For instance, in the mid-1970s the laboratory of cell biologist Howard 
Green achieved a breakthrough in the cultivation of human keratinocytes (Green, Rheinwald 
et al. 1977). They developed it into a method for growing epithelial grafts from a small piece 
of autologous epidermis, and demonstrated the viability of this method in the treatment of 
burns victims (Gallico, O'Connor et al. 1984). In 1987, this technique became the cornerstone 
for a startup company named BioSurface Technology that offered cultured epidermal 
autografts commercially. Genzyme acquired the company in 1994 and became Genzyme 
Tissue Repair (now Genzyme Biosurgery), where the product is still marketed under its old 
name, Epicel. Similarly, in 1977 Ioannis Yannas was granted a patent for a multilayer 
membrane useful as synthetic skin from his work investigating the use of acellular collagen-
glycosaminoglycan matrices as wound dressings designed to serve as biodegradable 
templates for viable skin regeneration (Yannas, Burke et al. 1977). Shortly thereafter he 
described the successful use of such artificial skin to treat extensive burns (Yannas and Burke 
1980; Yannas, Burke et al. 1982). This research resulted in the development of a commercial 
product, Integra® Dermal Regeneration Template, which is currently licensed to and 
manufactured by Integra Life Sciences Corporation. In 1979, Eugene Bell  et al. reported the 
production of a tissue-like structure by seeding fibroblasts on a collagen lattice (Bell, 
Ivarsson et al. 1979). Later, in 1981, they further reported successful grafting of their live 
skin equivalent seeded with epidermal cells (Bell, Ehrlich et al. 1981) for which they were 
awarded a patent in 1984 (Bell November 27, 1984) .This led to the commercial development 
of the living skin equivalent as in 1986 Bell launched Organogenesis Inc. to develop and 
market the product. Following suit, less well equipped universities sought to exploit their 
intellectual property in a similar manner. This increase in intellectual property licensing 
around the basic science in the late 80s early 90s probably exacerbated the peak in the 
Gartners’ hype curve and inflated associated expectations (Figure 4-2). Also the retrospective 
analysis shows clustering of multiple products in the application and clinical trials phase in 
the period between 2003 and 2008 clearly suggesting increased preclinical activity in the 90s.  
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The roadmap describes industrial emergence in stages from science to technology to 
application to market, with transition phases in between each of them. These phases have 
been defined as precursor, embryonic, nurture, growth, maturity and decline phase (Table 4-
1) (Phaal and O'Sullivan 2008).  
PHASE DESCRIPTION 
Precursor phase Original observations/events based on enabling science lead to 
first demonstration of scientific achievement which induces 
serious industrial interest and investment. 
Science to technology 
transition 
Demonstration of technical capability (prototype system) and 
practical application within the regulatory framework and 
appropriate reimbursement mechanism 
Embryonic phase Technology and process improvement for commercial viability 
Technology to application 
transition 
First commercial sale after demonstrating potential benefit to 
the customers at an acceptable level of functionality, 
performance and price. 
Nurture phase Performance and functionality improvement of the application, 
focussing on customer (payer, regulator, clinicians, end-users) 
requirement  
Application to market 
transition 
Establish early market through premium users for novel 
application 
Growth phase  Focus on market and commercial aspects to grow the business 
through a mass market 
Maturity phase Economies of scale 
Decline/renewal phase Either industry declines or is renewed through development of 
new science based technologies 
Table 4-1: Stages and phases of industrial emergence (Phaal and O'Sullivan 2008) 
When these stages on the RM roadmap were marked it was clear that the technology push 
balanced the market pull, and the field is presently in the growth phase after the initial 
precursor and embryonic phases (Figure 4-5). Therefore this roadmap, as well as providing 
intelligence for strategic planning and aligning technology enablers with commercial 
perspectives, also illustrates, through these stages, the present state of the overall RM 
industry. This can support the innovative and strategic goals of investors and manufacturers, 
respectively. It provides a structured means for exploring the relationships between evolving  
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Figure 4-5: Technology Roadmap showing the phases and stages in the RM industry emergence
Industry Investment Readiness Model 
 
101 
 
markets, products and technologies over time. It is valuable and gives a preliminary 
framework for the overall RM industry emergence in the current critical fiscal conditions as it 
captures key enablers and barriers to emergence. These factors hold the key in deciding the 
industry’s future growth by translating the evidence from historical cases into appropriate 
strategies and policies for more recent technologies and ventures. 
Thus technology roadmapping, as presented here, can be an effective tool for RM based 
technology planning and coordination. Therefore, it can be a useful tool to support innovative 
RM technologies, and related strategic planning and policy development, at company, 
industry and sector levels (Garcia and Bray 1997). Further, such a roadmap provides 
information to potential stakeholders in making well-informed technology investment 
decisions by identifying critical technologies, inherent technology gaps and ways to leverage 
R&D investments, particularly when investment decisions are not unambiguous, as in the 
case of RM (Garcia and Bray 1997).  
RM technology roadmaps together with Gartner’s hype cycle are an important tool for 
driving business strategy and technology planning and therefore, assist in making better 
investment decisions. They can together assist to identify, evaluate, select and develop key 
technologies and their corresponding application needs, and determine technology/process 
alternatives, if required. They reflect fundamental aspects of the business by demonstrating 
integration of technology/process, product and commercial perspectives in a firm or the 
overall industry. They also help to forecast the technological future trends together with 
identifying the relationships between markets, product/applications and their underlying 
processes/technologies over time. However, both these are high level strategic tools with a 
broad scope, and therefore further assisted in identifying specific indicators of investment 
readiness. As a result, together with the key indicators, the technology roadmap and Gartner’s 
hype cycle can be used as a strategic technology management tool and integrated in the form 
of a reference model as presented in this chapter. Together they seek to capture the RM 
industry landscape and associated uncertainties and opportunities for potential stakeholders. 
The next two sections, 4.4 and 4.5, state the key indicators of industry investment readiness 
and the investment readiness reference model for RM, respectively, before describing each 
indicator in detail in section 4.6. 
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4.4 Key indicators of industry readiness 
In order to describe the investment readiness of the overall RM industry, this section states 
the key indicators in the form of a parallel timeline (progress of business activities that reduce 
uncertainty with time) as the investment readiness reference model that is described in 
section 4.5. The timeline analyses the industry across six broad indicators to distinguish 
strengths and weaknesses in specific characteristics, and enables a balanced assessment of the 
principal risks associated with investment. This is centred on understanding the reduction and 
integration of multiple dimensions of uncertainty, as reduced uncertainty complemented by 
increasing value in the application ultimately equals investment readiness (Parson 2008). This 
thinking arose from the understanding generated by examination of the evolving regulatory 
framework for RM products (as presented in Chapter 5). The timeline ensures that the 
assessment of investment-readiness of RM as an industry is conducted within an integrated, 
structured, evidence-based framework that will allow conclusions to be drawn in a consistent 
manner. Such a model will be dynamic (and non-linear) and will particularly reflect the 
current appetite of the “markets” for financial risk. 
The six indicators are: 
- Technology Readiness 
- Business Models 
- Regulation 
- Reimbursement 
- Organisation/People 
- Investment Readiness 
These indicators are discussed in detail in section 4.6 below. 
 
4.5 Industry Investment Readiness Reference Model  
4.5.1 Introduction 
The reference model (Figure 4-6) builds an investment risk profile by examining the six key 
indicators against reducing uncertainty as RM investments are inherently high-risk with long 
time-lines to maturity (Kemp 2006) and, in the present economic climate, many investors are 
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Figure 4-6: Industry Investment Readiness - Reference Model
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awaiting greater certainty in the market before investing (Mason and Dunnill 2008). 
However, simultaneously, major pharmaceutical and medical device companies are signalling  
interest and moving in a direction to launch partnerships or invest in companies developing 
stem-cell based therapeutics (Regalado 2005; Alamo-Bethencourt 2008) (Figure 4-7). In 
addition, these companies are moving into the field and taking a very strong position by 
initiating research on new treatments, for instance urging endogenous stem cells to become 
active in healing i.e. the auto regeneration principle (Regalado 2005; Evans, Palmer et al. 
2007). 
 
 
Figure 4-7: Major Pharmaceutical & Medical device players and their recent activity in 
the stem cell space 
 
Therefore, assisting investors such as venture capitalists and the pharmaceuticals and medical 
device companies, this reference model also assists evaluation of the underlying technology 
and its inherent risk for commercialisation. Such a model at the industry level indicates the 
• In November 2008,  Pfizer announced setting up an RM unit 
in US and UK
• Spend $100 million in next 5 yrs to harness SC biology
• Cardiac, Endocrine and Cancer focus in US labs
• Neural and sensory disorders focus in UK labs
Pfizer
• In July 2008, GSK and Harvard Stem Cell Institute 
announded a $25 million-plus collaborative agreement  
to explore stem cell science and develop new 
medicines 
GSK
• In September 2007 together with Roche bankrolled 
Cellerix, a spanish company testing stem cells from 
patient’s own adipose tissue to treat different skin 
conditions
Novartis
• In October 2007, acquired an equity stake in Tengion
Inc. , developing bladders and other different organs 
• Led a $25 million round of funding in July 2006 for 
Novocell, which uses embryonic stem cells to develop 
therapies for diabetes. 
Johnson & Johnson
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requirement of the following components to be in place for success – product technology 
readiness; candidate business model readiness with identified value creation steps and a 
sound exit strategy; a level of maturity in regulation and reimbursement mechanisms with 
quantified risk and return; and people, particularly management teams comprising 
experienced leaders. With these in place there is consequently a strong investment 
proposition 
 
4.5.2 Description of the Model 
Research and development in RM technologies is among the riskiest of innovative activities 
and therefore organisations advancing the state of the art have to face and cope with 
associated uncertainties while developing products. Presently, as evident from the hype cycle 
and technology roadmap, RM industrial emergence is in a phase of dynamic change 
characterised principally by a high degree of uncertainty present in all aspects of the overall 
business. Investing in prospects with such high uncertainty is intrinsically risky. Averaging 
potentially profitable prospects by assembling a sizeable portfolio is one way of reducing the 
risk, although one cannot diversify risk away fully. Pharmaceutical companies hedge against 
risk by forming a portfolio of development projects, many in different therapeutic classes and 
seeking diversification through mergers and acquisitions. However, for RM developers to 
launch a new high‐technology product is more difficult given the limited resources they start 
with as most are SMEs, they are unable to use portfolio strategies and thereby face the full 
panoply of technological, investment valuation and policy risks. The six indicators identify 
the key elements of uncertainty which can be dealt by considering the individual components 
of the indicators and changes with time. 
Individual indicators may require radical capability changes in the supply of a product or 
service as developments move through the timeline. This will involve strategically 
rearranging the individual indicator configuration in order to support the emergence of a new 
technology, new business model, new regulatory or reimbursement strategy or putting 
together a new management team. Understanding appropriate indicator configuration, or in 
some cases reconfiguration, and their interactions is a critical part of this process. The 
ultimate goal of this chapter is to generate a reference model that shows the individual 
indicators of overall RM industry emergence, and indicates to what extent industry success is 
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influenced by their dynamics. The reference model illustrates how strategies for different 
indicators emerge from the value chain, including upstream new technologies and novel 
downstream routes to market. 
From a technology perspective, the first effective therapy has a first-mover advantage 
yielding both price and market share advantages and hence enhancing profitability. This may 
not always be true as some of the second generation drugs (Eg: H2 antagonists) have 
performed better both clinically and commercially than their first generation counterparts. 
Similarly in the RM domain, where the final application decides the effectiveness of the 
product, pioneering is also difficult. Organogenesis, a pioneer in manufacturing tissue-
engineered skin equivalents, ultimately overcame their initial financial setbacks and 
demonstrated a viable business model with reasonable profits using the benefit of experience 
and advocacy through industry leadership.  
Uncertainty in the context of technology development implies forecasting of utility, and is 
therefore discussed through technology readiness levels (TRLs) in this chapter. Forecasting 
the impact of the upstream science associated with a novel technology is required to provide 
a potential stakeholder/decision-maker with knowledge needed in the conceptual and 
exploratory phases. Increased knowledge of the enabling technology allows proper allocation 
of resources and infrastructure management for technology implementation and later 
adoption in a particular application. However, success in clinical trials is the primary 
consideration and therefore is the key transforming event for the technology to move forward 
towards the implementation stage. The TRLs describe the milestones to be encountered 
during the development of the technology and describe the uncertainty during the 
development process, and consequently act as a means to understand the impact of 
technology uncertainty associated with the emerging technology.  
Successful business models build a coherent rationale to connect an early-stage technology 
with the realisation of economic value by unlocking latent value from the technology to be 
employed. In general, a novel innovative technology successfully employs a business model 
already familiar to the sector. However, early RM businesses which did employ the 
traditional pharmaceutical business model could not achieve economic success as the model 
did not fit the circumstances of either the technological capability or market opportunity. 
Therefore, technology managers must expand their perspectives in order to find the right 
candidate business model in order to capture value from the underlying technology. Once, a 
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candidate business model is identified and executed, a firm’s technological position can 
further assist its entry into related business areas as experience and infrastructure in those 
technologies can reduce the costs of entering into adjacent areas. Depending on the 
technology capability, either the initial business model can be utilised or a hybrid business 
model can be employed. For instance, in case of a human embryonic stem cell based therapy, 
the cells can be used as a therapeutic themselves (product-model) or can be employed as a 
drug-testing model (product based service-model). Similarly, a technology platform 
providing an autologous therapeutic may also be ultimately utilised to provide an allogeneic 
therapy. Clearly, such combinations will ultimately depend upon the underlying technology. 
Further, if developers want to manage innovations outside their experience and practice they 
will need to invest in integrative capabilities and complementary assets or start separate 
businesses.  
Therefore, the key challenge in defining the business model is linking the underlying 
technology to a profitable economic output with reducing technical and corresponding market 
uncertainties. As both these uncertainties are involved in the linkage, identification and 
execution of a business model to capture maximum value requires understanding of the 
fundamental technology, available resources and potential market. This insight, together with 
the economic environment, should enable developers to decide whether to pursue a vertically 
integrated business model for their product/service or completely license their corresponding 
underlying technology. 
Creating value from technology is not merely managing and reducing technical uncertainty, 
there is significant uncertainty in the commercialisation phase i.e. post technology 
development. The process of shaping an initial business model requires the shaping of 
regulatory and reimbursement strategies, and these strategies are important contributors to 
success. In industries such as RM, which are characterised by high technical and market 
uncertainty, the process of identifying the right strategy for product development may be a 
critical determinant of creating economic value. The lack of a comprehensive, clear and 
uniform regulatory framework creates uncertainties and leads to market fragmentation. 
Methods of enforcement and compliance together with ambiguity about the criteria for 
market approval owing to the uncertainty surrounding the distinction between a biological 
product (BLA/PMA) and a device (510k), are some of the major challenges facing 
developers. Such uncertainty in product classification together with unpredictability in 
marketing approval strategies may impede product development. Resolving regulatory 
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uncertainty by identifying a regulatory strategy with help from the regulator at the earliest 
stages of product development is a vital and necessary element of capturing value from a 
technology. 
The reimbursement potential of any product must be both realized and maximised in order to 
off-set the initial product development costs and provide a significant return on investment. 
However, it is now being recognized that achieving reimbursement for RM products is a 
poorly understood process that is potentially an even greater barrier to commercial success 
for product developers than gaining regulatory approval. Identifying payers is the initial step, 
the real challenge lies in defining the needs of the payer for the appropriate reimbursement. 
The payers can demand clinical evidence that at least equals or even exceeds that required by 
a regulatory authority. This presents the possibility of the requirement to execute additional 
clinical trials in order to satisfy the payers that the product is sufficiently cost-effective to 
justify reimbursement. Payers may want to see more comprehensive clinical evidence ranging 
from safety studies through to large double-blinded multi-centre trials. Therefore, with 
limited resources and increasing uncertainty, it is crucial that product developers place 
substantial emphasis on their initial due diligence process to establish the conditions for 
clinical evaluation before initiating their activities to translate upstream science into a 
commercial venture. 
Effective organisation of a RM company is one of the critical factors for success, together 
with access to capital and robust business models. Leadership needs to be conversant with the 
underlying technology and simultaneously explore alternative business models to evaluate 
both technical and business risks together with reducing uncertainty. They need to explore 
both technical and economic aspects thoroughly so as to effectively manage technology 
commercialisation. Experienced leadership is rare, especially in the early stages of an 
industry. 
 
4.5.3 Conclusion 
The overall reference model for investment readiness is presented as a timeline of the six key 
indicators with reducing uncertainty and increasing value with the aim of assisting late-stage 
translation of RM based products. It was found useful to visualise the industry as trajectories  
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Figure 4-8: Industry Investment Readiness reference model overlaid on the RM Technology Roadmap
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of emergence where value is released by the reduction of uncertainty with time in each of the 
trajectories as the technologies are applied to meaningful clinical applications. In addition to 
reduction of uncertainty along the technology trajectory, it has also been necessary to reduce 
the uncertainty associated with regulation and reimbursement. With this reducing uncertainty, 
business model and consequently investment proposition can become clearer, in particular the 
opportunities for exit for early investors. Industry leadership (people) has been critical to 
progress. Ultimate success will be demonstrated by evidence that allows viable rates of 
adoption of the technologies in clinical practice 
It illustrates that the complex nature of these products means that the issues affecting the 
overall RM industry development go well beyond the primarily scientific and technology 
readiness. Therefore, this model integrates key RM business issues, particularly technology, 
regulation, market and reimbursement together with the coupling of business and investment 
financial strategy, and will consequentially assist research-based technology-intensive RM 
firms as they move closer to market.  
The performance of these firms ultimately hinges upon the successful clinical application of 
their developed products, the key step for creating and realising value, and their ability to 
deal with the fundamental business issues specific to the area. This was particularly evident 
when the reference model was overlaid on the RM technology roadmap (Figure 4-8). Each 
parameter trajectory of the reference model was overlaid on its corresponding domain in the 
technology roadmap. The technology readiness corresponded to the enabling science whereas 
business models together with organisation and reimbursement matched to the business and 
potential market of the products. Regulatory trajectory was overlaid on regulations, standards 
and government policy. Reimbursement is complex with aspects of both market behaviour, 
and regulations and government policy. Therefore, public policy is particularly significant for 
the sector. The investment proposition equated with value creation, thereby suggesting the 
key factor related to any investment related decision is the corresponding value created by the 
enabling science and technology. Finally, by reducing uncertainty and increasing value, the 
trajectory is moved towards the ultimate product/application of the initial upstream science. 
The ultimate business success for an RM venture depends upon the successful application of 
the product or service developed. 
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4.6 Description of the Individual Indicators 
The section describes the six indicators individually in relation to present and potential future 
activity in the RM domain.  
 
4.6.1 Technology Readiness 
Better management of a novel technology to enhance its degree of maturity before 
incorporating it into the appropriate product development programme can directly affect the 
success of the programme and consequently the product. The higher the level of readiness of 
core technologies when incorporated into a product, the greater the probability of a useful 
result (U.S. Army Medical Research 2003). TRLs form a common language for discussing 
and quantifying technology maturity, originally developed by National Aeronautics and 
Space Administration (NASA) in the 1980s (Mankins 1995). The levels provide a repeatable 
system for measuring a technology’s maturity at different stages and assist risk assessment 
when included in an existing or new product development programme. These TRLs are not 
product specifications but only supplement a developmental programme progress 
management system. TRLs for medical technologies have been derived based on present 
industry practices with their R&D processes considered with the relevant FDA regulatory 
framework (U.S. Army Medical Research 2003). The associated risk with a technology 
increases with a lower TRL, and for medical technologies risk reduction is non-linear across 
TRLs as the rate of risk reduction remains fairly low until the very late stages i.e. until the 
safety and efficacy of the specific technology is proved. 
The TRLs can be used to track the progress of an RM based technology as they provide a 
systematic method to evaluate the level of maturity and identify the applicable category 
essential for successful product development. A technology with a TRL of 7 or higher 
indicates it is ready and has been validated at least once, and therefore it is reasonable to 
build new systems based upon it (Mackey, Some et al. 2003). TRLs predict how a technology 
or its associated product behaves in specific environments (Mankins 1995), for instance how 
a certain cell population responds to an in vivo environment or the consequences of the 
disease process on the local milieu which might have some effect on the transplanted cells in 
terms of their viability, differentiation and integration within the host tissue (Singh and 
Williams 2008). As the technology is better defined and thoroughly proven through its 
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refinement and testing, the associated risk diminishes. The technology readiness for RM 
products will further be enabled by the readiness of cell processing techniques including 
automated production and instrumentation systems where the cell product platforms are 
driven by the unmet clinical needs of contemporary medicine (Thomson 2007). The 
underlying challenge is the translation of basic developmental research and data 
accumulation into commercial products for human health. Such translation demands thorough 
validation of the results of carefully constructed technology validation experiments to mark 
the technology readiness steps. Strategic alliances between the practicing medical 
community, university-based research groups, contract research organisations, major 
healthcare players and RM product manufacturing companies will help achieve this (Narula 
and Hagedoorn 1999; Hogan 2005).  
The discovery period during basic research can itself take three to five years or more. This, in 
turn, is followed by a development period of similar or longer length. If the technology 
reaches an appropriate TRL relevant to commercialisation then process definition and risk 
reduction is crucial during these periods. This can be achieved by defining requirements for 
the unmet clinical need during the basic upstream science. Businesses must plan and manage 
the maturing of their technology with time using the TRL model, which assists management 
of risk reduction. The most significant element of the TRL framework is determining the 
relevant environment, in which technologies must be tested to reach TRL 5. In case of RM 
products, relevant environments are an animal model for initial laboratory based studies and 
then human subjects during phased clinical trials. Such test subjects will sufficiently stress 
the cellular product to give an accurate estimate of how the product will perform in its 
intended application.  
Further, it is not sufficient to solely demonstrate the technology readiness and the associated 
reduced risk of such therapies to the clinician, the patient and the regulator; technology and 
supply chain networks must also be in place to realize these therapies at an acceptable cost 
with appropriate distribution networks. Acceptable cost forms a key part of the case for 
reimbursement; further, repeatability of the process is a key requirement of the regulator 
(Singh and Williams 2008). The establishment of such networks and standardized protocols 
on a TRL framework for the development of RM products will have a real and practical 
impact on the overall RM sector. 
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Figure 4-7: Comparison of generic Technology Readiness Levels (TRLs) with TRLs for 
a specific RM based product (TRLs 1-3: Discovery; 4-5: Feasibility; 6-7: Practicality 
and 8-9: Applicability) 
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An example (Figure 4-9) of a typical cellular product from inception to commercialisation is 
shown to illustrate the process. It studies the development of a new technology to produce a 
novel cell based product intended as a therapeutic. For comparison, general TRL levels are 
also presented. 
Example - Development of an RM based cellular product for sensori-neural hearing loss 
(SNHL). This example considers the developmental stages of a typical allogeneic cellular 
product. (Figure 4-9) The initial three TRLs are specific to the discovery phase and define the 
basic principle and technology concept together with initial development activities. In terms 
of SNHL, note that the first three TRLs are confirmed through the experimental demonstrator 
presented in chapter six. Initial therapeutic cell population, cell processing and differentiation 
protocols together with in vitro characterisation studies (marker expression) were defined and 
accomplished. Further, although the evidence requirements are product specific, TRLs 
relating to feasibility, practicality and final applicability are still generic for any cell based 
therapy and not specific for the SNHL therapeutic area, which introduces technological 
uncertainty within the overall development process. TRLs simplify the R&D process by 
furnishing a common language for realizing technology maturity and by providing a 
framework to assess technology risk. Future product specific work validating critical function 
together with safety and efficacy in human subjects will reduce uncertainty, thereby 
enhancing the technology readiness of a cellular product for SNHL. 
 
4.6.2 Business Model 
It is evident from Gartner’s hype cycle that there was unprecedented infusion of capital in 
tissue-engineering based companies from both the public and private sectors on the basis of 
unproven potential (Figure 4-2). Investments and mergers were made across companies 
which made the company valuations reach levels that did not correspond to their underlying 
performance or future prospects (Grisham 2000). Many of the products presumed to be 
blockbusters did not even reach the clinical trials stage. When the hype bubble burst 
valuations tumbled for companies and some had no choice but to file for bankruptcy 
(Bouchie 2002) (Box 2).  
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Despite the scarcity of new capital and the reconsideration by private venture capitalists of 
their investment strategies, some companies have persevered by entering into license and 
partnering agreements. In November 2008, Genzyme and Osiris Therapeutics created a 
partnership to formulate two mesenchymal stem cell based products, Prochymal (a Phase III 
stage product) and Chondrogen, developed initially by Osiris (Mack 2009). Genzyme made 
an up-front payment to Osiris of US$130 million to form a broad based partnership to 
develop the platform technology (2008).  Similarly some service industries did survive by 
entering contract manufacturing, a new commercial activity (Mason 2007). At present 
contract manufacturing organisations (CMOs) constitute a growing sector within the RM 
industry. These organisations own GMP and bio-process resources to produce cellular 
products from mammalian cells. New Jersey based Cambrex (now a part of Lonza) is a 
service provider to the life sciences industry. They have technology platforms to develop bio-
processes to manufacture substances for toxicology and clinical studies. Another contract bio-
manufacturing company, Angel Biotechnology based in Edinburgh, offers pre-GMP and 
cGMP manufacturing support for the development of cellular therapies. Using the services of 
a CMO allows scarce company resources to concentrate on their R&D, core product 
technologies and sales. The definition of industrial standards will further facilitate 
collaborations and outsourcing within the industry. 
 
 
 
 
 
 
 
 
 
 
 
 
Box 2. Recovery and Derivation of a Successful Business Model 
The commercial challenges facing RM induced rethinking of the RM industry value 
chain and consequently of the industry’s fundamental business models (Mason and 
Dunnill 2008). Organogenesis, one of the very first tissue engineering companies signed 
a licensing agreement with Novartis as their global distributor for commercialising their 
skin substitute Apligraf®. While the revenue increased, the cost of producing Apligraf® 
exceeded sales due to the high costs associated with low unit volume production. Further, 
the structure of their agreement with Novartis gave them insufficient royalty on 
Apligraf® sales. The compound effect of these factors forced Organogenesis to file for 
Chapter 11 protection from its creditors in September 2002 (Bouchie 2002). The 
reformed and reorganised Organogenesis, with support from business angels, exited from 
bankruptcy in a better shape and adopted a vertically integrated business model focussing 
solely on their signature commercial product, Apligraf®. Presently, it has become one of 
the most successful RM companies and operates as an independent firm undertaking its 
own research, product manufacture and commercialisation. Its sales have been growing 
steadily at approximately 50% per year, with positive cash flow. Similar overestimation 
of potential markets and a frail business model forced another company, Advanced 
Tissue Sciences which had an approved artificially engineered skin substitute, into 
bankruptcy (Bouchie 2002). 
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The risks associated with the field led to a dearth of private sector venture funding which 
pushed some companies to adopt hybrid business models (Giebel 2005). Companies 
developing clinical cellular products are turning towards marketing these products as toxicity 
assays and disease models for pharmaceutical and biotech customers in the short term. Cells 
used as an alternative to animals for testing will offer an in vitro representation of human 
response second only to the real thing. Scientists at the Harvard Stem Cell Institute have 
initiated a USD 25 million endeavour over five years sponsored entirely by GSK to create 
disease specific cell lines and screening/research/modelling cell based tools across a variety 
of disease areas (Alamo-Bethencourt 2008) (Figure 4-8). Their plan is to study a number of 
diseases that have a mix of genetic and environmental roots. This will also provide the 
pharmaceutical and biotech firms with a clinically reliable screening system that they can 
apply for drug discovery processes (Sartipy, Bjorquist et al. 2007; Crook and Kobayashi 
2008). Also, Vistagen Therapeutics has a major focus in developing stem cells for 
toxicological testing. They use stem cell screens as a part of the prioritization process for 
compounds early on in the discovery and development process. Such cell lines can be used by 
pharmaceutical companies to understand disease mechanisms or screen and/or optimise their 
promising compounds (Jensen, Hyllner et al. 2009). These companies supplying cell screens 
deliver services in return for direct revenue, royalty streams, funded research, or other 
bilateral arrangements. One of the major pharmaceutical firms, Astrazeneca, is working with 
Sweden-based Cellartis on human embryonic toxicology screens. Such screens, using 
embryonic stem cells with a specific ethnic genome, could be used to create ethnic cell 
populations to screen for potential toxicity of drugs as some have deleterious effects in ethnic 
subpopulations. These could never be predicted by conventional animal models (Jensen, 
Hyllner et al. 2009). Systemic toxicity, however, can not be modelled with these approaches 
as they represent only a single cell type’s response to a drug (Sartipy, Bjorquist et al. 2006). 
Thus, stem cells will not replace animal models entirely but will definitely reduce their use. 
However, this identifies multi-cellular/organelle models for pharmaceutical testing as a 
potential business opportunity. 
Such stimulating prospects have again caught the imagination of not only entrepreneurs and 
venture capitalists but also of scientists. These persuasive commercial prospects are driving 
ab initio spin outs. Recent spin outs include Nellone Therapeutics from Battelle Ventures, 
Odontis from King’s College London Dental Institute and Keranetics from Wake Forest 
Institute. As is argued frequently, good science does not equal a good business. Therefore, 
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companies manufacturing RM products must have strong product screening procedures and 
agile funding mechanisms to utilize their research based technology and move towards 
developing their proprietary products in an integrated business model or by outsourcing so 
that they can be quickly translated to the clinic (Bonfiglio 2007). Further, investors and 
entrepreneurs recognise the superior value of the patent protected product, with less value 
residing in the associated high profile science.  
Investors constantly seek to characterize the part of manufacturers in the capital market in 
order to measure their role in the value chain so that they can determine the returns they gain 
from the contribution of the manufacturers in the end product. This is because ultimately true 
commercial value is determined by the value a technology has in realising a novel proprietary 
product with the power to defend itself in the marketplace via patents (Bergman and Graff 
2007). Consequently, firms have a variety of business models to build value. But, due to 
limited resources in the initial stages of a business, the determining factor for commercial 
success is the management of technical and intellectual property assets (Pisano 2006).  
Further, RM products may be analogous to hospital drugs, i.e. typically supplied directly to 
the healthcare providers from the manufacturers. The absence of middlemen in the value 
chain will lead to a narrow buffer zone in the case of supply and demand disequilibrium, 
thereby forcing manufacturers to carry more inventories (Figure 4-10). This might be further 
exacerbated by their short shelf-life. The providers including hospitals, “focussed factories” 
and physician groups are the central actors in the health care value chain and are placed 
where the maximum value is delivered. They cumulatively determine the level of innovation 
they can afford to employ in patient treatment in accordance with the limited supply of 
capital obtained from fiscal mediators. Such distinctions from the conventional healthcare 
industry, particularly pharmaceutical, business models have to be borne in mind before 
investors can unravel the potential of RM products commercially. 
The current economic scenario and the changing dynamics of the overall healthcare industry 
emphasise that RM product companies must continuously rethink and reassess their business 
and revenue models. Creation of value from core technology will be the universal business 
model but the revenue model will hinge upon the nature of the marketing transaction to 
realise this value. This may be done through direct product sales, service sales, licensing of 
technology and related royalties or a hybrid of any of these. In the ideal condition companies 
aim to develop, manufacture and market their products, and create value by inserting their 
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products or services in to the customer’s value chain. However, bearing in mind the 
complexities of RM technologies and an uncertain economic climate, business models will 
have to adapt continuously to shift within value chain networks. Decisions regarding 
operating as a fully integrated company, partnering through collaborations at different levels, 
licensing or outsourcing different processes, would have to be made after due diligence. This 
due diligence has to identify opportunities in the value chain with greatest value and how the 
company can exploit these opportunities using their own resources. Scientific skill, access to 
intellectual property and capital with managerial experience should be used to identify such 
opportunities of maximum value and thereby lead novel, viable business model creation and 
adoption. Other reasons which demand flexibility of business models relate to the emergence 
or decline of a particular manufacturing process, and the behaviour of incumbent players or 
new entrant companies developing similar capabilities. 
 
 
Figure 4-8: RM product value chain 
 
RM products are cell based with or without scaffolds, therapeutic proteins and growth 
factors, and are therefore expensive to produce. This is because the bulk process relies on cell 
processing in a sterile operational environment (Parson 2006). However, helped by high 
potency, the gross margin on these products is typically very attractive. To derive them, the 
platform chosen and process development investment will have a significant impact on the 
overall manufacturing efficiency and cost of goods for a given product (Joannides, Fiore-
Heriche et al. 2006). Early products have required dedicated capacity and hence significant 
capital investment (Polak and Bishop 2006). But with the present process advancement and 
technology improvement, a single business can have a portfolio of products in its 
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development pipeline. Developers are beginning to formulate strategies to build flexible 
process platforms that may be used for multiple products. For instance, as suggested by 
hybrid business models, a single cell culture platform could be used to generate both cellular 
products and cell systems ideal for toxicology testing of drugs and antibody production 
thereby providing significant cost savings. 
The ability of this thesis to arrive at inferences from specific company cases is constrained by 
the relatively short time the industry has been in existence. The nature of the research and 
development process and competition also make it difficult to resolve true best practices from 
specific firm examples. However, robust and flexible business models with appropriate value 
creating strategies will help RM products to create a niche in the market place. This is due to 
the ability of RM products to provide novel and disruptive cost-effective therapeutics to the 
healthcare system, recognising that at present this system rations its economic resources 
(Singh and Williams 2008). 
 
4.6.3 Regulation 
Initially the regulatory framework for the use of human tissues for research and product 
development was not well articulated and regulatory oversight varied. However, at present 
the regulatory agencies worldwide are evolving their strategies for managing cellular 
therapeutics and increasingly using consistent product classification and product approval 
paradigms (Halme and Kessler 2006; Dodin and Singh 2009). Early engagement with the 
regulatory authorities will help the developers to understand their perspective on their 
proposed actions and assist product development at their inception. 
The main objective of enforcing regulatory compliance on product manufacture and testing is 
to provide patients with a product that has equivalent identity, safety, strength, quality and 
purity to the one used to establish the initial proof of concept (Halme and Kessler 2006). The 
regulatory agencies governing RM products aim to protect the safety of the user-population 
and indirectly foster competitiveness amongst the industry (Dodin and Singh 2009). 
Recognising the complexity of these products, the US FDA acted as a leader by initiating a 
comprehensive approach to regulate cellular and tissue based products in 1997. In US federal 
regulation, tissue engineered products are referred to as human cells, tissues, and cellular and 
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tissue-based products (HCT/Ps) and are defined as “articles containing or consisting of 
human cells or tissues and intended for implantation, transplantation, infusion or transfer into 
a human recipient” . The Federal bill deals with “all stages of manufacture from recovery 
through distribution” (US federal Register, 2003). On the basis of this general definition, an 
assignment process has been designed to decide which one of the three FDA centers (the 
Center for Drug Evaluation and Research –CDER-, the Center for Biologics Evaluation and 
Research –CBER- or the Center for Devices and Radiological Health –CDRH-) will become 
the lead center for the pre-market approval review and have primary jurisdiction over a 
specific RM product. The regulatory framework applicable in the EU has some alignment 
with its US counterpart and is expected to foster a similar supportive environment (Dodin and 
Singh 2009) (EU regulations for RM based products are discussed at length in Chapter five). 
The assignment process in both frameworks involves a primary mode of action (PMOA) 
criterion, which is defined in statute as the single action that provides the most important 
therapeutic action. In the case of a combination product in the US, if the lead center lacks the 
requisite information concerning components that are beyond its scope and expertise, it can 
consult with other centers on the basis of inter-center agreements before drawing the final 
judgement on product designation (US Department of Health and Human Services March 
1998). 
The regulations address the current stage of product development and include the necessary 
flexibility to keep pace with technology changes. However, there is a risk that regulations, in 
particular for nascent stage RM products, might be outpaced by technological changes as the 
regulators remain reactive to emerging science and technology. For the first generation RM 
based products, one of the prime regulatory challenges was the absence of precedent for 
regulators with regard to evaluation of their properties (Naughton 2001). Such a state of 
affairs is likely to repeat itself as second and third generation RM products are emerging. 
Lack of disease models and appropriateness of conventional test methods are some of the 
issues which are likely to be raised, emphasising technological uncertainty (Waltz 2008).  
The first embryonic stem cell based product GRNOPC1 consisting of hESC-derived 
oligodendrocyte progenitor cells, a cellular therapeutic for acute spinal cord injury, developed 
by Geron Corp., was put on hold when the Investigational New Drug (IND) submission was 
placed after four years of direct interactions regarding the product with US FDA (May 2008). 
It has now been cleared after nearly 8 months from filing in Jan 2009, for clinical trials to 
assess safety (and efficacy) of the product. Geron stock rose 20 percent following the 
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approval. Such a delay directly reflects the ambiguity and uncertainty surrounding the 
regulatory requirements for conducting such groundbreaking trials. Similarly, the UK 
Medicines and Healthcare products Regulatory Agency (MHRA)  recently approved the use 
of genetically modified foetal cortical cells, developed by a UK biotechnology firm 
ReNeuron, for treatment of stroke, in a clinical trial (Pilcher 2009). This approval also led to 
a 117 percent increase in the firm’s share price. Such regional introduction of products and 
the targeting of corresponding regulatory bodies can act as a barrier or enabler to product 
development and commercialisation depending on the business perspective. It can also affect 
the availability of a particular therapeutic in specific geographical regions where the product 
is approved (MacDonald 2002). Therefore, regional harmonisation will allow SMEs to 
market their product in multiple markets with minimal additional costs and delay (Dodin and 
Singh 2009).  Plus, regulatory regions can learn from each others’ experiences and reduce the 
regulatory burden, as agencies confront an increasing number of complex products. However, 
businesses recognise that the failure of a product due to rejection by a harmonised regulator is 
potentially extremely damaging. 
Carticel®, a first generation tissue engineering product to repair cartilage defects, was 
launched in 1998 in the USA as a surgical device before the FDA called for its withdrawal, to 
later ask for it to be licensed as a biologic. Therefore, to keep pace with the existing 
regulations, the product classification as well as manufacturing strategies (note GMP is 
regulated) for RM products are being designed by recognising the regulator as one of the 
customers during the initial development stages (Dodin and Singh 2009). Such an approach 
might assist later navigation through the regulatory approval process, a substantial challenge 
for SMEs developing RM products. This challenge is largely due to the limited resources of 
SMEs in comparison to the duration and extent of the complex regulatory process, unlike 
large biopharmaceutical companies who have the scale and are well equipped to work 
through the regulatory framework.  
 The recent regulatory developments highlight the new role emerging for regulators. They 
were, especially in the healthcare sector, considered as watchdogs for safety (Naughton 2001) 
but are now more perceived as enablers and are becoming partners to support innovation, 
growth and competitiveness by bringing not only clarity to the regulations but also engaging 
in pre-IND and pre pre-IND submission discussions with the manufacturers (2008). A 
number of public reports have highlighted the role regulation plays in shaping a congenial 
environment for industry and it is now recognised that the pace of the transition from 
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emerging technologies to a new industry significantly depends on the degree of clarity and 
predictability provided by the regulatory framework in place (DTI 2003; EU Commission 
2005). From a business perspective, the common perception of regulation as a red tape 
burden has progressively given way to a more positive approach according to which 
regulation is perceived as a tool to facilitate innovation and commerce (Kent, Faulkner et al. 
2006).  
 
4.6.4 Reimbursement  
The traditional fundamental decision maker in determining treatments to be used by patients 
was the physician. Consequently, the marketing strategy of pharmaceutical and medical 
device companies was essentially in the form of educational campaigns directed to 
physicians, designed to encourage physicians to prescribe a treatment from their product 
portfolio for patients with a particular condition (Lexchin 1993). However, over the last 
decade, payers have acquired the power to influence and determine which treatments patients 
use for different afflictions (Zarkowsky 1999). Previously, managed care was mainly driven 
towards overseeing medical costs but lately it has broadened its focus to support the use of 
cost effective, scientifically sound therapeutic regimes and technology. Stringent evidence-
based medical policies push physician groups to adhere to high standard cost effective 
medical practices. Such a paradigm shift from a physician-prescriber to a stakeholder-payer 
model may ultimately assist cost-effective therapies such as RM products (Mason and 
Dunnill 2008) which are likely to only require a one-off therapeutic procedure. 
Also, managed care organizations (MCOs) have advanced and become sophisticated. They 
also rely increasingly on evidence-based medicine together with regulatory approval to drive 
the reimbursement process. The technology assessment organizations, for example the 
Technology Assessment Program at the Agency for Healthcare Research and Quality, 
evaluate new technologies for these MCOs on the basis of clinical, scientific criteria 
including regulatory approval, improved net health outcome, advantages over incumbent 
technologies and results of controlled clinical trials (Zarkowsky 1999). They also consider 
cost and cost effectiveness. Therefore, the manufacturer, the reimburser and regulatory 
professionals can no longer work individually and must work in conjunction to enable 
appropriate RM product success (MacKay 2006). This necessitates the simultaneous presence 
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of, or access to, these stakeholders during the product planning and clinical strategy forming 
process so that developers do not merely meet the set regulations but also ensure adequate 
reimbursement of the products, thereby allowing ultimate market success.  
Imparting clarity to the key elements of the medical product reimbursement process, i.e. 
coverage, coding and payment, by the partners involved is crucial to the market success of 
any new medical technology. The implications of this for the manufacturers are significant 
and addressing them will also improve the value received by the user-groups and providers in 
the long run. This is because the primary concern of patients and the health providers is 
coverage, i.e. whether the corresponding therapeutic is covered by a payer or not. Coding 
with payment is another issue, i.e. product classification according to payers, mode and 
amount of payment. The integration of the main stakeholders, or those within the business 
representing their perspective, assists the solution of these issues substantially. The regulatory 
affairs professionals verify the type and quality of studies expected by the regulator for 
clearance. Results from such studies form the key component or evidence to support 
favorable coverage decisions. Also, the standard of rigour of the supporting studies carried 
out for the product influences the likelihood of coverage by a reimbursing agency. Further, 
the reimbursement agency involved can demand clinical evidence that may even exceed the 
requirements of the regulatory authority 
As inadequate reimbursement rates can frequently be an impediment to product acceptance 
and adoption by end users in the healthcare environment, cost-reimbursement issues have to 
be identified as we progress towards investment readiness and commercialisation of RM 
products. Matters related to cost recovery and its consequence on clinical and economic 
outcomes are important to identify in the early stages of product development. As the RM 
industry is inching towards the commercialisation of its products, efforts are being made to 
shape its cost-reimbursement and regulatory approval strategies (Hellman 2006). The present 
economic uncertainty has led to budget deficits which are likely to necessitate refinement of 
healthcare reimbursement structures and patterns. Evaluating the impact of expected shifts is 
important to formulate sound investment models. With time, as regulatory pathways become 
clearer and regulators more open, both reimburser and purchaser should provide input to 
initial business decision-making. Such engagement with the product developers will assist in 
coherently identifying and defining the requirements of reimburser and purchaser/provider, 
thereby reducing uncertainty. 
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At present there are few precedents for RM product reimbursement and this is thus likely to 
be influenced by other key gatekeepers i.e. prescribers and providers. Therefore, to get RM 
products reimbursed, a strategic approach will have to be followed by their manufacturers. 
First, provision of pharmaco-economic data early in the clinical program and inclusion of 
Medicare patients in clinical trials will add weight to an overall strategy. Second, apart from 
demonstrating definitive cost effectiveness, a key step is to develop relationships with 
important physicians and patient advocates. Third, an in-depth understanding of the policies 
of the private payers would assist in increasing the probability of product reimbursement. 
In the US, often the primary reimbursement body to be targeted is Medicare, a federal 
program for the aged and disabled, due to its leadership position. It covers 42 million 
Americans and has a very high budget allocation accounting for around 17 percent of total 
healthcare spending (2009). It inevitably has an influence on the healthcare system as a whole 
and the policies and operating practices of other agencies, private insurers and Medicaid (a 
health program for eligible individuals and families with low incomes and resources). This 
implies that exploration of Medicare’s coverage process would enhance the understanding of 
the overall coverage decision-making process, allowing early inclusion of the requirements to 
support reimbursement. 
Therefore, a well-considered and coordinated regulatory-reimbursement scheme with 
relevant and high-quality of clinical evidence supporting the product will increase value and 
reduce the inherent uncertainty in the present reimbursement mechanism. The standards for 
determining what is reasonable and necessary, in terms of a therapeutic regime, by a payer 
are constantly evolving and subject to continuous change. Herein lies the opportunity for RM 
products to carve their niche in the healthcare sector. This will require satisfaction of the 
reimburser by provision of sufficient data based on scientific and clinical studies that clearly 
demonstrate cost-effective medical benefit to the patient (McAllister, Dusserre et al. 2008). 
 
4.6.5 Leadership/Organisational Development 
It is often quoted that venture capitalists invest in people rather than ideas and that a team 
with a good reputation has more chance of attracting funds (MacMillan, Siegel et al. 1985). 
Further, composition of a management team is a key determinant of organisational outcomes 
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and performance as it can influence the process of strategic decision making and 
implementation (Carpenter, Geletkanycz et al. 2004). Management ability, technical skills 
and previous experience are often the deciding factors in taking a novel idea from an exciting 
scientific concept to a real commercial entity while simultaneously reducing uncertainty. The 
team should balance well with one another and the past experiences and achievements of 
individual members should fill in all skill-gaps with little duplication. Successful innovation 
rests predominately on the skills and the art of management practiced inside a firm by the 
team. Industry experienced managers and leaders within the management team can further 
facilitate growth as their competencies can assist in capturing new growth opportunities and 
assigning the limited resources of the venture to competing projects efficiently (Kor 2003). 
From the outset it is necessary that roles are distinctly defined for the team members at 
management level who will contribute to the development of the overall business. This is 
especially crucial during the start-up and initial growth phases when members are likely to be 
asked to assume more than one significant role. This ensures no area is over-looked and a 
successful route to business expansion is identified. The team leadership must be capable of 
understanding the relevant science, recruiting outstanding talent, and managing investors and 
multiple projects together with allocating resources effectively. Appointment of leaders in a 
scientific advisory board not only enhances the credibility of the business to investors, but 
they also mentor and advise on scientific direction by providing an objective assessment of 
the progress, goals and timelines. They further contribute in shaping profitable business 
models and consolidate pipelines for the overall business (MacKay 2006). The RM industry 
has experienced ups and downs and is presently consolidating its position in the healthcare 
arena. Each company is in the phase of forming competitive teams and incorporating unique 
skill-sets to facilitate integration of their novel technology based RM products into the overall 
healthcare system.  
As in the case of any high-tech industry, founder teams in RM are mostly composed of 
scientists who were involved in developing the firm’s basic technology. These scientists are 
familiar with the overall technology development process and know its strengths and 
weaknesses. Their tacit knowledge is crucial to correct strategic decisions and allocate 
resources for further technology development and optimisation. However, the benefits a 
venture can gain from such founder experience appear to depend upon the business model 
employed. Firms employing a service/platform model have a basic technology at the core of 
their business which draws on the knowledge related to the underlying technology to 
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facilitate strategic decisions for further technological development. In contrast, businesses 
involved in developing products might employ different technologies for product 
development which involves high knowledge turnover; therefore, a founder scientist’s 
knowledge about a specific technology becomes less important for these businesses (Casper 
2000). 
Further, industry specific experience of management teams is also important for business 
success as industry familiarity assists in reducing uncertainty associated with a new 
technology or business within the same industry. This is primarily due to their network and 
their transferrable knowledge of the opportunities, competition and regulations specific to the 
industry (Kor 2003). When a company launches its first product onto the market, it has to 
manage resources and balance its commercial expenses against its research and development 
funding. Intercytex, after placing their aesthetic medicine Vavelta® product line for skin 
rejuvenation and repair in the market, which was somewhat easier to navigate through the 
regulatory network, effectively balanced earnings growth with funding research and 
development of its skin and hair products pipeline. In some cases where the product 
technology does not meet initial success, a change of strategy is an alternative to liquidation 
or selling the remaining value of the company. In this regard Organogenesis had filed for 
Chapter 11 bankruptcy in 2002 but was then taken private by an investor group led by a new 
management team which focussed solely on their signature product, Apligraf®, and became 
essentially debt free. As part of their reorganisation plan they paid off their 35% debt and 
ended the agreement with Novartis Pharma AG as exclusive distributor. At present they are 
profitable and are fully integrated with a sales figure reaching $25 million. This demonstrates 
the strength of the technology and the resilience depicted by leadership under difficult fiscal 
conditions (Kemp 2006) (Box 2). 
The size and scale of RM companies does not allow for separate functional units for each 
stage of product development. Instead, RM companies could organise around integrated 
business units grounded on their respective therapeutic, customer or technology area of focus. 
Such units allow for specific business-area profitability, increased return on investment and 
functional productivity instead of focussing only on overall product revenue (Gilbert, Henske 
et al. 2003). While restructuring will assist in reducing uncertainty related to other 
components of the reference model, it will also enhance coordination and decision making 
with increased accountability around each area of focus. For instance, Johnson and Johnson 
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have successfully created a decentralised organisational model based on discrete business 
units, one of which includes an RM incubator. 
 
4.6.6 Investment Proposition 
The costs and risks associated with the development of an RM based cellular products can be 
higher than those for the development of conventional new drugs (Pangarkar and Hutmacher 
2003). First, most of the cell based therapies currently under development are directed at 
treating conditions that have more complex etiology and/or are difficult disease targets (Singh 
and Williams 2008) (i.e. conditions which at present have either no or subnormal 
pharmaceutically based therapeutic regimes), thereby increasing the cost of the basic research 
and development process with limited probability of commercial success (Lysaght, Nguy et 
al. 1998). Second, the research and development process for cellular products is being driven 
by new scientific discoveries, a process that is far less predictable from a commercialisation 
perspective (Mironov, Visconti et al. 2004). This is why, despite significant preclinical data 
with some clinical successes (Higgs 2008), several promising RM companies have gone out 
of business (Bouchie 2002). 
Globalisation is a powerful force sweeping through this industry and which affects the 
security of investment. The business is no longer limited to the US or EU, but includes 
developing countries (Greenwood, Singer et al. 2006), in terms of both the development of 
new treatments and as potential future markets for these products (Salter, Cooper et al. 2007). 
With sophisticated lab space and US/EU trained scientists, these labs operate at relatively 
small research costs under rigorous regulatory regimes with maturing intellectual property 
laws in these countries (Ahdieh, Lee et al. 2007). For instance, in India the intellectual 
property rights protection is now strengthened after the establishment of the product patent 
regime in 2005 (Smith 2000). The new regime allows patent protection for products instead 
of the earlier system of patenting 'processes'. Under the earlier system, regional companies 
could legally develop a low-cost version of the innovator's product through the application of 
different processes (Smith 2000). This new regime of product patent protection works as an 
incentive for Indian companies to produce their own intellectual property and emphasises a 
rational approach to building up a globally competitive biopharmaceutical industry in a 
controlled regulatory environment to produce safe and superior products (Kumar, Quach et 
Industry Investment Readiness Model 
 
128 
 
al. 2004). As a result some Indian pharmaceutical companies have jumped to globally 
prominent positions. The indigenous market size and the capacity to manufacture and supply 
biopharmaceutical based products (Salter, Cooper et al. 2006) to the West has become an 
attractive option for both investors and manufacturers to base their operations in India, China 
& South America (Frew, Kettler et al. 2008; Lander, Thorsteinsdottir et al. 2008). It is 
estimated that drug production costs in India are 50% less than those in US (Morel, Acharya 
et al. 2005). Further, the federal governments of these countries are also in the process of 
funding RM based-initiatives as these are deemed vital to their future economic success, as 
well as giving the societal benefits of improved health care (Greenwood, Thorsteinsdottir et 
al. 2006). The FDA’s “beyond our borders initiative” is another indication of the increasing 
globalisation in this sector (Eschenbach 2008). The increase in the number of FDA 
inspections in these countries by competent authorities with third-party certification will 
certainly ensure that all imported products are to the applicable FDA safety and 
manufacturing standards. These countries are also embarking upon RM capacity-building 
initiatives to address their own health needs and create opportunities for economic 
development (Greenwood, Thorsteinsdottir et al. 2006). 
A unique idea with a therapeutic application and robust intellectual property protection that 
has emerged after completion of core research and establishment of proof of concept studies 
forms the basis for reaching out to potential investors to start a business (Spar 2004; Murray 
2007). The first point of contact to acquire financial support in addition to personal finances 
can be traditional government funds, which have financial initiatives in this area, to set the 
stage for further activities (Box 3). 
 
 
 
 
 
 
 
Box 3. Government funds for private spin-outs 
The first spin-out venture from the Cambridge-MIT Institute, Orthomimetics, a medical 
device company, received a third government grant through the Technology Strategy 
Board (TSB) to support their research and development. The project is based on a 
combination cell therapy technique with their proprietary tissue specific 3-D scaffolds for 
improving joint tissue regeneration and hence broaden their product portfolio for 
cartilage, ligament and tendon repair in joints (Company Press Release, Oct 2008). 
Intercytex, another UK based RM company, is part of a group selected to establish the 
US Armed Forces Institute of Regenerative Medicine (AFIRM). AFIRM, a multi-
institutional, interdisciplinary network, is supported by a foundation grant from the US 
government totalling $85 million to develop RM based advanced therapeutics for 
battlefield injuries. 
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In national territories public funding of healthcare based research is well established, driven 
by the central goal of improvements in health with the secondary intention of significant 
economic benefits (Lysaght 2005; Moses, Dorsey et al. 2005). Also, regional venture capital 
investment is influenced by the concentration of technological, entrepreneurial, professional 
and financial activity together with the level of network connectivity (Cortright and Mayer 
2002). The level of technological expertise and the number of entrepreneurial opportunities 
with the presence of professionals and business infrastructure are proportional to the capital 
demand in a specific regional area (Hayden 2008). USD 3 billion was authorised as tax-free, 
general obligation, state bonds to an institute dedicated to stem-cell research, the California 
Institute for Regenerative Medicine (CIRM), by the State of California following dialogue 
with its electorate (Dalton 2005). This investment by Proposition 71 is anticipated to render 
income for the state from fresh royalty and tax revenues ensuing from increasing economic 
activity in the biotechnology industry. By leading to new treatments that researchers believe 
could be treated or cured with stem cells, Proposition 71 has the further potential to furnish 
substantial reductions in the state’s health care expenditure, which at present adds up to 
greater than $110 billion per year (Baker and Deal 2004; Longaker, Baker et al. 2007). Such 
a regional focus with superior intellectual capital provides a better quality business 
environment and support in terms of high-skilled human capital, consultancy and general 
infrastructure that are integral to business development. This ultimately influences the 
development of more viable investment opportunities, particularly to make businesses 
“investor ready” by demonstrating the potential of the new technology with an appropriate 
business plan (Mason and Harrison 2001). 
Further funding can come from corporate venture groups, venture capitalists and for profit 
product companies (Regalado 2005) or corporate investors. At the same time, creative 
sources of funds can be sought by either forming an alliance with a strategic partner or out 
licensing non-core technology or generating cash flow by supplying lab services. Another yet 
unexploited source is the health insurance industry, they already account for a small-scale 
share of capital invested in the biotech sector. They can not only provide funds but can also 
help in distinguishing ideal markets towards which the start ups can develop their product 
technology (Mason and Dunnill 2008). 
Recently, expiring patents with a limited product pipeline are diminishing the pharmaceutical 
industry’s revenues. This economic change has led to a vigorous evolution of the large 
pharmaceutical industry’s business model, which is shifting towards mergers and acquisitions 
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(Higgins and Rodriguez 2006) together with external alliances (Whittaker and Bower 1994) 
for better risk management and cost containment (Heracleous and Murray 2001). In this 
scenario, RM start ups may give investors a powerful exit strategy on the basis of being 
acquired by a large pharmaceutical business at a later stage when increased capital is required 
to navigate the regulatory framework and maintain growth, which pharmaceutical industry 
will be in a better position to afford. Also, they might have an interest in RM based 
technologies complementary to their present product portfolio, giving them an opportunity to 
capture a larger market in a particular domain or control a bigger portion of the value chain 
(Regalado 2005). They also may have an interest in entering a new therapeutic domain in 
which they have not been active previously or have any kind of presence (Alamo-
Bethencourt 2008). Another option is based on exploiting the patents held by major 
pharmaceutical companies for drugs which are on the verge of expiry with consequent effect 
on their cumulative revenue (Relman and Angell 2002). Outsourcing or selling off 
technology related intellectual property that allows patent extension could be another exit 
strategy for RM start ups. Therefore, to replace the lost revenues on either products or 
patents, the pharmaceutical companies need to find new products to consolidate their 
pipelines. Cellular products may be able to fill this void, and to their advantage may get the 
requisite capital needed for their development to reach the market. 
To sum up, the limited funds available at present for these innovative-research technology-
intensive SMEs, together with the imperfections of the capital market, suggest that the 
sourcing of external financing is significant to reduce the funding gap and realise the 
therapeutics these SMEs are capable of generating. Due to the initial lack of sales, together 
with the high risk associated with technology and market acceptance (Ahsan and Nerem 
2005; Giebel 2005), the firms have limited access to (public/bank/govt.) loans. Therefore 
these SMEs require the external equity of venture capital companies or corporate investors to 
develop their final products even though it is the most expensive financial resource. 
Alternatives may be found in regional grants, but these are location specific. Capital is 
required over the product development life-cycle in the form of regular cash injections from 
target identification to commercialisation (Leuty 2009). The growth and eventual size of the 
market for such products and the radical nature of innovation creates an expectation of high 
financial returns for investors. Long-term business sustainability increases revenue quality 
and prospective revenue trends assessment is vital to accurately assess risk and earning 
power. Hence RM firms developing novel healthcare applications with demonstrable markets 
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and with the new technology platforms to develop such applications offer an attractive 
investment opportunity. The industry is investment ready for those businesses aiming to 
create cost-effective therapies and building an appropriate portfolio of venture, grant and 
other stakeholder funding. 
 
4.7 Key Factors offering High Growth Potential 
The emergence roadmapping process and the Gartner’s hype cycle for RM clearly show the 
progress and setbacks of the industry as a whole. They demonstrate the different enablers and 
value creators for the products, many of which are at present in the later stages of clinical 
development, and some have reached the market. Of the many potential opportunities for 
products in their later stages of clinical development, the research in this chapter identifies six 
key factors of the industry that must be in place for high growth potential: 
1. Intellectual Property Strategy: It is clear that initial RM companies emerged too 
rapidly from their academic labs as spin outs to exploit their early scientific IP in the 
commercial arena. The complex and varied intellectual property landscape at present 
is challenging, therefore a strategy based on trade secrets could be reasonable; 
exclusivity protected in this way may be kept more simply and for a longer duration 
for competitive advantage when compared to protection through classical patent 
applications. It would also be sensible to carefully examine the intellectual property 
environment globally as some other countries may have fewer barriers. 
 
2. Flexible Business Models: This is the key for survival as some of the early businesses 
have survived by reshaping their business models from totally integrated to 
decentralised or vice versa and by identifying alternative funding mechanisms. The 
research suggests that ultimately the RM sector will include a variety of business 
models, each directed at different categories of innovation. This eventual structure 
will be dependant on the enabling science and its associated applications, market 
potential, presence of investors, contract manufacturers and distribution channels, 
within the overall prevalent economic scenario. 
 
3. Early liaison with regulation: Early engagement with the regulatory authorities to 
discuss and resolve product development challenges will be a key. Lessons from the 
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past clearly demonstrate that the regulation has been a negotiated process and as such 
has been reactive to technology and product developments in the whole field of RM. 
Such early interactions facilitate an efficient and effective product review process. 
 
4. Reimbursement: Gaining reimbursement for RM products is a substantial yet 
manageable challenge. The probability of getting appropriate reimbursement is more 
likely if these issues are part of the overall product development strategy and data is 
compiled from early on in the development process for payer evaluation. Inclusion of 
clinical as well as financial impact into trial designs to generate pharmaco-economic 
data will be essential as clinical outcomes, particularly those that positively affect 
patients’ quality of life and overall costs to the healthcare system, will be intensely 
audited and scrutinized. 
 
5. Convergence of the RM industry with the pharmaceutical, medical device and 
biotechnology industry:  These big players are identifying potential partnering 
opportunities to strengthen their product portfolios. Products that will be able to 
attract these players can be expected to be those that have clear advantages in terms of 
health economics and clinical value, as well as a robust manufacture and supply chain 
to balance price, value, cost-effectiveness and outcomes. 
 
6. Target stakeholders:  Engaging stakeholders such as patients, patient groups and 
physicians to help build support for regulation and reimbursement of the 
corresponding products will assist in navigating both these frameworks in a more 
efficient manner. 
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4.8 Conclusion 
The chapter has described six strategic indicators which enabled a balanced assessment of the 
principal investment risks associated with investment readiness of the RM industry. These are 
organised into a parallel timeline as trajectories – the investment readiness reference model. 
The use of such a model helps to assess the investment-readiness of RM as an industry in an 
integrated, structured, evidence-based framework to create and foster commercialisation of 
RM based products. The behaviour of the model will be dynamic (and non-linear) and will 
particularly reflect the current appetite of the “markets” for financial risk. 
At present RM is in the process of carving a niche for itself in the overall health care sector. It 
is building momentum with new technologies and products and providing partnering 
opportunities. As the RM industry is in the process of adapting to the transforming regulatory 
and reimbursement regimes combined with continued pressure on cost, associated risk can be 
mitigated and expectations of the stakeholders can be met by matching risk with return. This 
ultimately signifies investment readiness of the industry. 
A billion dollar RM industry is being predicted in the coming decade with serious global 
players and others entering the territory as the commercial potential is becoming clear. With 
continuous growth and commercial success big pharmaceutical companies are likely to 
become major players in the field. A merger with such a player, as the key exit strategy, will 
provide RM product manufacturers capital, familiar branding, increased efficiency in 
manufacturing and distribution, and a strong presence in the overall healthcare sector. In 
return, the pharmaceutical company will add products to its failing pipeline. Such deals 
would lead to promising therapies entering the commercial market not only to produce 
revenue but also to save or improve lives. If the RM industry is to develop into a profitable 
sector/business, it will have to manage risk and capitalise on the opportunities in the overall 
sector and work globally. The emergence trajectories give healthcare investors an enhanced 
understanding of the RM value chain and the impact of the uncertainties in the market forces 
operating in the RM sector. This understanding will ultimately assist in the creation of a 
sustainable new healthcare domain. 
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5.1 Introduction 
This chapter focuses on the emergence of regulations for advanced therapy medicinal 
products (ATMP), particularly in Europe. It explores the impact of these recent 
regulations on RM product definition and the consequent complex interactions 
between regulatory requirements and product and process design, product 
development and manufacture and ultimately business risk. Section 5.2 discusses the 
methodology applied to compile this chapter, and section 5.3 presents the procedural 
strategy adopted by the regulators to establish the regulatory framework. The current 
critical gaps in the European regulation are identified by assessing the demarcation 
issues between different product categories in section 5.4 and the further implications 
on developers and hospitals are discussed in section 5.5 and 5.6, respectively. Section 
5.7 discusses how these regulations will help in promoting end-user confidence and 
section 5.8 discusses issues related to clinical trials of RM products. The chapter 
finally explores some of the potential shortfalls within specific product categories of 
the mandate in section 5.9 with regard to current and future research and development 
activities for RM products. The chapter concludes by discussing the implications of 
the research findings, and means by which the gaps can be closed. 
 
 
5.2 The ATMP regulations 
The latest regulatory regime introduced by the ATMP Regulation seeks to harmonise 
the diverse regulatory framework which has prevailed in the European Union (EU) for 
commercial ATMPs and led to market fragmentation across member states. By 
providing a centralised marketing authorisation, the new regulation is expected to 
have a positive impact on the availability of innovative treatments to patients across 
the EU as well as on other healthcare issues like the length of stay in hospital, the 
improvement of quality of care and, not least, the comfort of the patient. The 
Regulation (EC) No. 1394/2007 defined specifically for ATMPs, merges gene and 
somatic cell therapies, for which EU regulatory requirements already exist, with tissue 
engineered products (TEPs) (Figure 5-1), which before this legislation did not fall 
under the scope of a defined set of regulations at the EU level (Williams 2007).  
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Responding to industry concerns, the regulation aims to put an end to the existing 
patchy regulatory situation. In the absence of a comprehensive EU regulatory 
framework, member states have developed their own set of rules which have resulted 
in market fragmentation (Brevignon-Dodin and Livesey 2006). Manufacturers were 
confused about the “optimal path” to develop and commercialise TEPs (Sanzenbacher, 
Dwenger et al. 2007). This problematic assignment of products to the legislation, 
variable approaches taken by EU member states and a fragmented market introduced 
a number of issues for the developers from production, application and post-market 
follow up (of the products). In this context, the ATMP Regulation is designed by the 
EU Commission to set up a centralised marketing procedure and to achieve access of 
ATMPs to the whole community market while increasing trust of the user groups in 
these new products. It came into force in December 2008 and brings clarity to 
manufacturers in terms of the requirements of conforming to regulations set for a 
particular product and the overarching guidelines laid for medicinal products. In 
parallel, the common and transparent framework will minimize risks and uncertainties 
faced by the manufacturers. It is therefore anticipated to have a positive impact on the 
availability of ATMPs to patients(Kent, Faulkner et al. 2006). 
The framework adopted by the ATMP Regulation is a cohesive document built on the 
directives laid down for medicinal products (gene therapy and somatic cell therapy) 
for human use (Directive 2001/83/EC), quality and safety standards in respect of 
human tissues and cells (Directive 2004/23/EC), medical devices (Directive 
93/42/EEC), active implantable medical devices (Directive 90/385/EEC) and 
centralised procedures (Regulation No. 726/2004) (Figure 5-1). A timeline of defining 
milestones in the process of drafting ATMP Regulation since the early 2000‟s and the 
participation of industry/developers are shown in Table 5-1.The ATMP Regulation 
therefore represents an ambitious attempt to provide a harmonized regulatory 
framework addressing a large range of advanced therapies and has been welcomed by 
the RM industry. However questions remain as to the “umbrella” strategy it has 
adopted and the appropriateness of some of its requirements meant for gene therapy 
medicinal products, somatic cell therapy medicinal products and TEPs. Concerns have 
also been expressed regarding the capacity of the ATMP Regulation to adapt to 
further technology evolutions and to the development of complex applications, 
combining aspects of these different therapies. 
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Figure 5-1: Regulatory Pathway for a regulated biological medicinal product
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Date Defining Milestone 
July 2002 Public consultation launched by the DG Enterprise of the 
EU Commission to assess the need for a Community legal 
framework on TEPs. Contributions from SMEs represent 
55% of the overall contributions 
2004 Public consultation launched by DG Enterprise on the 
content of a future regulatory framework for TEPs 
16
th
 April 2004 Stakeholders‟ conference organised by the EU 
Commission 
2005 Public consultation launched by DG Enterprise on a draft 
proposal for a Regulation on advanced therapies 
16
th
 November 2005 Publication of the proposed ATMP Regulation by the EU 
Commission 
13
th
 September 2006 Rejection of the parliamentary report issued by the given 
committee on the ground that it contains ethical 
amendments 
30
th
 January 2007 Adoption of the parliamentary report with no ethical 
amendments 
25
th
 April 2007 Vote on the ATMP Regulation by the European 
Parliament 
31
st
 May 2007 Agreement on the ATMP Regulation by the EU Council 
of Ministers 
30
th
 October 2007 Formal adoption of the ATMP Regulation by the EU 
Council of Ministers 
10
th
 December 2007 Publication of the ATMP Regulation in the EU Official 
Journal 
30
th
 December 2007 Entry into force of the ATMP Regulation 
December 2008 Application of the ATMP Regulation to all economic 
operators 
 
Table 5-1: Timeline for the framing of ATMP regulations 
 
Therefore, the aim of this chapter is to understand the development of RM industry 
via an approach attending to emergence of regulations for ATMPs, particularly in 
Europe, and henceforth develop a regulatory strategy (as shown in Figure 5-1) which 
might assist product developers in successfully navigating through the overall 
framework. Europe allows the study of its impact on both socialised and private 
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medical care systems. The objective is to demonstrate how the regulatory trajectory is 
part of the reduction of uncertainty and consequent ordering of the overall RM 
domain (in the “reference model”, developed in chapter four). The discussion runs on 
two tracks. Firstly, the impact of these regulations on RM product definition and 
development is explored. The consequent implications for product developers from 
both technology and business context are discussed. Secondly, in parallel and equally 
important, given the inherent risks of RM, some of the potential shortfalls which the 
ATMP regulation still raises with regard to facilitating the research and development 
of advanced therapies are presented.  
The latest regulations on ATMPs are based on a regulatory strategy that aims to 
consolidate the increased activity in the RM domain while maintaining the pace of 
technical development and innovation. However, while providing a much expected 
harmonised regulatory framework, the new regulation has still to demonstrate its 
capacity to keep up with radical technology changes. The chapter identifies current 
critical gaps in the European regulation by assessing the latest provisions of these 
recently framed regulations and considers certain mandates which are anticipated to 
have significant impacts on developers particularly salient in shaping the prospects of 
RM. 
 
5.3 Methodology 
This chapter is based on a number of discussions with stakeholders in the RM domain 
and on conference attendance in order to define a scope of investigation. It is 
complemented by desk research using in particular the materials put online by the 
European Commission. The analysis draws upon data from documentary materials 
with a focus on European Union, gathered between 2006 and 2009. A wide variety of 
policy-related documents including European Parliament debates, drafts of European 
regulations and associated „public‟ consultation documents, position papers from EU-
level trade associations, regulatory agency documents, and manufacturers‟ and 
professional codes of practice were collected. A number of scientific, industry, 
regulator, and policymaker discussion forums were observed. 
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The chapter outlines the regulatory system for ATMPs in the EU and discusses the 
expected changes the new framework will bring in terms of the regulatory landscape. 
It also provides an overview of the emerging regulatory framework and then 
elaborates on issues related to developing platform products for hybrid business 
models, increased market size, and advantages to developers and hospitals, and expert 
assessment for product safety and public confidence. Further, the potential shortfalls 
of the ATMP regulation for the three product categories with regard to research and 
development activities of advanced therapies are explored. A number of issues, for 
instance, demarcation, trial design, bio-safety of gene therapy products and the 
characterisation requirements regarding cell therapy products are addressed. 
 
5.4  Procedural strategy adopted to establish the framework 
RM being an emerging and fast moving field whose technological development and 
potential risks are not fully foreseeable, EU regulators had to strike a difficult balance 
between the possibility for patients to gain rapid access to promising therapies and 
“appropriate guarantees on safety and quality”. Designing such guarantees was 
especially tricky as they need to allow for a certain degree of flexibility in order to 
keep pace with the technological evolution. 
 
5.4.1 Two-Staged Strategy 
EU regulators therefore opted for a two-staged regulatory strategy with a regulatory 
level built on existing and newly introduced EU provisions, the latter being laid down 
in priority to deal with TEP marketing authorisation procedure, and a technical level, 
encompassing all the technical requirements covering the whole development process, 
from production, handling, storage, transport and including traceability of the donor. 
The overarching framework was therefore limited to fundamental issues, like the 
centralised marketing procedure and the introduction of specific incentives for SMEs 
(small and medium sized enterprises), but when it came to GMP and GCP for instance, 
detailed rules were left blank. This way, the ATMP Regulation was quicker to draft 
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and adequate flexibility was introduced into the Regulation to keep pace with 
scientific developments. 
The combination of a general framework for all ATMPs with flexible provisions, to 
be drafted by the European Agency for the Evaluation of Medicinal Products (EMEA) 
or through an EU specific procedure named Comitology which involves the 
Commission, the European Parliament and member states‟ representatives, is a 
determining characteristic of the ATMP Regulation. It explains the complexity of the 
resulting regulatory structure proposed by the EU Commission which combines 
numerous pieces of existing legislation with new provisions and to be defined rules 
(Figure 5-2). 
 
 
 
Figure 5-2 EU Commission regulatory strategy towards TEPs 
- Adapted from the report on impact assessment (EU Commission 2005) - 
 
As a consequence of the regulatory strategy the EU Commission opted for, key 
technical requirements and guidelines for TEPs, entailing important implications for 
industry, are still in the process of being drafted. However, comparing the ATMP 
Regulation to an “empty shell” does not seem accurate (Akerblom 2006). The 
Regulation is far from being content free though it is true that numerous requirements, 
Dir. 2001/83/EC as amended by Dir. 2004/27/EC (Revised 
Community Code on medicinal products) + Reg. 726/2004 on 
medicinal products’ marketing authorisation + Dir. 93/42/EC 
and 90/385/EC on medical devices + Dir. 2004/23/EC on human 
tissues and cells + Dir. 2001/20/EC on GCP 
Regulation on TEPs 
(e.g. introduction of new definitions, requirements for marketing 
authorisation, fee reduction in the EMEA procedure) 
Existing legislation 
 
Specific  legislation 
introduced by the 
Proposal 
 
 
Main technical requirements 
(e.g. type of pre-clinical and clinical data required) 
Technical requirements 
still to be defined through 
a comitology procedure 
 
Further technical requirements 
(good clinical practice, good manufacturing practice) 
Guidelines 
still to be defined by the 
EMEA or the Commission 
 
existing rules rules to be established rules introduced by the proposal 
Technical 
level 
 
Regulatory 
level 
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upon which depends the practicability of the new regulatory regime, are not yet set 
with certainty (figure 5-3). 
Guidelines on GCP, GMP and traceability are now to be finalised by the Commission, 
and the EMEA is currently tasked with developing guidelines on post authorization 
risk management. A considerable amount of detailed work before implementation is 
therefore still required (Pickering 2007) . 
Even though the ongoing drafting of the technical requirements makes it difficult to 
foresee exactly all the possible impacts the ATMP Regulation will have on developers, 
some hypotheses may nevertheless be advanced. 
 
 
ARTICLES 
 
 
SUBJECT 
 
PROCEDURE 
 
ART. 4 
 
 
Good Clinical Practice 
 
 
Drawing up of guidelines by the Commission 
after consulting the EMEA 
 
ART. 5 
 
 
Good Manufacturing Practice 
 
Drawing up of guidelines by the Commission 
after consulting the EMEA 
 
ART. 15 
 
 
Post authorization risk management 
 
Drawing up of guidelines by the EMEA 
 
ART. 16 
 
 
Traceability 
 
Drawing up of guidelines by the Commission 
 
ART. 19 
 
 
Scientific evaluation and certification 
of SME data 
 
Comitology 
 
Art. 24 
 
 
Adaptation (of annexes) to scientific 
and technical evolution 
 
Comitology 
 
Figure 5-3: Requirements to be developed subsequent to adoption of the ATMP 
Regulation 
 
5.4.2 Expert Committee constitution 
The setting up, within the EMEA, of a special committee, the Committee for 
Advanced Therapies (CAT), to work with already existing working parties (BWP, 
GTWP, CPWP), echoes the complex nature of these products as well as the expertise 
required by a regulatory body to endorse such products. Tasked with drafting opinion 
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on the quality, safety and efficacy of a specific ATMP, the CAT will offer not only 
recommendations to the Committee for Medicinal Products for Human Use (CHMP), 
responsible for issuing the final scientific opinion, but also scientific expertise and 
protocol assistance to the developers. Developers have welcomed the creation of the 
CAT as the assessment requires specific expertise but they have also voiced some 
concerns. The CAT‟s demand for suitably qualified members might result in 
shortages as not many national agencies have experience in this emerging science, and 
competition for personnel from other related fields like pharmaceutical or medical 
devices will add further pressure. Possible conflicts of interest may further complicate 
the task of populating the new committee. 
 
5.5 Demarcation issues 
Gene therapy and somatic cell therapy medicinal products have been previously 
covered and defined by European regulations. They encompass products in which 
genes or cells have been transformed to perform a prophylactic, diagnostic or 
therapeutic effect once transferred into the patient body. However, TEPs have been 
recently defined by the ATMP Regulation. They involve the growing of living cells, 
seeded on a supporting structure, to form a three-dimensional tissue or organ to be 
implanted into the patient body to repair or replace tissue damaged by injury, disease 
or the aging process. They also include combination products containing viable 
human cells and tissues in addition to a medical device part. 
Including gene therapy medicinal products, somatic cell therapy medicinal products 
and TEPs under the same scope has been decided by EU regulators as they consider 
these therapies to compose a coherent therapeutic group. The rationale underpinning 
this decision is described in the impact assessment issued by the EU Commission in 
2005 (2005). These products share key common features and may involve in their 
composition elements of these different categories (Sanzenbacher, Dwenger et al. 
2007). They are based on complex and innovative manufacturing processes aiming at 
modifying genetic, physiological or structural properties of cells and tissues. Their 
evaluation encompasses crucial aspects in terms of traceability from the donor to the 
patient as well as long-term patient follow-up and they require a thorough post-
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authorisation risk management scheme. They are also subject to rapid and often 
radical innovation. 
However, forming a coherent group does not mean that demarcation issues cannot 
occur. EU regulators have foreseen this possibility by setting a „priority‟ rule. 
According to this rule, products falling both within the definition of a somatic cell 
therapy medicinal product and a TEP will be considered a TEP. According to the 
same rule, product that falls within the definitions of a somatic cell therapy medicinal 
product and a TEP as well as gene therapy medicinal product will be regulated as the 
latter (von Tigerstrom 2008). Such a hierarchy may be useful to work the scope of the 
ATMP Regulation but could also potentially lead to classification errors and possible 
lengthier evaluation time by regulators as the interfaces between the different types of 
advanced therapies are increasing. This can be seen in numerous cases wherein ex-
vivo transduction of stem cells including human embryonic stem cells with integrating 
retroviruses is being used as a strategy for several diseases and stem cells themselves 
from a range of different tissues are becoming targets for gene therapy applications. 
 
5.6 Implications for Developers 
 
5.6.1 Platform product 
The harmonised access and free movement of ATMPs will render effective operation 
of this sector assisting their internal market and commercialization in the EU. By 
including in its scope gene therapy, somatic cell therapy and TEPs intended for 
human use, the ATMP Regulation will be useful for SMEs as they can use their 
limited resources to manufacture more than one application from a platform product 
or multiple products to enhance their probability in terms of market success. The 
ATMP Regulation does not require them to distinguish between product categories 
upfront thereby conferring them freedom of action. The highly complex and 
innovative manufacturing processes involved can therefore be applied to generate a 
safe, efficacious and commercially viable platform product with a broad range of 
applications under the overall field of RM by adopting a hybrid business model. 
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5.6.2 Increased market size can balance cost-compliance 
Under the ATMP Regulation, TEPs will have to comply with the span of regulation 
established for medicinal products which encompasses a lengthy and costly approval 
procedure. This could lead to delays in TEPs reaching the market and, compromises 
the financial survival of small-scale operators. 
The manufacturing prerequisites and demands set forth by the centralised marketing 
authorization for products with high standards of safety, quality and efficacy, along 
with post-authorization vigilance, will increase the overall cost and duration of 
incurring market approval. Further, to comply with these new standards, experts 
identify that some of the research-based technology-intensive SMEs involved in this 
industry will need major procedural alterations and/or modifications to their products 
and processes (Kemp 2006). The magnitude of cost increase will hinge upon the 
individual position of the manufacturing business on the product cycle and individual 
regulatory specifications and enactment of the member state. The considerable 
increase in the size of the accessible market for a specific product may ameliorate 
some of the cost impacts.  
Also, the authorised products will have immediate access to all individual national 
markets in EU which will foster competition. A single unified market will intensify 
competition between manufacturers as they strive for increased sales to make up for 
higher compliance costs to meet the ATMP provisions. New innovative breakthrough 
technologies generated by product developers supported by robust pre-clinical and 
clinical data might further raise the bar of regulatory requirements across the EU for 
their rivals.  
To cut down costs associated with adaptation and compliance with the ATMP 
Regulation, and vigilant post-authorisation surveillance practice, larger firms may 
attempt acquisitions, process out-sourcing or product licensing to capable SMEs. The 
big businesses will be able to cater to the needs of the European community market 
more uniformly and efficaciously, which will lead to market integration on a wider 
scale. 
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5.6.3 Extra incentives for developers 
Placing RM products under a centralised EU pharmaceutical regime, the ATMP 
regulation, entitles manufacturers to benefit from a range of advantages granted to 
medicinal products for instance “orphan status”, conditional marketing authorisation 
and compassionate use (Hughes-Wilson and Mackay 2007). These special conditions 
are of considerable interest for developers as some of the products are likely to 
address unmet clinical needs. The RM industry is characterised by SMEs for which a 
shorter time to market could be crucial for their continued existence as financially 
viable enterprises. 
The free certification of quality and of non-clinical data for SMEs provided by Article 
18 of the ATMP Regulation could also positively impact the industry landscape. This 
provision allows SMEs to reach the stage at which they have established a proof of 
principle and assist them to raise funding to engage in clinical trials. The certification 
granted by the EMEA will help them to convince financial institutions to lend them 
the required funds or to make a deal with a larger business. The question remains as to 
whether the regulator has the capacity to deliver the volume of certification that could 
be required.  
The ATMP regulation also provides for economic incentives like a 90% reduction of 
fees for scientific advice (for instance on the design and conduct of 
pharmacovigilance and of risk management) and the possibility to defer the payment 
of fees until the marketing authorisation is granted. In addition, the fee payable by a 
SME for a marketing authorisation can be reduced by 50% if the applicant can prove 
that the product represents a particular public health interest in the EU. At last, if a 
marketing authorisation is not granted the applicant will not have to pay any fees. 
 
5.6.4 Partnership between developers and regulators 
It is through use that regulations get revised and refined. Developers need therefore to 
work together with regulators to ensure that the new regulation in place is practicable. 
For instance, the facilitation CAT will operate to exchange information and ideas 
along with providing in depth knowledge on navigating through the unique regulatory 
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processes, which represents an interesting route for communication and strategic 
approaches between regulators and developers.  
Further to help their cause, developers should regard regulators as a potential 
customer from the very inception stage of their product manufacture and thus should 
incorporate the EU community level regulatory protocol within their product 
manufacturing life cycle and clinical testing protocols from the beginning. This will 
help them comply with the demands laid down in the new regulation and prevent late 
stage process changes when the product is positioned for approval. 
 
5.7 Implications of Hospital Exemption 
The ATMP Regulation excludes custom made TEPs manufactured non-routinely and 
applied in the same member state in a hospital complying with an individual medical 
prescription for a patient under the exclusive responsibility of a medical practitioner. 
This provision, known as the “hospital exemption” has raised some concerns among 
SMEs as it could lead to a situation of unfair competition between companies and 
hospitals. Similar products when prepared commercially in industry, not under 
exemption, would require clinical trials in relation to ones prepared under the 
exemption in a hospital setting for a single patient for similar use. This would make 
the large scale industrial set ups endure the obligations of compliance whereas 
hospitals might ward off complying with the central regulation provisions associated 
with product safety. Therefore, in the common interest of public health protection, it 
would be fair to hold all developers to similar regulatory standards to ascertain safety 
and efficacy of RM products for their designated use. 
A further concern lies in the definition of hospital which varies from one member 
state to another and which could result in other regulatory divergences across the EU. 
Further, hospitals might offer experimental stem cell based therapeutics putting at risk 
patient safety and product quality (2005). If the provision remains, then it necessitates 
assessment of the adequacy of the existent legal framework governing medical 
professionals, and considers whether reforms or additional specific legislation, in 
terms of manufacturing, quality and pharmacovigilance standards, risk management 
and ethical guidelines are necessary at the national/EU level.  
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However, such exemption will provide freedom of activity to clinicians and promote 
innovation as each treatment will be assessed on its merit. Also financial impact on 
research driven hospitals would be minimal, as preclinical and clinical research is 
exempted from market authorizations. This freedom might create room for error as 
developers may get biased and deviate from standard protocol to offset production 
costs, or due to their unfamiliarity with the stringent testing and validation procedures 
undertaken by their commercial counterparts. For this local national and hospital 
authorities will have to be more vigilant so that applicable community principles 
consociated to quality and safety standards are not subverted. Such treatments with 
the promise of ultimately becoming a product can be singled out on the basis of merit 
and commercial prospects, and later floated in the market in accordance with the 
relevant regulatory requirements.  
 
5.8 Promotion of public/end-user confidence  
RM products may present risks for human health due to their complex constituents 
and procedures required in their manufacture and extended implantation in vivo. The 
ATMP framework which demands for rigorous attention to rules and procedures will 
help in building up the confidence of end users (patients and clinicians) towards these 
products, which will eventually contribute to more rapid development of their market 
as a whole. Harmonised requirements to conduct safety and efficacy analysis and to 
review clinical studies before placing the products in the market are also expected to 
prevent undue risks. In addition, the setting up of a post-marketing vigilance and the 
comprehensive reporting of adverse events are also expected to trigger a virtuous 
circle, resulting in increased patient safety and improved quality of life which will 
further boost the credibility of these products with the user groups.  
Moreover, the non-subjective segmentation of traceability obligations between the 
marketing authorisation holders (product developer) and the hospital, institution or 
private practice where the product is used will assist in detailed follow up of the 
product‟s efficacy, safety and adverse reactions, if any, and will contribute to foster 
public confidence. The obligation of the developer begins from sourcing of raw 
materials and ends at delivery to the end user. Further patient and product traceability 
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comes under the purview of the establishment where the product is used. This will 
help in associating each product to the recipient, and in addition maintaining and 
protecting the exclusive physician-patient confidentiality. However, the final 
traceability guidelines are still in the process of being framed by the commission. 
 
5.9 Issues related to Clinical Trials 
For successful generation of ATMP based innovative therapies, developers will also 
have to discuss with regulators the way to adopt a conciliatory approach towards the 
statistically significant efficacy testing of these therapies through alternative 
approaches as classic randomized, double blinded clinical trials may not be possible 
always, for instance where invasive procedures using autologous substances will be 
involved.  
A major source of concern lies in the fact that the engineered stem cells would come 
under the somatic cell therapy products as they have certain pharmaceutical-like 
characteristics. However, they can neither have large-scale classic randomized, 
double-blinded clinical trials nor will be mass produced as conventional 
pharmaceutical products. Therefore, the associated technical requirements will need to 
be documented with appropriate room for technical innovation and product evolution. 
The lack of a co-ordinated centralized system and differential application for clinical 
trials across EU is considered as much a barrier for stem cell therapy medicinal 
product developer as it is for gene therapy medicinal products. Having to approach 
each member state and adhere to their individual clinical trial requirements with 
varying concerns and expectations places significant pressure on SMEs, which often 
only take a product to early clinical development due to their limited resources and 
infrastructure. Further, safe clinical trial mandates for instance, stoppage of treatment 
on adverse event occurrence and in vivo cellular imaging, will further provide solidity 
to the overall product safety. 
Globalisation is playing a key role in manufacturing innovative therapeutics and 
conduction of clinical trials. The EU Commission also needs to control and influence 
the off shore manufacture of products which might reach the EU market ultimately. 
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For this, local presence or liaison with local regulatory authorities will be helpful for 
effectively auditing the manufacturing sites. Further, the larger pools of potential 
study subjects and lower costs attract trial sponsors to other countries. Monitoring the 
early phase data from such trials with their cultural and infrastructural differences 
would also be aided by local presence or linkages. Therefore, guidelines from the EC 
on appropriate trial design, patient follow-up, auditing manufacturing facilities, 
especially overseas, and assessing trial data from cohorts that may be non-
representative would assist developers in covering all the bases. 
 
5.10 Specific Product Issues 
5.10.1 Gene therapy medicinal products 
Gene therapy medicinal products are expected to provide promising treatments to cure 
or alleviate a wide range of genetic disorders and conditions like Alzheimer‟s and 
Parkinson‟s, certain types of cancer, and of infectious diseases including AIDS. Since 
their introduction in the early 1990s, they have evolved from being ex-vivo to 
becoming in-vivo administration of gene based DNA or RNA products and have 
experienced a few notable setbacks (Rolland 2005). The intense media scrutiny and 
focus on these failures led to the discontinuation of clinical trials in some countries, to 
stricter regulation as well as the flight of industrial investment (Cavazzana-Calvo, 
Thrasher et al. 2004).  
Whether the ATMP Regulation will foster the gene therapy field remains to be seen, 
since the requirements set by the EU Directive on clinical trials (2001) are still 
applicable and are generally considered stringent by gene therapy developers 
(Seymour 2006). In addition, as the Directive leaves some discretionary powers to 
member states to develop detailed procedures, it may lead to a number of 
discrepancies and inevitably to an uneven growth of this field across the EU. For 
instance, plasmid DNA is considered as a genetically modified organism in France but 
not in other countries such as Germany (Gonin, Buchholz et al. 2005). In the case of 
multi-centre gene therapy trials, across two or more EU member states whose 
definitions of genetically modified organisms differ, this could result in an increased 
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complexity of the process. In addition, the period of 210 days needed by the EMEA 
and its relevant subcommittee to assess the dossier of a gene therapy medicinal 
product prior to granting a potential marketing authorisation is considered too lengthy 
by many product developers (Gonin, Buchholz et al. 2005).  
Another issue lies in the contrasting expertise and talent pool which exists across the 
EU regulatory bodies that have the remit to evaluate gene therapy trials. Such trials 
may therefore be subjected to heterogeneous mix of evaluation and standard regimes 
depending on where in the 27 members of the EU the trial takes place. Information 
sharing between researchers and regulators also varies greatly between the Western 
EU states and the new member entrants (Gonin, Buchholz et al. 2005), as does the 
adoption of standards related to consent provision and bio-safety of gene therapy 
medicinal products. 
The stock taking report on the ATMP Regulation which is being planned by the EU 
Commission on December 2012 will reveal and even address some of these issues but 
this intervening period of 4 years may act as a deterrent for some gene therapy 
developers. This is meant to assess if the new regulation can keep pace with the 
technology changes, including issues such as the bio-safety of newly designed vectors 
and delivery systems, the use of new technologies and strategies such as antisense and 
RNA interference, enzyme-pro-drug activation and oncolytic virus therapy, amongst 
others (Palmer, Young et al. 2006). It should also be kept in mind that some gene 
therapy medicinal products, for instance for the treatment of cancer, are likely to be 
more effective as an adjuvant in combination with conventional therapies. In this case, 
assessing the efficacy of a gene therapy medicinal product will demand a new 
approach to clinical trial design (Palmer, Young et al. 2006). 
The development of gene therapy products under the ATMP regime also raises a 
number of economic issues. Many large companies developing gene therapy products 
have exited due to the setbacks the field has experienced as well as stringent 
regulatory requirements. This has led to a situation wherein the public research 
institutions such as universities are at the forefront of research and development. The 
increased cost of maintaining GMP and GLP, as well as the increasing cost associated 
with getting approval and conducting clinical trials, may act as an inhibitor on public 
research funding bodies.  
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With respect to the increasing cost, in the context of the UK, the accredited synthesis 
of a batch of viral vector for example could cost around GBP 500,000. This puts 
immense pressures on academic and public funding bodies. This high prohibitive cost 
in the UK could be contrasted with FDA in the USA which has the discretion not to 
demand some procedures and assays when there is a consensus that there are no 
imminent safety issues. Further, FDA had in its plans to set up the so called Phase 
zero trials which are subjected to less stringent regulation that permit exploratory 
studies in humans at sub-therapeutic levels. The policy intention for this is, while 
stringent GMP would be required during trial phases III and licensing, however 
slightly permissive phase zero trials might increase the flow of effective medicines to 
patients. 
 
5.10.2 Engineered Stem Cell Products 
Stem cell bio-processing for a therapeutic application involves a variety of approaches 
which necessitate the implementation of clear and tailored characterisation 
requirements. The practical use of stem cells to create human tissues ex vivo for 
transplantation into patients with medical conditions caused by degeneration or injury 
of cells, tissues and organs has existed since the first successful bone marrow 
transplantation (Bach, Albertini et al. 1968). Such replacement tissues may or may not 
include stem cells in the final therapeutic. Multi-potent cells may be transplanted that 
give rise to terminally differentiated cells in vivo. Alternatively, cells may be allowed 
to differentiate fully in culture before being transplanted or in other cases a mixture of 
both multi-potent and differentiated cells maybe transplanted (Singh and Williams 
2008).  
Addressing chemistry, manufacturing and controls (CMC) related product and process 
characterisation issues starting from early stages of raw material control, is therefore 
critical for manufacturing stem cell based therapies. The presence of undifferentiated 
or partially differentiated cells in the final cellular therapeutic could result in adverse 
reactions such as teratoma or adventitious tissue formation, genomic or epigenetic 
modifications, immunological reactions or transmission of infections (Maitra, Arking 
et al. 2005; Unger, Skottman et al. 2008). In most cases the presence of these 
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„undesirable' cells in the final cell product can affect product potency (Hentze, 
Graichen et al. 2007). Therapies involving a mixture of cell types in the final cellular 
product further add to the complexity of setting purity standards. 
Although the ATMP Regulation looks to establish integrated and harmonised 
procedures for product development, specific standards for measuring the risks and 
benefits of different stem cell populations remains mostly ill-defined. Therefore 
tailored characterisation standards involving multi-parametric analytical tests and 
definition of suitable animal models are required for preclinical safety testing of these 
cellular therapeutics. Typical safety tests range from morphological evaluation, 
detection of phenotype specific cell surface markers, gene and protein expression 
analysis, cellular impurities profile assessment, biological assays for potency and 
MHC/HLA expression to predict immunologic compatibility. Standardisation of 
preclinical safety tests and CMC is the key to ensure consistent measurement of safety 
and quality of these products. Short shelf-life and the use of autologous products 
restrict their end stage testing which further necessitates putting in place and 
implementation of alternative exemptions and appropriate standards. 
 GMP requirements represent another source of concern for developers of engineered 
stem cells as these have not yet been finalised (Brevignon-Dodin and Singh 2008). 
The general process risks can also be mitigated by following a set of GMP guidelines 
which add to the safety as well as potency of the final product. The publication date 
for the revised Annex 2 is not finalised. The authorities are still in a state of flux and 
are considering going for a second public consultation.  
Another challenge to the level playing field pursued by the ATMP Regulation lies in 
the subsidiary principle EU regulators have observed and which excludes from the 
scope of the new regulation any ethical decisions on the acceptance and use of certain 
cell types, like hESCs and their derivatives. As a result, each member state is entitled 
to forbid the use of certain cell types and therapies on its territory for ethical reasons. 
Consequently, some developers may find it impossible to commercialise their product 
in some member states even though it has been granted a centralised marketing 
authorisation. 
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5.10.3 Combination products 
Combination products are also covered by the ATMP Regulation and are defined as 
products which incorporate, in addition to a cellular or tissue part, one or more 
medical devices or one or more active implantable medical devices. Such products 
were traditionally problematic in terms of regulatory classification as they present 
characteristics of both medicinal products and medical devices (Faulkner, Geesink et 
al. 2003). This led to regulatory divergences across the EU countries, as a same 
product could be covered by different regimes depending on the country where it was 
commercialised, and to market fragmentation (Brevignon-Dodin and Livesey 2006). 
By including combination products in its scope, the regulation is therefore attempting 
to address this grey area. 
In order to assess combination products, the regulation provides for a differentiated 
approach depending if an assessment of the medical device part has, or has not, 
already been made by a notified body. A notified body is a body designated by the 
competent authority of a member state, the MHRA in the case of the UK, to carry out 
a compliance assessment of medium and high risk devices, including active 
implantable and relevant in vitro diagnostic medical devices. An application for 
marketing authorisation of a combination ATMP which contains a medical device has 
to present evidence that the device complies with the requirements laid down by the 
Medical Device Directives (1990; 1993; Warnock-Smith and Kingston 2007)  Such 
evidence is usually based on an assessment carried out by a notified body. Some 
applications do not include any assessment from a notified body. In this case, the 
EMEA may, or may not, commission a notified body to assess the medical device part 
if this assessment and the involvement of a notified body may be deemed unnecessary 
by CAT.  
This optional consultation process within the regulation for assessing medical devices 
raises a number of issues. For instance, rendering the consultation of a notified body 
possible/optional but not compulsory requires that the expertise needed to assess the 
medical device part of a combination product is sufficiently represented within CAT. 
A manufacturer is still allowed to have his medical device assessed by a notified body 
prior to submitting the authorisation application to EMEA but does not have any 
certainty about how this assessment is going to be taken into account. Second, the 
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expertise gained by notified bodies in assessing complex medical device may prove 
useful in the case of next generation combination products. Third, in a context of 
restrained economic resources and rising healthcare costs, the targeted integration of 
notified bodies in the authorisation procedure could help to prevent duplication of 
structures and of expertise. Establishing if and how such collaboration with notified 
bodies could be done seem therefore worth exploring. This is especially important to 
the development of devices to deliver these new therapeutics. 
 
5.11 Conclusion 
The analysis suggests that ATMP Regulation provides a necessary regulatory 
framework for advanced therapies but it still appears to provide a staging post rather 
than an end point. A common process of refinement, by partnering of regulators and 
developers, is required to define a clear terrain, which the field of RM might occupy. 
As well as framing regulations, the proactive participation of authorities at the 
frontend by engaging with developers throughout the lifecycle of the product will help 
alignment with the emerging framework and enable better decisions, thereby acting as 
a bridge rather a barrier. Also, such early engagement and active communication with 
the regulators will facilitate transparency in the overall regulatory oversight for RM 
products. The conclusion is that analysis and assessments, as presented in this chapter, 
of the regulatory emergence are mandatory in understanding regulatory ordering and 
emergence in the overall emerging zone of RM. As a consequence of such analysis, 
the regulatory strategy developed in Figure 5-1 might help product developers in 
successfully navigating the framework. 
The importance of standardising regulations for developers has become increasingly 
obvious seeing the ongoing conundrums in the development of these products and the 
market fragmentation for their trading. As evident, the ATMP Regulation was much 
needed and expected to address the market fragmentation and the lack of regulatory 
certainty which were prevailing in the EU. Manufacturers agree that normalization 
through regulatory standards is imperative across the field. Its swift passage was good 
news for product developers. The pressure on the developers to meet heightened 
regulatory compliance may lead some to bankruptcy but will also move others 
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towards cost- and clinically-effective product development with ultimately lower 
business risk as well as being attractive to investors.  
However, it is still too soon to tell whether the ATMP Regulation is supporting the 
development of the RM sector in an optimal way. Some concerns have already been 
raised about some of its potential shortfalls and when it comes to considering the 
future of the RM sector with the entry into market of complex and combined 
innovative therapeutic treatments, it has still to demonstrate its capacity to keep up 
with radical technology changes. 
Some of its requirements are open issues that need further refinement to take account 
of the specificities of the different categories of products it covers (as shown in table 
5-2). The goal should be to ease the navigation of the regulatory pathway without 
creating additional hindrances for developers together with providing support for the 
development of these products.  
 
Open Issues which need to be further explored 
 GCP guidelines 
 GMP guidelines 
 Traceability issues 
 Post-authorisation risk management 
 Capacity of the regulators to serve developers with incentives 
 Hospital exemption issue 
 Coordinated centralised system for conducting clinical trials within EU 
 Assessment of combination products 
 
Table 5-2: Open Issues requiring in-depth analysis 
 
The present case-by-case approach in regulating RM based therapeutic products is a 
way forward until the associated guidelines become adaptable and broadly relevant. A 
prescriptive regulatory approach challenges the regulators‟ capacity to keep up with 
radical technology changes. Failing to address the convergence/combination issues 
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that are likely to be raised by emerging complex innovative medical products 
combining cells, genes, supporting structures and delivery devices, together with the 
associated characterisation issues, may deprive patients of promising therapies, 
imperil the innovation process and are likely to result in loss of competitiveness in the 
overall European biotechnology sector. In the long run, the hope is that the regulatory 
framework set up by the ATMP Regulation will not only direct but cater to the growth 
and development of innovative-research technology-intensive SMEs. 
This chapter has focussed on the development of EU regulations (EMEA). 
Complementary issues exist in the United States (FDA) regulations and those in other 
geographies. It is important to recognise that business favours differences in the 
global regulatory framework, as this, while adding to requirements, allows alternative 
business strategies. 
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6 DEVELOPMENT OF SCALABLE HUMAN EMBRYONIC 
STEM CELLS CULTURE SYSTEMS APPROPRIATE FOR 
COMMERCIAL APPLICATIONS  
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6.1 Introduction 
This chapter presents a novel experimental programme that demonstrates 
development of scalable human embryonic stem cell (hESC) culture systems suitable 
for commercial applications. The experimental programme illustrates the expansion of 
hESCs to create cell banks and further demonstrates their maintenance on an 
automated cell culture platform. The results of a novel culture protocol to differentiate 
the above cell populations into otic progenitor cells using a scalable and translational 
friendly cell-culture protocol are further presented in section 6.5. The main aim of this 
experimental programme was to demonstrate and validate a scalable, serum-free and 
feeder-cell free differentiation protocol for hESCs. This demonstrator experimental 
programme further allowed the determination of key experimental costs to evaluate 
approximate cost of goods for input into the economic assessment exercise presented 
in Chapter seven. 
 
6.2 Human Embryonic Stem Cells 
6.2.1 Characteristic properties 
Human embryonic stem cells (hESC), characterized essentially by indefinite self-
renewal capacity and pluripotency, are being envisioned as therapeutic agents which 
have substantial possibilities for use in organ and tissue repair (Evans and Kaufman 
1981; Cowan, Klimanskaya et al. 2004). Since their derivation by Thomson et al. in 
1998 from the inner cell mass of donated blastocyst-stage embryos (Thomson, 
Itskovitz-Eldor et al. 1998), produced by in vitro fertilization (IVF) for clinical 
purposes, the cells have provided a means to explore various promising lines of 
research (Ameen, Strehl et al. 2008). Their derivation together with expansion has 
provided several cell lines which have become important tools for gaining deeper 
insight not only into their own biology and function, but also of other cell types they 
can generate (Thomson, Itskovitz-Eldor et al. 1998), through genomic and proteomic 
studies (Hescheler, Sachinidis et al. 2006; Hovatta 2006; Van Hoof, Heck et al. 2008). 
They have also furnished an exciting opportunity to facilitate their use in cell 
replacement therapies and therefore, in developing novel RM based products to 
provide alterative benefit post transplantation (Reubinoff, Pera et al. 2000; Soria, 
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Roche et al. 2000; Perrier, Tabar et al. 2004). Their employment as disease models to 
understand pathological processes has further opened up avenues for drug discovery, 
screening, target validation and toxicological assessment (Pouton and Haynes 2005; 
Harding, Ali et al. 2007; Pouton and Haynes 2007). 
 
6.2.2 Challenges of Conventional hESC Culture Systems 
hESCs are highly sensitive to culture conditions and therefore their in vitro expansion 
holds challenges in terms of maintaining their phenotype and controlled directed 
differentiation to therapeutic cell types (Stacey, Cobo et al. 2006). The cells 
themselves are prone to genetic changes during long-term culture, and the culture 
environment itself is ideal for cross-contamination and growth of numerous micro-
organisms (Buehring, Valesco et al. 1995). There have been instances of cross-
contamination at the source of cultures in the laboratories of their conceivers, when 
the derived cell lines have not matched their proposed origin (MacLeod, Dirks et al. 
1999; Stacey 2000). Further, in culture, hESC proliferation and their fate is dependent 
on various cell signalling pathways (para and autocrine self-renewal signals) and cell-
cell interactions (Cai, Ye et al. 2007).  Their survival at clonal density is very low 
(Pyle, Lock et al. 2006). Also continued and sequential passaging may have 
detrimental effects including spontaneous differentiation and loss of “stemness” i.e. 
pluripotency (Amit and Itskovitz-Eldor 2002; Sathananthan and Trounson 2005). This 
loss may be dependent on their source, culture duration, and culture and 
differentiation process. Therefore, it is critical that pure homogenous pluripotent cell 
populations are processed with normal growth, phenotype and stable genetic structure 
during their in vitro expansion, free from any adverse cross- or micro-biological 
contamination. 
To become a viable therapeutic and screening alternative, it is imperative to keep the 
number of passages of hESC to a minimum with consistent, robust and reproducible 
culture processes. Also, for screening purpose, primary cells are hard to procure in 
adequate quantity and can undergo batch-to-batch variation in quality, contingent 
upon the source. Therefore, to minimise the number of passages and avoid batch 
variability, the approach of establishing master/working cell banks was followed in 
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this particular study (Figure 6-1). Such an approach is widely used by the 
pharmaceutical industry for screening drugs and preparing formulations (Fieder, 
Wagner et al. 2005). This method prescribes the conception of a master cell bank, of a 
particular cell line in use, which will form the point of reference for future work with 
the cells of that line. The master bank is characterised by validating pertinent 
biological markers, and is subjected to applicable quality control tests. Vials from the 
master cell bank are then employed to produce bigger working banks that can be used 
to carry out further experiments. The working cell bank is once again validated by 
demonstrating expression of relevant surface markers and quality control tests. This 
tiered system provides two-levelled reproducible consistent supplies of identical cell 
populations for experiments. 
 
 
Figure 6-1: Schematic of establishing master and working cell banks 
 
  Cell Culture Systems 
 163 
6.2.3 hESC lines used in this study 
Since the reporting of the first hESC line, a plethora of genetically diverse cell lines 
have been derived from human blastocysts using various derivation techniques and 
subsequent culture protocols (Allegrucci and Young 2007; Luong, Smith et al. 2008). 
Out of the large and diverse set of available cell lines, Hues-1 and H9 were chosen for 
this particular study. Both lines provide a representative sample of those readily 
available worldwide (Andrews, Benvenisty et al. 2005; Adewumi, Aflatoonian et al. 
2007). They exhibit a similar expression pattern of a series of characteristic surface 
antigens and genes, despite their dissimilar genetic backgrounds and their derivation 
in different laboratories using different protocols (from different gene pool of donated 
embryos). They are considered as mainstream federally approved lines suitable for 
large scale processing. 
 
 
6.2.4 hESC Characterisation 
Demonstration of molecular and biochemical marker expression for characterising 
hESC lines is essential to validate their pluripotent and normal self renewing 
properties. The unique expression pattern and timing of expression of these antigens 
is of value in both identification and isolation of undifferentiated hESCs. Such marker 
expression has been investigated among several ESC lines by a variety of techniques 
including reverse transcriptase-polymerase chain reaction (RT-PCR), cDNA 
microarrays, immune-cytochemistry and flow-cytometry. A list of molecules 
comprised of known ESC-specific or -highly expressed genes and candidates that 
serve as markers for hESCs has been established (Table 6-1). For instance, pluripotent 
ESC can be characterized by high level expression of Oct3/4 (POU domain, class 5, 
transcription factor 1, Pou5f1) which is a member of POU family of proteins (Rosner, 
Vigano et al. 1990). Stage-specific embryonic antigens (SSEAs) (Kannagi, Cochran et 
al. 1983) and Trafalgar antigens (Andrews, Banting et al. 1984) are the other markers 
of undifferentiated hESC which are globoseries glycolipid antigens and keratin 
sulphate-related antigens, respectively. In the following set of experiments, initial 
characterisation was performed when culture conditions were altered to confirm that 
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no major adaptive changes have occurred to the cells, which was followed by routine 
characterisation after every second passage.  
Marker Type Family Expression Pattern 
SSEA-1 Surface Marker Globoseries glycolipid 
antigens 
Negative 
SSEA-3 Surface Marker Globoseries glycolipid 
antigens 
Positive 
SSEA-4 Surface Marker Globoseries glycolipid 
antigens 
Positive 
TRA-1-81 Surface Marker Keratan sulphate-
related antigens 
Positive 
Oct-3/4 Transcription Factor Pou5f1 Positive 
 
Table 6-1: A diverse range of hESC specific surface markers and transcription 
factor used in this study 
 
Further characterisation for quality control involved karyotyping to determine 
whether chromosomal abnormalities have occurred after extended passaging or 
change in culture conditions. This is usually performed by Giemsa (G)-banding of 
chromosome spreads. 
 
6.2.5 Conventional culture techniques 
Conventional hESC culture is carried out on mouse or human fibroblast feeder layers 
with serum and a cocktail of growth factors and cytokines. The cells are subsequently 
passaged by manual micro-dissection of healthy undifferentiated hES colonies using 
micropipettes (Thomson, Itskovitz-Eldor et al. 1998; Reubinoff, Pera et al. 2000; 
Heins, Englund et al. 2004). These clumps of colonies are later plated on fresh feeder 
layers. This protocol is advantageous because of the absence of cell dissociating 
enzymes and the ability to perform a positive selection at every passage by isolating 
undifferentiated hESC from more differentiated cells. However, the addition of feeder 
layers introduces extra procedures in terms of their irradiation or chemical measures 
for their inactivation which may further lead to batch variation and inability to 
standardise procedures between laboratories. For therapeutic applications, mouse 
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feeder layers may bring in xenogeneic contaminants and for pharmaceutical 
applications feeders themselves might be a limiting factor for screening assays. Being 
labour intensive, time consuming and requiring constant close human supervision 
makes such feeder layer based method undesirable for large scale hESC culture.  
Though this method is optimal for experiments that do not involve large-scale 
production of undifferentiated hESCs but future potential downstream applications 
such as cellular therapeutics, high throughput screening during pharmacological 
testing, toxicology assessments, gene transduction involving hESCs will require 
methods for their stable large-scale expansion. To enable this, enzymatic passaging 
has been reported by several groups (Amit, Carpenter et al. 2000; Xu, Inokuma et al. 
2001; Cowan, Klimanskaya et al. 2004; Hasegawa, Fujioka et al. 2006). However, 
genetic and epigenetic changes have become apparent, such as detectable karyotypic 
abnormalities (Brimble, Zeng et al. 2004; Draper, Smith et al. 2004; Maitra, Arking et 
al. 2005; Mitalipova, Rao et al. 2005) and potential hESC transformation to 
embryonal carcinoma cells with changes in their differentiation potential due to 
culture adaptation (Andrews, Matin et al. 2005). Furthermore, concerns have been 
raised that these culture techniques are associated with certain technical 
disadvantages. For instance, the necessity to maintain the hESCs in clusters within a 
narrow size range during passage rather than single cells (Rosler, Fisk et al. 2004; 
Sjogren-Jansson, Zetterstrom et al. 2005; Hasegawa, Fujioka et al. 2006), relatively 
low passage ratios (Cowan, Klimanskaya et al. 2004; Suemori, Yasuchika et al. 
2006), a dramatic decrease in plating efficiency during initial passages (Hasegawa, 
Fujioka et al. 2006) and the lengthy adaptation period required by established as well 
as newly generated hESC lines (Cowan, Klimanskaya et al. 2004; Hasegawa, Fujioka 
et al. 2006).  
 
6.2.6 Rationale for Present Study 
Considering the effects of the cellular microenvironment, the substrate and the culture 
medium, on cell survival and to circumvent the inherent disadvantages  of 
conventional culture techniques, the objective of this study was to demonstrate hESC 
culture in a highly supportive culture environment for their long term maintenance 
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and efficient expansion in an undifferentiated state. The method applied does not 
demand any transfer/adaptation period from the previous propagation method. It 
allows robust large-scale expansion of undifferentiated hESCs without compromising 
the genetic stability or pluripotency over extended culture periods. The method 
supported established hESC lines, Hues-1 and H9. It involves hESC culture in batch 
tested fully defined mTeSR medium (to be discussed in section 6.3.3.2) for their 
feeder cell independent maintenance on pre-qualified matrigel matrix coated culture 
flasks (Ludwig, Bergendahl et al. 2006). Subsequently, the cells are passaged in 
clumps using enzymatic detachment with dispase and re-plated on the matrix. Further 
to support automation of the culture process for large scale processing, single cell 
monolayer culture was demonstrated. This included a short intermediate transient 
phase of adaptation to the new passaging protocol. Thereafter, the cells were 
transferred to an automated platform (CompacT SelectT) for expansion, and 
subsequently checked for genetic stability and pluripotency by karyotyping and 
differentiation studies, respectively.  
The final objective of the study was to direct differentiation of the processed cells 
towards an important therapeutic lineage i.e. otic progenitor cells. These cells are 
capable of differentiating to inner ear hair cells, the sensory cells present in the inner 
ear. For this, a stepwise guidance protocol based on the principles of in vivo otic 
induction was followed to differentiate hESC and generate cells that are positive for 
Pax-2, a characteristic marker for otic lineage. 
An overall automated, single cell, serum-free culture protocol in the absence of feeder 
layers is a significant prerequisite for large scale manufacture of hESC populations for 
therapeutic and pharmacological applications. Thus, a simple, less labour intensive 
and reproducible culture system which uses consistent batches of hESC populations 
through a master/working bank principle in a scalable and translational friendly 
serum-free single cell culture process and tailored automation to produce homogenous 
therapeutic cell populations is presented. 
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6.3 Materials and Methods 
6.3.1 Materials 
All cell culture reagents were purchased from Stem Cell Technologies (Grenoble, 
France; www.stemcelltechnologies.com) and antibodies from BD Biosciences 
(Oxford, UK; www.bdbiosciences.com), unless otherwise stated.  
 
6.3.2 Instrumentation 
The CompacT SelecT (Figure 6-2) is a fully automated cell culture platform 
consisting of a robot arm that can access 90 x T175 flask or 160 x 96 multi-well plate 
incubators. Flasks and plates are bar-coded for identification and cell process 
tracking. Two flask decappers and flask holders, automated media pumping (or 
pipetting for volumes of <10 ml), medium warmers and a Cedex automated cell 
counter are also integrated within a Class II cell culture cabinet.  
This setup allows most cell culture activities, including passage or media changes, to 
be conducted and controlled to a schedule in a sterile environment with minimal 
human interference. 
6.3.3 Culture and expansion of hESC 
6.3.3.1 hESC Lines used in the experiments: 
hESC lines, Hues-1 (derived and characterised at Harvard) and H9 (derived and 
characterised at Wicell) were purchased/sourced after signing typical Material 
Transfer Agreement (MTA), as required by the suppliers. Prior to the experiments, 
both the cell lines were maintained on mitotically inactivated mouse embryonic 
fibroblasts (MEFs) in their respective laboratories/institutions. During the course of 
the study all hESC cultures were maintained at 37
o 
C, 5% CO2 in a humidified 
atmosphere with daily media changes. 
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Figure 6-2: Features of the CompacT SelecT. This automated cell culture 
platform can simultaneously manipulate 2xT175 flasks and house 90xT175 
culture flasks in a robot-accessible incubator. All culture processes are carried 
out within a sterile class II environment and require no manual intervention. 
The inset shows an enlarged image of the manipulation chamber and pipette 
head. Major processing components are labelled: A, Robot arm; B, Flask 
incubator; C, Plate incubator; D, Flask decappers; E, Flask holders; F, Media 
pumps; G, Pipette head; H, Cedex automated cell counter 
 
Three different culture methods were used (Figure 6-3). In the first method, cells were 
cultured as colonies in order to generate stocks in the form of master and working cell 
banks. Cells from working banks were used in the other two experimental methods. In 
the second method, cells were expanded as single cell monolayer cultures. A master 
and working cell bank of these cells was also created. In the third method the single 
cells from the previous method were cultured on the automated cell culture platform, 
CompacT SelecT. 
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6.3.3.2 Colony Culture: 
hESC lines, Hues-1 and H9, were cultured by dispase passaging in feeder-cell free 
conditions on BD Matrigel hESC-qualified matrix in fully defined mTeSR medium. 
The cells were seeded at an initial density of 4x10
4
 per sq. cm. mTeSR is a 
standardised, fully defined and serum-free medium which supports self renewal of 
hESCs, using matrigel as a substrate, without requiring feeder cells. The supplier 
(Stem Cell Technologies) pre-qualifies each batch of BD Matrigel thereby ensuring 
consistency, reproducibility and reliability in performance. Cells for this study were 
passage (p) 21 for Hues-1 and (p) 23 for H9. Culture plates (6-well plates) and flasks 
(T25 flasks) were coated with Matrigel cellular matrix by adding 0.8ml / cm
2
 of a 
1:25 dilution of hESC-qualified growth factor reduced Matrigel (BD Biosciences, 
Oxford, UK; www.bdbiosciences.com) in cold DMEM, and allowing polymerisation 
to occur at room temperature for 45 mins in a sterile environment. Prior to use, 
medium was aspirated from flasks and the culture surface washed with phosphate 
buffered saline (PBS). Cultures were passaged by incubating with 1mg/ml dispase for 
7 min at 37
o
 C, coupled with scraping the plates/flasks in mTeSR medium to liberate 
small clumps of cells. 
After three serial passages (1:3 split ratio) over 4 weeks, a master cell bank was 
created by cryo-preserving 15 cryo-vials containing hESC clumps in 1ml of fully 
defined serum free mFreSR medium. From the master bank, a single vial was thawed, 
characterised by flow markers and used to create a working cell bank using the similar 
protocol. 
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Figure 6-3: Process map for manual and automated hESC culture 
 
6.3.3.3 Transfer of colony to single cell monolayer culture and maintenance: 
To transfer colony cultures of hESCs to single cell monolayer culture, the colony 
cultures in six-well plates were washed once in PBS, after which 1ml of 
trypsin/EDTA (0.25% trypsin, 1mM EDTA) was added to each well and incubated at 
37
o
C for 8-10 minutes. When the hESC colonies started to round up and detach, the 
cell sheet was broken apart to a single cell suspension by repeated trituration with a 
pipette. After centrifugation (300g for 5 minutes), the supernatant was discarded, the 
hESC pellet was re-suspended in mTeSR medium and the single cell suspension was 
plated onto matrigel coated wells of a 6-well plate. Media was changed daily and cells 
were passaged and plated as single cells with trypsin digestion every 3
rd
 day with a 
1:3 split ratio. Population-doublings were calculated by the equation Log10(cell 
output/cell input)/Log10 2 (Denning, Allegrucci et al. 2006). 
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6.3.3.4 Transfer of single cell monolayer culture to CompacT SelecT automated 
platform: 
For automated culture, the single cell cultures generated above were bulked/scaled up 
to plate a single matrigel coated T175 flask which was placed in the CompacT SelecT 
flask incubator (cells from one well of a 6-well plate were plated onto a T25 flask, 
1:2.5 split ratio, which on confluence were passaged and plated onto 3 T25 flasks, 1:3 
split ratio and cells from all the three flasks on confluence were digested, passaged 
and plated on a single T175 flask, ~1:2.5 split ratio) (Figure 6-4). The bar code of the 
flask was registered to the automation database to track its history online once it was 
within the CompacT SelecT. The robot arm was programmed for daily media 
changes: (i) retrieve T175 flask from the incubator, remove flask cap and pour the 
spent media into the waste funnel, (ii) pump 40ml mTeSR to the flask, and (iii) 
replace flask in the incubator. Matrigel coating of flask and population doubling 
calculations were done as above (see Appendix for automated protocols). 
 
 
 
 
Figure 6-4: Process map for scale up from 6-well plates to T 175 flask for 
automation of the culture process 
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Automated passaging entailed step (i) as above with additional programming  of the 
robot arm to (ii) wash cells with 20 ml PBS (dispensed by pump and poured to waste), 
(iii) pipette 10 ml trypsin-EDTA to flask, swirl for 20s, pour enzyme solution to 
waste, incubate at 37
o
C for 8 mins, and shake the flask for 30 oscillations, (iv) pump 
15ml mTeSR to flask, swirl, place flask on holder, then mix, and pipette 1 mL cell 
suspension to the integrated Cedex cell counter, (v) pump volume of media to flask to 
dilute to 1x10
6
 cells/mL (calculated by the CompacT SelecT’s integrated Cedex cell 
counter), (vi) pump 30 mL mTeSR to a fresh Matrigel-coated flask, (vii) mix cell 
suspension, and pipette 10 mL (1x10
7
 cells; equates to 1:3 split) to the fresh flask, 
swirl, and replace into incubator. A gauge repeatability and reproducibility 
measurement system analysis (Liu et al., submitted) has already been carried out to 
measure the functioning of the Cedex system. This is an established method to assign 
the proportion of variation in a study to the measurement system or other sources. It 
showed that a manual cell count using a haemocytometer and multiple operators gave 
close to twice the amount (7.99%) to total study variation in comparison to an 
automated count by the Cedex system (4.92%). 
 
6.3.4 Creation of Master and Working cell banks  
In order to expand cells for creating master and working banks, feeder free and serum 
free culture systems for both hES cell lines were established. This was done by 
defrosting the principle vial. 4 x 10
5 
cells from the vial were seeded in a single 
matrigel coated well of a 6-well plate and supplied with daily changes of mTeSR 
medium until the cells reached confluence on the 7
th 
day. Sterility was maintained in 
the absence of antibiotic and antimycotic agents. In all subsequent cultures, the cells 
were dispase-passaged, split (approximately 1:3 split ratios) and re-plated in T25 
matrigel coated tissue culture flasks with daily medium changes. After three serial 
passages (1:3 split ratio) over 4 weeks, a master cell bank was created by cryo-
preserving 15 cryo-vials containing 1 ml hESC suspension (~4 x 10
5
 cells) in fully 
defined serum free mFreSR medium. Out of this bank, a single vial was thawed, 
characterised by flow markers and used to create a working cell bank using the similar 
protocol, from which vials were taken regularly, thawed and used to carry out further 
analysis and experiments. The cells showed good viability after thawing (viability 80-
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90%), attached well to the hESC qualified matrigel matrix and remained 
undifferentiated. Similarly, cell banks of single cell suspension culture were also 
maintained. 
 
6.3.5 Flowcytometry Analysis 
hESCs were regularly characterised by flowcytometry following every second 
passage. Single cell suspensions of live cells using trypsin digestion from all the three 
culture methods (manual colony culture, manual single cell culture and automated 
culture) were analysed for the presence of specific antibody markers (Figure 6-3). 
Cells were rinsed once with PBS and then trypsinized by adding appropriate volume 
of 0.05% Trypsin/EDTA solution which was incubated at 37°C for 8-10 minutes. 
Thereafter, cells were harvested by pipetting with a serological pipette to ensure a 
single cell suspension. Cells were transferred to a 15 mL conical tube. Culture 
flasks/plates were rinsed with additional PBS and the rinse was added to the tube 
containing the cells. Cells were centrifuged at 300 x g for 5 minutes at room 
temperature (15 - 25°C) and thereafter re-suspended in PBS to perform a viable cell 
count using Trypan Blue. The single cell suspension was then used for surface and 
intracellular antigen staining. 
 
6.3.5.1 Surface Antigen Staining: 
Approximately 2 x 10
5
 cells per sample in 2 mL FACS tubes were incubated with 10 
µl of SSEA1-PE, SSEA3-PE, SSEA4-PE, and TRA-1-81-PE (BD Biosciences) 
conjugated antibodies for 20 min at room temperature. Analysis was carried out on a 
sample of 1x10
4
 cells using a Beckman Coulter Cell Lab Quanta SC flow cytometer. 
 
6.3.5.2 Intracellular Antigen Staining for Oct-3/4 and Pax-2 
Approximately 2 - 5 x 10
5
 cells per sample in 2 mL FACS tubes were centrifuged at 
300 x g for 5 minutes at room temperature (15 - 25°C). After carefully removing the 
supernatant, 250 μL of 2% formaldehyde solution was added to the tube and 
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incubated for 15 mins. After incubation the tube was centrifuged at 300 x g for 5 
minutes at room temperature (15 - 25°C). Subsequently, supernatant was removed and 
500 μL of TritonX (permeabilization agent) was added, mixed gently, and incubated 
for 15 minutes at room temperature (15 - 25°C). Further, cells were centrifuged at 300 
x g for 5 minutes at room temperature (15 - 25°C) and supernatant removed. Then 
cells were incubated with FITC conjugated Oct-3/4 or Pax2 antibody. Analysis was 
carried out on a sample of 1x10
4
 cells using a Beckman Coulter Cell Lab Quanta SC 
flow cytometer. 
 
6.3.6 Karyotype Assessment 
Karyotype analysis was performed on Hues-1 and H9 cell lines to gain a perspective 
on the physical structure of the genome and monitor the genetic stability of the cell 
culture to screen for the presence of transformed cells. As the analysis is highly 
specialised, it was contracted out to a specialist genetic research laboratory (TDL 
Genetics, London, UK). The following protocol was followed: After 20 min of 
Colcemid pre-treatment (Sigma 10 g/ml D1925), 20 L per ml of culture medium in 
flask, dividing cells were removed by trypsinisation and loosened cells were poured 
off into a centrifuge tube containing 3ml hypotonic solution (1:12 Fetal Bovine 
Serum/TC grade water). The tube was incubated at 37 C for 25 mins. Cell suspension 
pre-fixed with 5 drops fresh cool fixative (3:1 methanol/glacial acetic acid – Analar 
grade reagents) was spun at 1500 rpm for 10 min in a bench centrifuge. Supernatant 
was discarded, and the cell pellet was loosened by flicking. This was repeated twice. 
After tipping off the supernatant, cells were re-suspended in a few drops of fixative. 
40 L of suspension was applied to top of a wet, washed slide (just below the frosted 
end) and the suspension was allowed to run slowly down the slide by tilting it. Any 
excess water was drained. Cells were allowed to dry onto the slide with the aid of 
gentle warming from an anglepoise lamp and gentle blowing to allow the metaphase 
chromosomes to burst out of the nuclear envelope and spread sufficiently to allow 
analysis. Slides were assessed with low power phase-contrast microscopy and cell 
suspension concentration adjusted to allow best spreading. Slides were aged in drying 
oven (92 C for 40 min or 63 C overnight) and then rinsed in HBSS for 5 min. Slides 
treated with trypsin and rinsed in HBSS containing serum to stop trypsin action were 
  Cell Culture Systems 
 175 
later stained in 3:1 Leishman/Giemsa (Merck) (2.5ml in 47.5ml pH 6.8 buffer). 
Finally, slides were rinsed briefly in purified water, gently blotted dry, and mounted 
with cover slips. They were analysed by conventional bright field microscopy. 
Scanned for metaphases at low power (~100x total mag) and examined with oil 
immersion high power objective (~1000x total mag). A typical metaphase was 
digitised and stored using a Cytovision image analysing system. 
 
6.3.7 Differentiation 
6.3.7.1 Embryoid Body Formation 
Pluripotency of both Hues-1 and H9, maintained and expanded in all three culture 
conditions, for 20 consecutive passages was assessed by embryoid body formation in 
aggrewell plates (Stem Cell Technologies). A high quality starting population 
(cultures with less than 10% differentiated cells) of undifferentiated hESCs was used. 
After rinsing the wells with DMEM, 1ml hESC maintenance medium was added to 
the wells. The plates were centrifuged at 100 x g for 1 - 2 minutes in a centrifuge 
fitted with a plate holder to remove any small bubbles from the micro-wells. 
Appropriate volume of undifferentiated cells was added drop wise to each well of the 
aggrewell plate and then evenly distributed by gentle shaking. The medium was 
topped to a final volume of 2 mL per well. Y-27632 ROCK Inhibitor was added at a 
concentration of 10 μM to enhance cell survival during EB formation. Thereafter, the 
aggrewell plate was centrifuged at 100 x g for 3 minutes to capture the cells in the 
micro wells (Figure 6-7c). After examining the plate under a microscope to verify 
even distribution of the cells among the micro wells, the plate was incubated at 37°C 
with 5% CO2 and 95% humidity for 24 hours. 
 
6.3.7.2 Differentiation towards inner ear hair cells 
To assess the differentiation capacity of hESCs, single cells from the single cell 
monolayer hESC culture were induced towards otic progenitor cells by a two-staged 
guided protocol (Figure 6-5). Stage 1: The cells (1×10
5
/ml) were cultured (37°C, 5% 
CO2) for 5 days in mTeSR containing 2.5 nM DKK-1 (R & D Systems) and 2.5 nM 
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Noggin (R & D Systems) along with N2 supplement in a 6-well plate. Stage 2: The 
cells were then cultured for 3 days in mTeSR containing 20ng/ml bFGF (Sigma-
Aldrich) and Heparan Sulphate (Sigma-Aldrich) along with N2 supplement. 
Appropriate controls with no differentiation supplements were also set. After 
completion of the protocol, cells were characterised by Pax-2 expression. Pax-2 
antibody was obtained from Abcam, and conjugated using a FITC-lightening kit by a 
single step conjugation procedure as detailed by the manufacturer, for flowcytometry. 
 
 
 
Figure6-5: Process map for otic differentiation from hESCs 
 
 
6.3.8 Cryopreservation of hESC 
When the initial clumps of primarily undifferentiated hESC or single cells were 70-
80% confluent i.e. one day before the cells are ready to passage, the colonies were 
treated with 1mg/ml dispase enzyme coupled with scraping the plates/flasks in 
mTeSR to liberate large clumps of cells. The cell aggregates were transferred into a 
15ml tube and centrifuged at 300g x 5 mins at room temperature. After aspirating the 
supernatant, the pellet was gently re-suspended in mFreSR medium, leaving large 
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clumps of cells. mFreSR is a defined, serum free cryo-preservation medium designed 
specifically for hESC by Stem cell Technologies. The clumps were mixed with 
mFreSR, and 1 ml of the suspension in mFreSR was transferred into each cryo-vial. 
The cryo-vials were frozen at a cooling rate of 1
o
/min in a controlled rate freezer, and 
maintained at -80
o
 C for 4 hours before long term storage in liquid nitrogen at -180
o
C. 
 
6.4 Results 
6.4.1 Colony culture expansion and maintenance: 
Preceding this study, all hESC lines were maintained on feeder cells and mechanically 
passaged every 4-5 days. Both lines had been passaged for more than 20 passages. 
Regardless of the inherent establishment/creation differences in the lines, the cells 
responded to culture in the fully defined serum free media formulation, mTeSR, with 
dispase dissociation in a similar manner, without requiring feeder cells (Table 6-2). 
The cells, after a short intermediate transient phase, acclimatised to the new defined 
conditions. The cells formed dense monolayer plaques that appeared homogenous 
when observed with phase contrast microscopy. Cells exhibited the morphology, 
characteristic of undifferentiated hESCs, including a high nuclear to cytoplasmic ratio 
and a bright nucleus with prominent nucleoli (Figure 7a). The cells were stably 
maintained for more than 10 passages without changes in their morphology or growth. 
Further, to support the morphological evidence of stable undifferentiated expansion, 
cells were regularly evaluated by flowcytometry during culture. At all time points, 
they expressed markers characteristic of undifferentiated hESCs (SSEA-3, SSEA-4, 
TRA-1-81, Oct-3/4; all>95%) and were negative for SSEA-1, the differentiation 
marker (Fig 6-6k, 7k). 
Further, to support the evidence for undifferentiated expansion, aggrewell plates with 
micro-wells (Stem Cell Technologies) were used to aggregate hESCs into embryoid 
bodies, the three-dimensional characteristic aggregates of hESCs. Single cell 
suspensions were added to the plate, centrifuged and cultured for 24 hours. Embryoid 
bodies were observed and harvested which were uniform and consistent in shape and 
size (Fig 6-6c,d;7c,d).  
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Culture 
Substrate 
Passage method Culture medium No. of passages 
tested 
Hues-1    
Matrigel Dispase, scraping, 
manual 
mTeSR with 
supplement 
15 (p21 to p36) 
 Trypsin, manual mTeSR with 
supplement 
12 (p24 to p35) 
 Trypsin, automated mTeSR with 
supplement 
5 (p30 to p34) 
H9    
Matrigel Dispase, scraping, 
manual 
mTeSR with 
supplement 
15 (p21 to p36) 
 Trypsin, manual mTeSR with 
supplement 
12 (p24 to p35) 
 Trypsin, automated mTeSR with 
supplement 
5 (p30 to p34) 
 
Table 6-2: Culture methods tested for Hues-1 and H9 together with the number 
of passages for each method 
 
6.4.2 Single cell monolayer culture and maintenance: 
From the respective working banks of both the cell lines, single cell monolayer 
cultures were established (Table 6-2). Confluent colony cultures were enzymatically 
dissociated with trypsin to form single cell suspensions which were thereafter plated 
on matrigel coated 6-well plates as single cells (4 x 10
5
 cells) in monolayers. 
Following the first two trypsin passages, the cells grew in small clusters which 
appeared heterogeneous in terms of size and number of cells when examined under 
phase contrast microscopy. However, thenceforth the hESC had acclimatised to the 
new culture environment, resulting in single cell cultures. Confluency was 
consistently obtained at 3-day intervals after which the cells were passaged in 1:3 split 
ratios. hESCs formed flat monolayer cultures with distinct single cell borders and 
showed typical hESC morphological characteristics (Fig 6-6b;7b). These cells also 
expressed undifferentiated hESC markers. Both cell lines exhibited SSEA-3, SSEA-4, 
TRA-1-81 and Oct-3/4, but not SSEA-1 (Fig 6-6k,7k). Further differentiation was 
assessed by EB formation, which were again consistent and uniform, when examined 
under phase contrast microscopy (Fig 6-6d;7d).  
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Figure 6-6: Analysis of HUES-1 cultures. HUES-1 cells displayed characteristic morphological 
features of high nuclear–cytoplasmic ratio with prominent nucleoli in both colony (A) and single 
cell monolayer cultures (B); They formed consistent uniform embryoid bodies (D) in aggrewell 
plates (C). Representative FACS plots are shown for control (E), Oct-3/4 (F), SSEA-1 (G), SSEA-
4 (H), SSEA-3 (I) and TRA-1-81 (J) flow markers; (K) percentage positive cells for the 
characteristic markers. 
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Figure 6-7: Analysis of H9 cultures. H9 cells displayed characteristic morphological features of 
high nuclear–cytoplasmic ratio with prominent nucleoli in both colony (A) and single cell 
monolayer cultures (B); They formed consistent uniform embryoid bodies (D) in aggrewell plates 
(C). Representative FACS plots are shown for control (E), Oct-3/4 (F), SSEA-1 (G), SSEA-4 (H), 
SSEA-3 (I) and TRA-1-81 (J) flow markers; (K) percentage positive cells for the characteristic 
markers. 
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Figure 6-8: Population doublings for Hues-1 and H9 cells in single cell 
monolayer cultures. cPD = cumulative population doubling 
 
6.4.3 Automated culture in CompacT SelecT automated platform: 
In order to transfer hESC cultures to the CompacT SelecT, Hues-1 and H9 starter 
cultures were first prepared manually by bulking up the single cell monolayer culture 
into T175 flasks (Figure 6-4) (Table 6-2). Appropriate manual controls were kept to 
define and compare the outcomes of automated culture method. All subsequent 
automated culture was performed by the CompacT SelecT with sterility maintained 
without the use of antibiotic or antimycotic agents. The automated process included 
passage of the T175 starter flask of both lines to triplicate flasks, and their complete 
subsequent maintenance with regard to medium changes, serial passaging and 
monitoring of proliferation rates using the inbuilt Cedex cell counting platform. As 
with manual single cell culture, both lines showed consistent proliferation during 
serial passages and typical hESC characteristic morphological features.  
Pluripotency of these cells was evaluated on the basis of their marker expression and 
in vitro differentiation potential. Throughout the culture period, cells expressed 
SSEA-3, SSEA-4, TRA-1-81 and Oct-3/4 and were negative for the differentiation 
associated marker, SSEA-1 (Fig 6-7k,8k), and formed uniform coherent EBs 
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indistinguishable in size and shape from manually cultured cells (Fig 6-6d;7d). These 
culture conditions did not require forced aggregation for EB formation due to minimal 
time of trypsin exposure (~1 min) during passaging. Both lines Hues-1 and H9 
showed consistent growth rates when cumulative population-doublings were plotted 
over a ten passage period (Figure 6-8). 
 
6.4.4 Karyotype assessment and long-term stability: 
Both hESC lines had a normal karyotype, which was assessed at the end of the study. 
The lines had been subjected to long-term cultivation using enzymatic bulk passaging 
on both manual and automated culture systems. They retained a stable diploid normal 
karyotype after all the processing (passages, n~20), confirmed by analyses of 20 
metaphase spreads per flask for each line (Figure 6-9). 
 
6.4.5 Differentiation to inner ear hair cells 
H9 cells were subsequently differentiated as single cells to an ectodermal derivative 
i.e. sensory inner ear hair cells. Pax-2 positive cells indicative of early otic placode 
were observed after the 8-day long guided differentiation protocol in which factors 
that mimic normal development of ear placodes in vivo were used in a defined, 
mTeSR with its supplement, culture formulation. The results show the propensity of 
single cell cultures derived from H9 cells to be responsive to otic inducers, such as 
bFGF. This stepwise guidance protocol makes use of inductive signals that reflect in 
vivo inner ear development, and generated Pax-2 expressing otic progenitors from H9 
cells over the 8 day long differentiation protocol (Figure 6-10a). Oct-3/4 expression 
was down-regulated (Figure 6-10b), which is essential for the overall developmental 
of subsequent cell types when hESCs are induced to differentiate. 
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Figure 6-9: Karyotypic assessment of G-banded chromosome preparations of 
Hues-1 (P38) and H9 (p40) cells showed karyotypic stability of both cell 
populations after undergoing manual and automated culture processes 
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Figure 6- 10: Differentiation potential of H9. Pax-2 (A) expressing cells with negative oct-3/4 
expression (B) and control population (C). 
 
 
 
6.5 Discussion 
The hESC culture process is one of the most sensitive cell culture paradigms as their 
growth and expansion typically calls for complex labour intensive culture protocols. 
Culture conditions (Cai, Ye et al. 2007) together with variation in cell density 
(Lorincz 2006), culture medium (Skottman, Stromberg et al. 2006), presence of serum 
(Bettiol, Sartiani et al. 2007) and feeder cells (Xie, Lin et al. 2005) can have a distinct 
effect on the phenotype of hESCs. Current methods of propagating these cells using 
feeder layers of mouse embryonic (Thomson, Itskovitz-Eldor et al. 1998) or human 
foetal or adult fibroblasts (Richards, Fong et al. 2002; Choo, Padmanabhan et al. 
2004) with serum (bovine or human) components are inexpensive and well accepted. 
However, both feeder cells and serum have problematic batch variability and poorly 
defined composition and give variable effects in hESC culture conditions. There are 
well established studies that use conditioned media derived from such feeder cells 
(Richards, Fong et al. 2002; Braam, Denning et al. 2008) to drive hESC expansion 
and differentiation. However, conditioned media can also give rise to batch variability 
as the cells on which the media is conditioned are primary cell populations derived 
from foetal mouse/human foreskin tissue. In addition the use of murine cells 
incorporates an animal derived component to hESC cultures, validated by Martin et 
al. when they observed hESC cultured on murine embryonic fibroblasts comprised 
significant quantities of N-glycolylneuraminic acid (Neu5Gc). Neu5Gc is an 
immunogenic mammalian sialic acid expressed on the surface of non human 
mammalian cells (Martin, Muotri et al. 2005). As humans do not produce Neu5Gc, 
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transplanted cells expressing this antigen will be distinguished as foreign and initiate 
an immune response which will lead to their rejection. 
 
6.5.1 Defined Culture Conditions 
The systematic production of safe, standard and reproducible cell sources for analytic 
and therapeutic applications depends on usage of well defined culture conditions, 
elimination of animal products and minimal inter-individual variations (Ludwig, 
Levenstein et al. 2006; Chiao, Kmet et al. 2008). Also it is essential to keep the 
number of passages of hESC to a minimum so as to limit genetic changes and cross-
contamination. In this thesis, to enable this, serum-free and feeder-cell free culture 
systems for the propagation of two hESC lines (Hues-1 and H9) have been developed 
with the establishment of master and working banks. Ampoules from the working cell 
bank were used for developing serum-free and feeder-free culture systems using 
standard fully-defined mTeSR medium with its supplement on hESC-qualified 
matrigel matrix. The master cell bank was used as a reference point to validate initial 
results. This tiered master/working bank system gives reliable and reproducible 
supplies of identical cultures for experiments over a long period of time.  
Feeder cells secrete growth factors necessary for blocking spontaneous differentiation 
and help in overall hESC survival and proliferation (Dravid, Hammond et al. 2006; 
Richards and Bongso 2006) . Similarly, matrigel matrix along with defined mTeSR 
medium sustains long term culture and undifferentiated proliferation of hESC with 
normal karyotypes and high sub-cloning efficiency. Hence by substituting a feeder 
cell based culture method with a defined culture method, hESCs tend to retain their 
normal defining characteristics. 
 
6.5.2 Enzymatic Digestion 
Treatment of both lines with trypsin resulted in complete dissociation of each colony 
to a single cell suspension without affecting their proliferation kinetics, evident by 
population doubling times. Trypsin digests cell surface proteins that mediate 
intercellular as well as cell-matrix contacts, in contrast to dispase which digests only 
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the extracellular matrix. This allows efficient dissociation of cells from both the 
centre as well as the periphery of hESC colonies at each passage (Trish, Dimos et al. 
2006). Single cell dissociation of hESC colonies with trypsin resulted in pluripotent 
continuous cultures for all the 20 passages without acquiring any karyotypic changes. 
These results alleviate the previous concerns regarding selection and propagation of 
genetically abnormal subpopulations of hESCs under bulk culturing conditions 
(Buzzard, Gough et al. 2004; Mitalipova, Rao et al. 2005). Single cell cultures of 
hESCs can be grown at high density as monolayers with increased recovery ratios 
(Heng, Liu et al. 2007). Also, trypsinisation with gentle pipetting is less detrimental to 
cellular viability than dispase treatment with scraping as it is hypothesized that 
scraping may induce physical damage to the cells, thereby leading to a lower recovery 
of viable cells (Heng, Liu et al. 2007). The viable single hESCs can be isolated by cell 
sorting techniques, such as FACS, to be further expanded as pure pluripotent 
populations and used in animal models to examine in vivo functionality. 
 
6.5.3 Marker Expression 
Although hESCs can be best defined functionally, a number of surface and 
intracellular markers have been used to identify populations of various stem cells and 
for characterisation during processing. A critical amount of Oct3/4 expression is 
required to sustain characteristic stem-cell pluripotency, and it is down-regulated as 
cells differentiate in vitro and in vivo. In this regard, antibodies to Oct3/4 which cross 
react with human Oct3/4 were used to monitor the presence of undifferentiated cells 
in hESC cultures. As Oct3/4 is expressed by germ cells and may be expressed by 
specific populations later in development, therefore, Oct3/4 as a single marker is 
insufficient for identifying hESCs. Consequently, stage-specific embryonic antigens 
(SSEAs) were used to further characterise the cells. These are cell-surface molecules 
that exhibit lineage-restricted patterns of expression during development and thus 
provide useful markers for identifying embryonic stem cells and their differentiated 
derivatives. SSEA-1 provides a surface marker for human primordial germ cells and 
mouse embryonic stem cells and is negative in hESC cultures. SSEA-3 and SSEA-4 
provide surface markers for hESCs. Monoclonal antibodies directed to SSEAs are 
valuable research tools that can be used to determine the percentage of 
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undifferentiated hESCs and their spatial distribution. Therefore, this combination of 
positive and negative markers that together unambiguously allows the definition of 
the state of hESC cultures was used over the entire culture process. 
 
6.5.4 Karyotyping 
Karyotypic characterisation is essential to check for chromosomal abnormalities, as 
these can occur during extended culture passages and changes in culture conditions. 
G-banding was performed to detect chromosomal aberrations including 
translocations, deletions and gain or loss of individual chromosomes. Like other 
human cells, cells from both lines maintained stable diploid normal karyotype post-
processing. 
 
6.5.5 Automation 
Further, the single cell culture protocol favours the transition to large scale automated 
processing of these cells, an essential step towards their widespread clinical and 
analytic use (Rodriguez, Galan et al. 2006; Crook, Peura et al. 2007). The automated 
hESC culture established, permits large-scale processing of these cells. The defined 
feeder-cell free and serum-free conditions prevent feeder cell and xenogeneic 
contamination together with batch variation, which may interfere with late stage 
analysis and/or therapeutic applications. Single hESCs, harvested using trypsin, 
seeded in microwells of aggrewell plates developed into embryoid bodies in each of 
the wells. While forced aggregation is necessary due to the seeding of trypsin 
dissociated (~ 10 mins) hESCs in manual culture (Burridge, Anderson et al. 2007), 
automated conditions did not require forced aggregation due to the minimal time of 
trypsin exposure (~1 min) during passaging. 
These conditions will assist in improving the safety, quality control, scalability and 
control of the expansion process, further prerequisites for GMP compliant cell 
population manufacture for commercial applications (Ameen, Strehl et al. 2008; 
Unger, Skottman et al. 2008). Large-scale cell culture automation brings 
exponentially greater efficiency and enables high-throughput cell-based compound 
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screening. Early use of automation during assay/therapy development would help to 
adapt the work-flow, as general basic lab techniques are radically different, and 
therefore bridge cell biologics research to the more efficient translational friendly 
scale-up technologies for future downstream applications.  Such automated hESC 
processing will facilitate high throughput drug screening, gene transfection and cell 
based RM approaches. 
 
6.5.6 Differentiation to Otic Progenitors 
Stem cells have been introduced as an approach for regenerating cochlear hair cells. 
Differentiation of murine embryonic stem cells into sensory hair cells is a lengthy 
procedure with low efficiency. In this thesis, a stepwise guidance protocol, based on 
otic differentiation of murine embryonic stem cells (Li, Roblin et al. 2003), was used 
to differentiate hESC into human inner ear progenitor cells. Following the principles 
of in vivo otic induction, Pax-2 positive cells were observed after the 8-day long 
stepwise guidance protocol indicating that such a culture system was capable of 
inducing differentiation of these cells into tissue specific cells. 
The protocol presented in section 6.3.7.2 is based on suppressing endo/mesoderm 
lineages by applying environmental cues to inhibit primitive streak formation, 
followed by mimicking otic induction using bFGF. Therefore, the first step during this 
protocol was generation of early ectoderm that was reactive to otic induction, later 
assayed by expression of early otic markers. Primitive streak formation, an important 
structure for induction of endoderm and mesoderm during mammalian gastrulation, 
was inhibited by blocking WNT and TGF-β signalling via Dkk1 and Noggin. The 
resultant ectoderm was then exposed to bFGF, an otic inducer, and later tested for 
expression of otic marker gene, Pax-2. Cells expressed this early otic placodal marker, 
Pax-2 (Sanchez-Calderon, Martin-Partido et al. 2005), which is expressed throughout 
the development of inner ear (Lawoko-Kerali, Rivolta et al. 2002; Zou, Silvius et al. 
2006). Pax-2 expressed in sensory epithelia is restricted to hair cells (Lawoko-Kerali, 
Rivolta et al. 2002) and Pax-2 expression is required for cochlear duct development 
(Hutson, Lewis et al. 1999). These Pax-2 expressing cells require further functional 
characterisation in terms of their electrophysiological properties to match resemblance 
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with developing hair cells in vivo and, further exploration about their ability to graft 
into animal models of deafness and facilitate functional recovery.  
Such differentiated populations of otic progenitors could be used as an in vitro model 
to study inner ear development in humans and also could prove a useful tool for drug 
testing and design and more importantly, should facilitate the development of a hESC 
based clinical therapy for hearing loss (Corwin 1997). The underlying rationale for 
such a therapeutic is the irreversibility of hearing loss in mammals because of the 
incapacity to replace lost hair cells by cell division or by regeneration of endogenous 
supporting or other neighbouring cell populations (Corwin 1992). These cells can also 
be used for high-throughput assays for drug discovery to treat hearing loss or identify 
genes that regulate in vivo hair cell differentiation. The differentiation method 
presented here is a reproducible and consistent protocol to create inner ear hair cells, 
which will assist the realisation of a novel cell based therapeutic to treat hearing loss. 
 
6.6 Conclusion 
In summary, the hESC culture systems developed here allow manufacturing in a 
translation friendly manner that assists clinical compliance and therapeutic 
application. An automated process has been developed and applied, comprising 
standard protocols with defined serum free culture reagents and materials. Both the 
lines remain pathogen free, karyotypically stable, and undifferentiated after expansion 
(upto ~ 20 passages), cryopreservation for banking, thawing, and prolonged 
subculture. Surface and intracellular antigens of undifferentiated hESCs with in vitro 
EB formation confirm the developmental potency of the hESCs cultured. Directed 
differentiation to inner ear hair cells further confirms the capacity of the cells to be 
converted to specialized somatic cell types. The cell banks generated will act as a 
source of hESC grown in well-defined culture systems and will therefore facilitate the 
translation of hESC research and development to cell-based therapies for other 
diseases. In addition, as fully characterized cell lines they are suitable candidates for 
use in drug screening. 
One of the prohibitive factors for maintenance of such sequentially defined culture 
conditions on a routine laboratory research scale is the cost involved in using batch 
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tested and defined culture media. Therefore, to establish defined systems practical for 
routine research and therapeutic cell replacement applications, lower cost alternatives 
are necessary which may be achieved when simpler media and synthetic substrates are 
identified and tested for hESC cultures. 
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7.1 Introduction 
The chapter describes the economic assessment process for a novel cell-based therapeutic 
based upon the experimental demonstrator presented in Chapter six. The process enables 
assessment of business performance of a novel RM based product at the supply side based on 
health economics principles. It uses a cell based therapy for hearing loss as a focussed case 
exemplar. The impact of hearing loss on quality of life, and current treatment options are 
presented in section 7.3. The general pattern of the net present value (NPV) curve is 
discussed in section 7.4 to identify the drivers of a potential financial opportunity. The 
quantitative and qualitative assessments are based on these drivers as discussed in sections 
7.5 and 7.6 respectively. As part of qualitative assessment, key factors affecting the economic 
positioning of the RM therapeutic are presented. 
 
7.2 Background 
Escalating health care costs continue to be problematic for the overall healthcare industry 
compounded by continued economic distress, policy changes, increased demands for 
transparency by consumers, and the integration of complex innovative technology 
implementation into the health care ecosystem. Consequently, to be integrated within the 
broader healthcare portfolio, cellular therapeutics will have to prove their cost effectiveness 
by tapping innovative sources of value and be realised by well-integrated and cost-efficient 
manufacturing operations with a robust business model that gives advantage to healthcare 
delivery. Such an approach may assist balancing both short- and long-term challenges to 
create value for patients as well as stakeholders. The objective of this chapter is to determine 
the economic positioning, both by quantitative and qualitative evaluation, of a cellular 
therapeutic for hearing disorders at early/initial stages of its development. In turn this may 
allow efficient interventions and effective resource allocation by demonstrating value in 
terms of required investment, and thus inform both R&D as well as investment decisions. In 
the research intensive RM industry, such decisions can have long-term ramifications as the 
analysis can be a strategic input in the business cycle during problem definition. Hearing 
disorders were chosen due to their wide psychosocial and economic implications on quality 
of life, and the incumbents not furnishing a permanent cure. 
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Economic positioning by mapping net present value (NPV) and financial analysis by 
estimating available headroom, cost of goods and return on investment (ROI) are important in 
establishing the budgetary impact of including a new intervention, and the affordability issues 
associated with the resources of supplier, user and payer. In this chapter, the cost 
effectiveness and potential profitability for a cell based hearing therapy have been estimated 
from cost of goods determined from the work on stem cell manufacturing described in 
chapter six. The available headroom calculated gives the financial advantage against the 
incumbent. In turn both cost of goods and headroom allow the potential revenue to be 
estimated. Finally, the study allowed qualitative exploration of parameters affecting 
economic positioning of the cell therapeutic. This was found to be particularly sensitive to 
rate of adoption which is influenced by reimbursement decisions of healthcare providers; 
competition; cost of product development; effectiveness; and final pricing (Figure 7-1). 
 
7.3 Target Disease: Hearing Loss 
This section describes the characteristics of the clinical problem, i.e. Hearing Loss. 
 
7.3.1 Impact of Hearing Loss on Quality of Life 
Hearing disorders requiring therapeutic options are associated with a significant impact on 
quality of life. Impaired hearing results in social, psychological, cognitive and health effects. 
Regardless of their etiology and type, hearing impaired individuals endure anxiety, self-doubt 
and depression all contributing to social isolation and withdrawal thereby affecting their 
overall successful ageing. The hearing disabilities & handicap scale (HDHS) and hearing 
disability score (DIS) indicate that the most important indicator for life satisfaction is the 
social support network, followed closely by the handicap score (Miyakita, Ueda et al. 2002). 
Lack of effective communication and speech intelligibility are the primary reasons for 
restricted social support amongst hearing impaired individuals. Amongst professionals and 
those who are still a part of the workforce, uncorrected hearing loss can have a negative 
impact on their respective job efficacy which might further lead to loss of employment and 
therefore, overall functional health status. 
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7.3.2 Current Service Provisions - Treatment Options 
A hearing aid is an electro-acoustic device comprising of a microphone, amplifier, receiver 
and a power supply. The microphone is a transducer that converts the external acoustic 
signals into electrical energy and sends them to an amplifier. The amplifier acts as a 
transformer and thereby increases the amplitude of the electrical signal sent to the receiver. 
The receiver then changes the modified electrical signal back into acoustic signal that is 
directed towards the inner ear (Palmer and Ortmann 2005).  
Cochlear implants provide electrical signals directly to the auditory nerve via multiple 
electrodes implanted in the cochlea. An external microphone and processor convert sound 
waves to electrical impulses, which are transmitted through the skin electromagnetically from 
an external induction coil to an internal coil implanted in the skull above and behind the ear. 
The internal coil connects to electrodes inserted in the scala tympani in the inner ear (Wilson 
and Dorman 2008). 
Auditory brainstem implants are prosthetic devices surgically implanted in the brainstem 
directly on the nerve centre (cochlear nucleus) of deaf patients lacking the auditory nerves. 
They lead the sound signals from the ear straight to the brain. The implant consists of a small 
electrode applied to the brainstem where it stimulates vital acoustic nerves by electrical 
signals. The technology also includes a small microphone on the external ear which digitally 
transmits the sound signals to a decoding chip placed under the skin. A small wire connects 
the chip to the implanted electrode in the brainstem. Depending on the sounds, the electrode 
delivers different stimuli to the brainstem making patients hear different sounds. They are 
mainly used in patients deafened by bilateral vestibular schwannomas or neurofibromatosis II 
(Schwartz, Otto et al. 2008). 
 
7.4 Net Present Value/Cash Flow Pattern 
RM products like patented pharmaceuticals and biomedical products have revenue curves, in 
terms of net present value (NPV), of a predictable form. A product must establish optimal 
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market share and peak sales performance within the patent-protected time to recoup years of 
investment, and fund the next generation of products. 
Successful product developers constantly seek new opportunities to overcome obstacles and 
to grow profitably. The key drivers of short and long term revenues to maximize commercial 
value at all stages of product life cycle were identified in the standard NPV curve (Figure 7-
1). The initial capital engaged in product development includes costs related to R&D, scale-
up, clinical trials and early marketing exercises which in turn result in negative cash flow. 
Cash flow rises after market introduction i.e. after approval (from regulatory authorities) and 
peaks depending upon rate of adoption, effectiveness (both clinical and cost) and pricing 
schemes. As seen in Figure 7-1, patent expiration and introduction of competing technologies 
result in decline of revenue.  
 
 
 
 
 
 
 
 
 
 
 
Figure 7-1: Standard net present value (NPV) graph showing key parameters which can impact the 
product lifecycle 
Accurate forecasting of emerging RM products requires the integration of the effects of these 
multitude variables. Therefore, product profile, competitive position, price, and rate of 
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adoption/promotional effort must be considered to identify a product's potential revenue 
stream. The initial product strategy and resultant output gives both positive and negative 
scenarios in terms of cash flow, as evident by shift of the NPV curve. (Figure 7-6). Products 
that meet sales expectations generally have high rates of adoption due to improved clinical 
and cost effectiveness together with favourable pricing. During their life cycle they remain 
superior to their competition by consolidated intellectual property protection. Factors that 
hasten decline include a low rate of adoption (mainly low patient uptake and slow physician 
acceptance), pricing pressures, alternative novel therapy introductions, aggressive 
competition and sales force ineffectiveness (Figure 7-6). 
The initial negative cash flow period will depend on product development time. Thus, the 
cost of product development is approximately proportional to the length of the development 
phase depending on the amount of time the product spends in preclinical and clinical 
development and testing. It can take several hundred million dollars to discover, develop and 
gain regulatory approval. Thus, for successful execution of the business model applied, 
significant financing is required to raise the large amount of initial high-risk investment 
involved in furnishing a successful RM therapeutic with adequate financial return. Although 
the figures are difficult to identify exactly, experts agree that it is expensive and requires time 
and patience. For instance, Paul Kemp, CEO Intercytex, recently stated requirements of 100-
200 and 300-500 patients in phase II and phase III clinical trials, respectively, with costs 
ranging from £30-50k per person, in addition to product unit costs, and five to fifteen years of 
development time for a single therapeutic. Cost of product development for RM products 
continues to exceed sales due to the associated scalability issues and the corresponding low 
volumes of production (Mason 2007). This necessitates stepwise integration of production 
strategy with product manufacture. High up-front cost to discovery is followed by cost to 
market, which includes cost for regulatory approval, marketing exercises and the logistics 
concerned with product distribution. Therefore, to fund R&D activities that require 
continuous sustained access to capital, developers need to be innovative especially at present 
when access to more conventional routes of funding is limited. 
In this regard, the available financial opportunity from the development of a new therapeutic 
can be estimated by adoption of health economic principles on the supply side i.e. the 
headroom analysis. It is a straight forward threshold approach which estimates the maximum 
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cost at which a technology can be developed and brought to market while being considered 
cost-effective and therefore, a viable commercial proposition. Further, cost of goods 
assessment at the research scale can give a rough estimate of product unit costs. Following 
the quantitative assessment, the Chapter establishes the economic dynamics of this putative 
hearing therapy by analysing issues impacting return on investment, which will further assist 
in early evaluation for an emerging cellular therapeutic. 
This chapter therefore now, presents the quantitative analysis by estimating available 
headroom, cost of goods and return on investment (ROI) for a putative hearing therapy. 
 
7.5 Quantitative Analysis 
7.5.1 Headroom Analysis 
The analysis assists in calculating the incremental cost of a technology to determine where it 
is cost-effective i.e. the headroom for its adoption (Cosh, Girling et al. 2007). If this 
differential cost is less, relative to the net cost of using the product, then the technology is not 
worth adoption and therefore investment should be engaged elsewhere. However, the reverse 
might not always hold true. The new intervention might “still” fail despite adequate 
headroom for its utilization as it may prove ineffective (clinically) in comparison to the 
incumbent, or costlier than expected, or superior alternatives may emerge. Nevertheless, the 
analysis can assist to lower the risk of embarking on an investment by screening the ones 
which might not lead to cost-effective therapies, at the very beginning of the project. 
Headroom analysis builds on a cost effectiveness analysis, which compares relative value of 
different interventions for better health. In this instance, the headroom was calculated 
following a clear definition of the clinical problem, i.e. hearing disorders, and a 
corresponding initial market analysis, presented in chapter three (Singh and Williams 2009). 
The headroom is the maximum incremental cost (maximum additional cost compared to the 
current gold standard therapeutic option) of a novel technology under consideration which 
could still be considered cost effective. Cosh et al. provide a detailed account of the 
methodology for headroom analysis (Cosh, Girling et al. 2007), and an accessible 
presentation of the method is shown by McAteer et al (McAteer, Cosh et al. 2007). 
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To generate the headroom value, first the incremental cost effectiveness ratio (ICER) needs to 
be quantified. ICER is specifically the extra cost of obtaining health gain per unit of gain in 
health from a candidate intervention, technology or program when comparing this candidate 
against the one which is most often used, on a cost per quality adjusted life year (QALY) 
basis.  
ICER is calculated by dividing the incremental cost (∆C) by the incremental benefit (∆E), 
which results in a cost per QALY (Equation 1).  
ICER = ∆C / ∆E   …Equation 1 
A QALY is a time adjusted health utility which considers both quantity and quality of life 
generated by the overall healthcare practice. Quantity is expressed in terms of life expectancy 
and quality is depicted on the basis of Health-Related Quality of Life (HR-QoL).  
A health utility measures the strength of an individual’s preference for a particular health 
outcome on a scale where 0 is death and 1 is perfect health (Figure 7-2). As a year of perfect 
health is equivalent to 1 therefore, 1 QALY equals 1 year of perfect health. Total incremental 
QALY gain for a technology is a function of improvement in health utility (∆ utility) and the 
duration over which this improvement is sustained, on comparison of the new technology 
with the incumbent (Equation 2). 
Therefore,  
QALY = Utility x duration of time (years) with that health state 
And change in QALY, 
∆QALY = (utility score of new treatment x duration (years) of that health state) - (utility 
score of incumbent treatment x duration (years) of that health state) …Equation 2  
Rearranging equation 1, the headroom method calculates the maximum incremental cost 
based on the most optimistic but plausible estimate of effectiveness of the new technology.                
max ∆C = ICER x ∆E    …Equation 3 
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In the UK, National Institute for Health and Clinical Excellence (NICE) uses a willingness to 
pay (WTP) threshold value per QALY, which represents an estimate of the health benefit 
forgone based on the estimated productivity of a new candidate treatment option. This WTP 
threshold is equivalent to ICER and effectiveness can be measured as change in QALY, thus, 
equation 3 can be rewritten as: 
max ∆C = WTP threshold x max ∆QALY  …Equation 4 
In the UK, the WTP threshold is considered between GBP 20-30,000 i.e. the healthcare 
provider will pay this amount per QALY for a new candidate intervention. Therefore, the 
headroom can be denoted by the maximum change in cost, expressed as: 
max ∆C = 20,000 x max ∆QALY, 
where max ∆C is the headroom i.e. the maximum additional cost of a new treatment over the 
incumbent, for the new treatment to be deemed cost effective and 20,000 was used as a 
conservative estimate of WTP threshold used by NICE. 
Case Exemplar: Regenerative Medicine for Hearing Loss 
The comparator in this study was the present incumbent to treat hearing loss, i.e. hearing aids, 
as an improvement on the performance of this device will support the reimbursement of a 
novel cellular therapeutic for the hearing impaired. For the economic analysis in this study, to 
calculate QALY, median utility scores from a publication (Barton, Bankart et al. 2004) were 
used. The authors compared utility scores within a group of 609 hearing impaired individuals 
with an average age of 68.4 years. The scores were quantified using a formal empirical 
observation method, i.e. the pre-scored multi-attribute utility function, HUI-3 (Health 
Utilities Index Mark III) score (Feeny, Furlong et al. 2002). HUI-3 is a generic, preference-
scored, comprehensive system for measuring health status, health-related quality of life, and 
ultimately producing utility scores. It comprises eight attributes (vision, hearing, speech, 
ambulation, emotion, dexterity, cognition and pain), the responses to which are converted 
into utility scores. As HUI-3 explicitly takes into account a person’s capability to hear and to 
be understood while speaking, it gives a more realistic utility score. The mean utility score 
(pre-intervention=0.58 and post intervention=0.06) was 0.64. Based on the potential of stem 
cells to take over the function of the diseased inner ear hair cells and restore the hearing 
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pathway, an assumption of 100% effectiveness of the novel cell therapeutic was made, which 
leads to perfect health. Therefore, the utility score of the new treatment was taken as 1. 
As hearing aids are used by the patients for their remaining life, an assumption of utility score 
remaining constant during this period was made. On average a hearing abnormality is 
diagnosed in the age group ranging from 30 to 40, and average life expectancy was taken as 
70 years. Similarly, an assumption of patients maintaining a healthy state after cell 
transplantation for their remaining life (~30 years) was made, with diagnosis in the same age 
group.   
 
 
 
 
 
 
Figure 7-2: Health Utility scale 
Therefore, as the duration of health state is similar after both set of treatment regimes, 
equation 2 can be written as, 
max ∆QALY =  ∆utility x duration of health state. 
i.e. (1 – 0.64) x 30 = 0.36 x 30 = 10.8 
Further as,   
max ∆C i.e. the headroom = WTP threshold x ∆QALY 
Therefore,  
Headroom = 20,000 x 10.8 = GBP 216,000 
 
Perfect health = 1.0 
Death = 0 
Hearing aid = 0.64 
A health utility is expressed 
on a scale from 0 to 1, for 
example, a hearing aid gives 
a mean utility of 0.64 on 
HUI-3 Index. 
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This suggests the therapeutic will be cost effective if it costs below GBP 216,000 to treat a 
patient. In the same publication, from which the HUI-3 scores were taken, the mean utility 
scores were also quantified using EQ-5D measure of utility. EQ-5D is a standardised 
instrument used to measure health outcome. It provides a simple descriptive profile and a 
single index value for health status (Gerard, Nicholson et al. 2004). The EQ-5D score in the 
publication was 0.81. Therefore,  
max ∆QALY = (1 – 0.81) x 30 = 0.19 x 30 = 5.7 
and, 
Headroom = 20,000 x 5.7 = GBP 114,000 
The estimated headroom for the provision of a cellular product is therefore likely to be 
dependent on the instrument used to measure utility as these utility measures yield different 
headroom values to assess cost-effectiveness (Figure 7-3). However, even the lower value, 
GBP 114,000 per intervention, provides adequate headroom for the development of a novel 
cost-effective cellular therapeutic for hearing loss. Further, available headroom was also 
calculated for a lesser duration in healthy state post-intervention (Figure 7-3). The least 
headroom calculated was £38,000 with 0.81 utility score and 10 years of healthy state post-
intervention, which again seems appropriate to initiate the development of such a therapy, 
bearing other factors in mind. 
In the above calculations, conservative figures regarding WTP threshold (NICE value: 20-
30,000) and number of years in healthy state (maximum 30 years) have been applied. Also, 
the net cost savings to the health service in terms of follow up visits for modifying or 
changing the hearing aids have not been included which, when added, will further increase 
the available headroom. Further, as profits would be volume dependant and bearing in mind 
the huge market potential for such a therapeutic (Singh and Williams 2009), it is likely that a 
cellular product for the hearing impaired is potentially viable from a commercial standpoint.  
This is the first instance where the headroom analysis has been used for a non-surgical 
disease state which if cured can improve the quality of life of a patient for his/her remaining 
life. This is clearly evident from the large headroom available, derived from the increased 
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number of QALYs post-treatment. Further, cost of goods was calculated to get an 
approximate unit cost at research scale. 
 
 
 
 
 
 
 
 
 
Figure 7-3: Graphical representation of headroom for a hearing therapy depicting 
duration in healthy state post-intervention with corresponding utility scores derived 
from two different methods 
7.5.2 Cost of Goods 
One of the major issues in formulation and supply of RM based cellular products is bio-
manufacturing. In this regard, cost containment of goods manufactured under GMP 
compliant conditions is one of the most complex issues that must be addressed by the 
developers. Hence, cost of goods for their manufacture is a major concern, cost-effective 
manufacture and delivery is essential for ultimate profitability and appropriate 
reimbursement.  
Primary adult stem cell processing involves large costs as individual and different therapies 
with different specifications are costlier to produce and harder to regulate. The primary 
advantage of using hESCs is that they do not involve donor variability and therefore can be 
used for multiple patients as allogeneic therapies. Also, the hESC based cellular product 
allows a hybrid business model, where the product can be used as a therapeutic as well as in 
other downstream applications as previously discussed in Chapter six.  
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Hence, a key objective of this work was to calculate the direct cost of goods involved in 
developing a cellular product for hearing loss based on the demonstrated scale-up and 
differentiation of hESCs into otic progenitors in Chapter six (Tables 7-1 to 7-7).  
The master cell bank established consists of hESCs, characterised for both pluripotency and 
genetic stability. This was the point of reference to initiate manufacturing. A scalable 
translation friendly culture protocol on an automated cell culture platform was used for 
growing, maintaining, and scaling up undifferentiated hESCs as described in Chapter six. A 
defined culture formulation in feeder cell-free and serum-free conditions was employed. Such 
a system not only eliminates concerns about viral or animal protein contamination but also 
brings down costs involved with serum procurement and feeder population manufacture. 
Also, the process enables superior control with minimal variation. Further, a stepwise 
guidance protocol, following the principles of in vivo otic induction, was used to differentiate 
hESC towards human inner ear progenitor cells to develop the therapeutic population. 
In human beings, the hearing sensation is the output of a relatively small number of sensory 
cells - fewer than 15,000 per inner ear. SNHL is mainly attributed to the loss of these cells; 
therefore, a biological approach encompassing replacement of damaged cells by a functional 
cell population is what is required. To realize this therapy, the bioprocess required to meet the 
individual patient demand can be achieved by a single cryovial containing 4 x 10
5
 progenitor 
cells. The model process used to generate this vial with functional cells in the experimental 
demonstrator consisted of 27-fold expansion and three passages over 25 days. 
To estimate the cost of goods major sources of process costs, i.e. cost categories, were 
identified from the experimental demonstrator presented in Chapter six. These costs were 
categorised and tabulated as raw materials, consumables, operations and person time. Costs 
related to scale up and differentiation experiments were tabulated separately (Tables 7-1 to 7-
8). Calculations were further facilitated by process diagrams for the two main processes 
involved, i.e. expansion and differentiation, (Fig 7-4). In particular, sub processes were 
examined individually to identify their respective time duration for calculating person and 
process costs. The usage of raw materials and consumables was individually determined for 
different passages and the process they were employed in. Similarly, from the process 
diagrams, process and person costs were segregated in accordance with the different sub 
processes of the overall process. 
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Table 7-1: Raw material usage costs for cell expansion on research scale. The raw 
materials enlisted were used during regular feeding of cells, passaging (P1-P3) and 
cryopreservation. After passage 1 (P1), two flasks were cryopreserved for the master 
cell bank. 
 
Consumables for Expansion 
Description Quantity Cost (£) Usage Costs (£) Total 
Passage Number (P)   P1 P2 P3 (£) 
Number Flasks IN 
 
 [3] [3] [9]  
Number Cells IN   3 x 10
6 
3 x 10
6
 9 x 10
6
  
Flasks 54 1 3 3 9 54 
       
Plastic 
Consumables 
  1 1 3 5 
       
General use 
consumables 
  1 1 3 5 
       
Cryovials   1 0 0 1 
       
Number Flasks OUT 
 
 [3] [9] [27]  
   [2 frozen]    
Number Cells OUT   9 x 10
6 
9 x 10
6
 27 x 10
6
  
       
Total   9 14 42 65 
       
 
Table 7-2: Consumable usage costs for cell expansion on research scale. The 
consumables enlisted were used during regular feeding of cells, passaging (P1-P3) and 
cryopreservation. 
Raw Materials for  Expansion 
Description Quantity Cost (£) Use/Process Usage Costs (£) Total 
Passage Number (P)    P1 P2 P3 (£) 
Number Flasks IN 
 
  [3] [3] [9]  
Number Cells IN    3 x 10
6 
3 x 10
6
 9 x 10
6
  
H9 cell line 1 vial 1000 1 vial 1000 0 0 1000 
Base media (mTeSR) 500 ml 200 5ml/flask(3)/ 
day(3)=45 
18 18 54 90 
Trypsin 500 ml 30 3ml/flask(3)/ 
day(1)=9 
.54 .54 1.62 2.70 
PBS (washing) 500 ml 1 50 ml .10 .10 .30 0.50 
Freezing media 50 ml 150 5ml/flask(2) 30 0 0 30 
Number Flasks OUT 
 
  [3] [9] [27]  
    [2frozen]    
Number Cells OUT    3 x 10
6 
9 x 10
6
 27 x 10
6
  
        
Total   * Split ratio 1:3 1048.64 18.64 55.92 1123.2 
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Table 7-3: Process time involved with cell scale up on research scale. Scale up steps (A1-
A6) are identified in the process map (Figure 7-4) 
 
Table 7-4: Person costs for cell scale up on research scale inferred from Table 7-3 based 
on the process map in Fig 7-4 
 
Process Costs for  Expansion 
Passage Process 
Parameter 
  Person Costs (£) 
    [Cost of Labour at £30/hr] 
 Scale up steps 
(A) 
Flasks 
IN 
Flasks 
OUT 
A1 A2 A3 A4 A5 A6 
 Process Time 3 3 0.30 0.50 0.50 0.30 0.30 1.50 
P1 Person Time   0.30 0.50 0.50 0.30 0.30 1.50 
 Person Cost   10 15 15 10 10 45 
          
 Process Time 3 9 0.00 0.50 0.50 1.00 1.00 1.50 
P2 Person Time   0.00 0.50 0.50 1.00 1.00 1.50 
 Person Cost   0.00 15 15 30 30 45 
          
 Process Time 9 27 0.00 1.50 1.50 3.00 3.00 1.50 
P3 Person Time   0.00 1.50 1.50 3.00 3.00 1.50 
 Person Cost 
 
 0.00 45 45 90 90 45 
  
 
       
Person Costs for  Expansion 
Description Passage Person Costs (£) Total 
  [Cost of Labour at £30/hour] (£) 
Scale up steps (A)  P1 P2 P3  
 Number Flasks IN [3] [3] [9]  
 Number Cells IN 3 x 10
6 
3 x 10
6
 9 x 10
6
  
A1  10 0 0 10 
A2  15 15 45 75 
A3  15 15 45 75 
A4  10 30 90 130 
A5  10 30 90 130 
A6  45 45 45 135 
      
 Number Flasks OUT [3] [9] [27]  
  [2 frozen]    
 Number Cells OUT 3 x 10
6 
9 x 10
6
 27 x 10
6
  
Total  105 135 315 555 
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Raw Materials for Differentiation 
Description Quantity Cost (£) Use/Process Usage Costs (£) Total (£) 
Aggrewell 
plates 
5 40 Embryoid body 
formation 
200 200 
Number of cells 
 
    
H9 cell line 1 vial 0 1 vial 0 0 
Base media 
(mTeSR) 
500 ml 200 2.5 ml/well (24) 24 24 
Trypsin 100 ml 20 1 ml/well (24) 4.80 4.80 
Differentiation 
supplements 
 1000  1000 1000 
      
Total     1228.80 
 
Table 7-5: Raw material usage costs for inducing cell differentiation on research scale. 
The raw materials enlisted were used during regular feeding of cells with supplemented 
media during the stepwise guidance differentiation protocol.  
 
Table 7-6: Consumable usage costs for cell differentiation on research scale. The 
consumables enlisted were used during regular feeding of cells with supplemented 
media during the stepwise guidance differentiation protocol 
 
 
Table 7-7: Person costs for cell differentiation on research scale based on the 
differentiation steps (B1-B5) as identified in the process map in Figure 7-5 
Consumables  for Differentiation 
Description Quantity Unit Cost Usage Costs (£) Total (£) 
Number of cells 3 x 10
6 
 0  
6-well culture plates 4 5 20 20 
Plastic consumables   1 1 
General consumables   1 1 
Cryovials 10 5 50 50 
     
Total    72 
Process steps involved in Differentiation 
Description Passage Person Costs (£) Total(£) 
  Cost of Labour at £30/hour  
 Number Flasks IN [3] [3] [3]  
 Number Cells IN 4 x 10
5 
4 x 10
5
 4 x 10
5
  
B1  10 10 10 30 
B2  15 15 15 45 
B3  15 15 15 45 
B4  45 45 45 135 
B5  30 30 30 90 
 Number Cryovials OUT [3] [3] [3]  
 Number Cells OUT 4 x 10
5 
4 x 10
5
 4 x 10
5
  
      
Total  115 115 115 345 
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Figure 7-4: Process diagrams to identify sub processes involved in the expansion (A1-
A6) and differentiation (B1- B5) of the starting cell populations 
 
Considering the expansion costs first, at GBP 1745 (sum of raw material, consumables and 
process costs), 27 vials containing 1 x 10
6
 undifferentiated cells were generated. Therefore, 
unit cost of each vial was GBP 65, approximately. Secondly, each of these vials could be 
differentiated into the therapeutic cell population at an additional approximate cost of GBP 
180 (sum of differentiation supplements, consumables and process costs (GBP 1645.80) 
divided by total vials (9) of differentiated cells generated). Consequently, each final vial 
consisting of differentiated cells would cost approximately GBP 245. 
The costs calculated here involve only the derivation of the therapeutic cell population. After 
deriving the differentiated population, its characterisation and sorting to remove undesirable 
cell types may be required. Also GMP manufacture will add costs for provision of 
appropriate validation and requisite documentation to ensure traceability and reproducibility. 
Appropriate quality control release tests to validate genetic identity and pathogen-free state 
will be further required before initiating safety and efficacy trials (non-tumorigenic potential, 
optimal passage number, etc). 
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Protocol definitions for inclusion/exclusion criteria, number of passages, cell culture 
conditions and differentiation assays form a key part of the whole supply chain under the 
GMP requirements. GMP is a quality assurance system used in the healthcare and 
pharmaceutical industry. It ensures that the end product meets preset specifications during 
both manufacturing and testing of the final product. It requires traceability of raw materials 
and also that production follows validated standard operating procedures for the entire 
process, from cell isolation to freezing and storage of the cells (Hesse and Wagner 2000). 
GMP manufacture costs together with indirect commercial scale up and indirect costs can 
range from five- to twenty-fold more than the conventional lab based manufacture of any 
therapeutic. And the post-process delivery costs are generally estimated equivalent to the unit 
price. Therefore, taking a conservative ten-fold increase in the unit price post GMP 
production and addition of indirect costs, a cell based therapeutic for hearing loss might cost 
approximately GBP 4900. 
To compare this cost with the development and commercialisation costs of other RM based 
products, it was compared with RM products presently in the market. These are in the range 
of USD 5000 to 10000 per unit (Table 7-8). Given the lack of published economic data on 
clinical applications in RM, some of the parameters affecting these costs are bound to differ 
from each other. Further, at present, these costs are not seen to be representative of RM 
development costs due to different underlying technologies and processes for product 
development, different sample size for different applications and disease areas, number of 
investigational therapeutics and difference in costs on the basis of therapeutic class (DiMasi, 
Grabowski et al. 2004).  For instance, estimations regarding the number of RM products in 
the market would depend on its rate of adoption, cost effectiveness and disease prevalence. A 
frequently used procedure or treatment might benefit from the economies of scale depending 
on process and product scalability. Also, the costs of product development in terms of 
delivery logistics would be affected by whether the final product includes live cells and 
consequently has limited shelf life.  
Due to the non life-threatening nature of hearing loss and the presence of incumbent 
technologies, cost effectiveness is probably the greatest driving force in the overall 
development process, even more than time to market. Therefore, in a competitive market like 
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this, profitability for an RM based hearing application will be influenced heavily by 
effectiveness (cost and clinical) and cost of development. 
 
RM based product Cost per unit 
Apligraf (Dermal Skin Equivalent) GBP 3,825 (maximum course) : UKMI data 
Infuse (Bone Graft consists consisting of a 
recombinant protein rhBMP-2 (human bone 
morphogenetic protein-2) and a sponge of 
bovine Type 1 collagen 
USD 8,900 (Cage, sponge and BMP dose) : 
Medtronic data 
 
Carticel (Autologous cultured chondrocytes 
for knee cartilage treatment) 
USD 10,360 (culturing, growing, and 
shipping the cells): Brown University data 
 
Table 7-8: Comparative costs of other RM based products presently in the market 
 
7.5.3 Return on investment 
RM based treatment regimes are often significantly more expensive than traditional small 
molecule products because of the high development costs associated with RM technologies 
(Mason and Hoare 2006). Any new therapeutic products based on research in RM will 
require extensive testing and face regulatory challenges that might impose delays to 
commercial product introduction. Research and development tools developed from the 
product platform may generate revenue with a shorter delay.  
Technologies with adequate available headroom (assuming strategic fit within the business 
model), present a strong rationale to continue their development with the required investment 
for at least the next stage in the process. Therefore, in order to further consolidate the case, 
the next step in this study was to determine whether or not the applied technology carries the  
potential to generate revenue (which effects ROI) once it is brought to market. It is important 
to note here that ROI can also be affected by the incidence, epidemiology and geographical 
distribution of the condition. A viable business needs substantial unit volumes to recover 
development costs and secure the ROI.  
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The generated revenue is a function of the headroom (max ∆Cost), the likely per unit cost 
(C’) and volume (Equation 5). The expected profit should also be discounted over a time 
horizon in accordance to the company strategy. 
Revenue = (max ∆Cost – C’) x Volume … Equation 5 
The market size for an RM based cellular product for hearing loss is significant as discussed 
in chapter three and sensitive to rate of adoption. Therefore, being conservative and assuming 
100 procedures are done in the first year (i.e. 0.1% market penetration) at available headroom 
of £38000 (minimum headroom value from Figure 7-3), unit price GBP 4900, the net revenue 
generated would equal: 
Revenue = (38000 – 4900) x 100 = £3,310,000 
This is the approximate revenue taking into account the estimated cost of goods for 
manufacturing from the above calculation (section 7.5.2). Strong revenue will enhance ROI 
and therefore, will positively influence decision makers and potential early stakeholders. This 
will consequently assist development of start ups, increase portfolio of products at the proof 
of concept or investigational level, thereby, making the industry pipeline robust. In this 
particular instance a strong initial revenue generation opportunity works in favour of 
proceeding towards the development of an RM based therapeutic for hearing loss. It further, 
enhances the business proposition early in the business development lifecycle when clinical 
effectiveness may not have been demonstrated fully. Therefore, it informs investment 
decisions by indicating towards a product with great potential to direct development efforts, 
for instance working towards first in man. 
As noted earlier, the RM industry is capital-intensive and therefore such estimations at proof 
of concept level or even earlier are likely to assist in raising capital and provide access to the 
capital markets thereby impacting the pace of development and ultimate success. Venture 
capitalists are increasingly favouring investments with more predictable capital needs and 
return on investment with sound exit strategies. For this, such ab initio analysis of early stage 
technologies to get a reasonable estimation of revenue from investing in the asset will prove 
useful to both investors and developers. Similarly, public investors are becoming increasingly 
selective in picking out companies in which to invest, and are inclining towards deploying 
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larger amounts of capital in enterprises with competitive advantage and more beneficial 
prospects in terms of ROI.  
In this exemplar, as the cell population prior to differentiation could be used for screening 
and toxicological assessments for various drugs, the product developers would be able to 
adopt a service/platform business model initially or a hybrid business model overall to 
generate revenues from very early stages of product development, even before scaling up the 
differentiation process for the final therapeutic cell population. The valuations above confirm 
a promising platform to carry forward the development of a cell based therapeutic for hearing 
loss. Though the valuations are inexact and somewhat speculative, they do provide a useful 
initial assessment. When technologies are tracked in terms of their expected valuations at the 
time of financing and investment events, such assessments may help investors in taking well 
informed decisions both at the start up and through commercialisation, as the model is 
refined. In addition, it indicates overall market size, structure and composition. 
 
7.6 Qualitative Assessment: Factors Impacting Return on Investment 
Economic assessment of healthcare reflects the present healthcare reforms globally, which 
primarily focus on cost-savings by eliminating inefficiency. Fostering novel innovative cost-
effective approaches for disease treatment and prevention could be the first step towards 
achieving such sustained cost reductions over time. Innovation is a key driver to achieve 
these reductions continuously together with quality improvement, and this further drives 
competition. The desire for long-term cost savings, the growing health needs of the ageing 
population and the changing patterns of demand due to the ever-increasing awareness and 
expertise of patients are further reasons for continuous innovation to improve upon present 
technologies. The objective of this study reflects this as it was aimed to establish economic 
dynamics by analysing the issues in early evaluation of a cellular therapeutic using hearing 
disorder as an exemplar. 
The cash flow pattern (Figure 7-1) depicts cost of product development, including costs 
related to R&D, scale-up, cost of goods, clinical trials and initial marketing which result in 
negative cash flow. Cash flow rises after the first years of market introduction and peak 
before declining once patents expire and superior products reach the market. Given the 
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uncertainty surrounding many of the parameters that affect ROI, the key variables were 
identified. 
 
7.6.1 Inherent Variables 
Contribution margin is a key parameter effecting ROI. An industry contact at a medical 
device company, confirmed a representative value of 70% margin on product costs with a 
discount rate of 30% in their discounted cash flow calculations over time. Average 
contribution margin can be assumed at 40% over time, which continues to rise post-approval 
and market introduction. Heavy promotion and marketing expenditures are required during 
the launch phase of the life-cycle and as the product matures these promotional costs decline, 
increasing the contribution margin in the later years of the product life. Costs maybe expected 
to reduce as the product matures.  
Cost of capital can result in changes in the NPV during product development, whereas 
changing tax rates do not have significant effect as these rates equally affect the cost of 
product development and the corresponding revenue generated.  
Patent expiry and introduction of substitute products, in general, erode sales and lead to a 
decline in ROI over time. However, taking into account the complexity of manufacture and 
delivery issues for RM products and the consequent importance of know-how, it is still not 
clear how intellectual property expiration will affect their niche market position and 
corresponding ROI. As a result, it is difficult to predict at present the degree of sales loss in 
the later parts of product life-cycle.  
Further, the duration of regulatory review will affect the capitalised value of R&D costs. If 
the duration is shortened both NPV and ROI can increase, thereby resulting in significant cost 
benefits to the supplier.  
However, it should be noted that these predictions in the RM domain are still uncertain, and 
are difficult to predict owing to a lack of real data. It remains unclear how quickly these new 
technologies will result in important new therapies and how they will influence industry 
returns. 
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7.6.2 Dynamic and Application/Product dependant variables 
Further dynamic parameters are at work which can have an effect on ROI. These primarily 
include rate of adoption and the reimbursement decisions of healthcare providers; cost of 
product development; competition; effectiveness (both cost and clinical); and final pricing, 
and are discussed below. The impact of these parameters varies across the healthcare delivery 
value chain (Figure 7-5). The value chain is used here to assess the degree of impact of the 
parameters involved. It analyzes the entire sequence from supplier to payer. Each link seeks 
to maximise its contribution and return, however, the impact varies across the value chain. 
 
 
 
 
 
 
 
 
Figure 7-5: Degree of impact of key parameters involved in a novel healthcare product 
delivery value chain (Impact of different parameters varies across the chain, 
+++=Major Impact, ++=Moderate impact, +=Minimal Impact, No + sign= Impact 
negligible) 
Products that will meet business expectations generally have a high rate of adoption due to 
either better clinician uptake, i.e. clinical effectiveness, or better payer uptake, i.e. cost 
effectiveness, together with favourable pricing. During their life cycle they remain superior to 
their competition with consolidated intellectual property protection (Figure 7-6a). Factors that 
hasten decline include low rate of adoption including low patient uptake, slow physician 
acceptance, pricing pressures, other novel therapy introductions, aggressive competition and 
sales force ineffectiveness (Fig 7-6b). 
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Figure 7-6: Parameters affecting the net present value of a product over its entire life 
cycle. (Dashed line represent normal economic positioning of a product during its life 
cycle, Solid lines represent the effect of sensitivity parameters on the economic 
positioning) 
 
 
7.6.2.1 Rate of adoption 
The contribution of a new innovative healthcare technology to clinical practice can only be 
realized when the new technology is widely adopted and used. Adoption results from a series 
of individual decisions regarding the diffusion of the new technology, based upon the 
comparison of its benefits with the incumbent, the status of competing technologies and cost-
effectiveness (Figure 7-7). Therefore, adoption can be seen as the cumulative result of 
individual parameters that weigh the incremental cost of a technology where it stands cost-
effective (i.e. headroom for its adoption) and the incremental benefits of adopting that 
technology against the costs of change, as estimated by both the supply and demand side, 
respectively. The benefit over the incumbent is the primary factor affecting rate of adoption. 
The estimations above were made in an environment characterised by uncertainty as to the 
future evolution and benefits of the technology, and by limited information about its 
associated indirect costs. However, these estimations can assist early financial stakeholders 
and healthcare providers to evaluate a therapeutic and make well informed investment and 
reimbursement decisions. While the final adoption decision is made by the demand side, the 
costs can be influenced by decisions made by the supply side, depending upon the available 
headroom, cost of goods and anticipated ROI.  
  a b 
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Adoption of a new technology by the users will ultimately affect the rate of diffusion and the 
rate of change of productivity in clinics. The relative advantage and compatibility of a new 
therapy over the incumbent defines its rate of adoption. Since RM based innovative therapies 
can have direct economic significance, therapies perceived as the most rewarding with the 
least risk and uncertainty are most likely to be accepted by both payers and providers. 
 
 
 
 
 
 
 
 
Figure 7-7: Factors affecting rate of adoption 
 
7.6.2.1.1 Rate of adoption by providers/physicians 
Innovations in RM will have important implications for the nature of future clinical practice. 
Stem cell implantation procedures for hearing loss can range from a modest additional step in 
an existing procedure to devising an entirely novel surgical approach (Mason and Dunnill 
2008). Also cellular therapies, due to their procedural complexity, may be offered by 
relatively few highly skilled ENT surgeons and they may take some time to become 
proficient in these procedures (Mason and Dunnill 2008). Thus, cell therapies which come 
with detailed guidance documents to clinicians regarding implantation protocols will give rise 
to better prognosis and less patient risk. Their increased prognostic capability to define 
outcomes together with a shorter recuperation period requiring a reduced number of follow-
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up visits for complete rehabilitation, with associated reduction in costs will increase the rate 
of adoption of these procedures by surgeoons (Nelson, Behfar et al. 2009).  
Further, as RM products incur high material costs for therapeutics, high prices might be 
placed on these novel innovative procedures initially. However, in case of SNHL, it is 
anticipated that cell therapy will be a one-off treatment regime providing improved health 
status and symptom alleviation, increased workplace productivity, and substitution for more 
expensive, prolonged and non-biological therapies. Therefore, their adoption will be 
compatible with mainstream clinical practice and will enable long-term comprehensive 
benefits by offering single procedures requiring less nursing time and early discharge, 
resulting in lower aggregate treatment costs. Such pharmaco-economic advantages driven by 
reduced costs and recovery time together with early functional restoration clearly indicate 
clinical and economic advantages of a cell therapy for SNHL (Strong, Farrugia et al. 2009).  
 
7.6.2.1.2 Rate of adoption by payers:  
At present, payers tend to concentrate on identifying cost effective therapeutic regimes with 
fewer complications and better long-term results. Primarily, such cost reduction measures 
focus on one-time cost savings rather than identifying measures that lead to sustained cost 
reduction. Unfortunately, such measures can only stifle innovation and raise overall costs as 
they exacerbate recurrent or prolonged health problems through patient lifecycle. Thus a 
dynamic farsighted vision of decision makers and key opinion leaders, within the involved 
socio-political system that fosters innovation will push down overall system-wide costs and 
simultaneously enhance quality of life of patients. Further, with the increase of user expertise 
and volume of procedures, quality concerns amongst patients and procedural costs would 
reduce, respectively. 
Further, as cellular products are being generated under a highly regulated regime early 
engagement of decision makers in early stages of product development, statistically 
significant results of controlled trials, where possible, and quality controlled scale up 
activities for manufacture are critical. As a result, once these products prove their safety and 
efficacy, with appropriate adoption and diffusion routes they have the potential to supplant 
the conventional procedures. 
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Also, in the present innovation driven rigorous competitive environment suppliers could 
assist diffusion by increasing comparability, for instance, in the US, by providing information 
to the reimbursing body about positive results in local coverage regions, adoption rates in 
other regions can be increased. The theory is that by approaching each intermediary body 
individually in the US, the uptake of a product on a national level will be further facilitated 
by a “snowball” effect whereby other regional bodies will follow suit. 
 
7.6.2.2 Competition 
Therapeutics compete in challenging markets, where existing products are continually 
threatened by rival products. Such rigorous competition leads to innovation, and price-
competition which further leads to reduction in costs (Tang 2006). Developers also compete 
on the development and marketing of new products. Competition determined by effectiveness 
and positive results can further drive innovation and may lead to improvement in commercial 
value. Value speeds up the rate of adoption of new technologies thereby making innovation 
based competition even more significant.  
A novel innovative RM product for hearing loss may begin as an expensive approach and 
may be relatively difficult to adopt initially, however it would demonstrate increased value by 
reducing hospital time and frequency of follow-ups. Thus, such competition driven 
innovation to generate novel RM products holds the potential to increase longevity or quality 
of life in a more cost-effective way than merely increasing medical expenditure (Cutler and 
McClellan 2001). Further developers compete by innovative approaches to navigate the 
regulatory approval process and in product promotion. 
Initially, this cell-based hearing loss therapeutic will face little competition at the point of 
introduction and therefore, holds the potential to earn relatively high revenue (Figure 7-1). 
However, these high returns can be short-lived as they attract fast following competition with 
time and finally this increased competition along with patent expiry translates into reduced 
profits, thereby bringing down the NPV in the later part of product lifecycle (Figure 7-6b). 
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7.6.2.3 Effectiveness 
Effectiveness includes both clinical and cost-effectiveness. Presently, clinical effectiveness 
exclusively is not sufficient as cost containment is the primary issue for healthcare providers. 
Multiple phased clinical testing is an absolute requirement with the earliest phases primarily 
intended to demonstrate safety and later phases addressing both safety and efficacy 
considerations. Data from both the clinical (clinical trial data) and cost effectiveness 
(headroom analysis) studies of these therapeutic regimes needs to be included in pharmaco-
economic studies to allow comparison with the incumbent to demonstrate clear economic 
advantage to the payer. For RM, the regulators also emphasise the process quality criteria 
used in manufacture (Kirouac and Zandstra 2008).   
Effectiveness describes the effect of a treatment in a clinical setting. Utility tries to describe 
the value of an intervention to a person. While reduction of mortality is an excellent value-
adding measure for an intervention, this will have little meaning in the case of hearing. One 
of the most important healthcare outcomes of a hearing intervention is quality of life (QoL), 
dependant on effectiveness and utility. Also a stem cell based therapeutic being a one-off 
procedure will engage patient willingness to undergo the procedure as they prefer achieving a 
specific state of health immediately rather than over a period of time. 
 
7.6.2.4 Pricing 
Pricing is another key way in which developers compete, though price competition usually 
attains significance in the later stages of a product’s lifecycle i.e. during the upward trend in 
the NPV graph (Figure 7-1). Initial RM products will cater to niche markets, therefore a 
higher price might be justified considering the small market opportunity and their 
development associated with high risk funding and greater manufacturing complexity. The 
total cost argument holds true for RM developers as the anticipated superior clinical benefits 
of their products warrant higher prices. However, the key would be how much more superior 
the benefits from the incumbent need to be to offset the other influencing parameters. 
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7.7 Conclusion 
This chapter presents early-stage evaluation of an innovative novel cellular product, which is 
important for both healthcare decision makers and manufacturers. Basic cost-effectiveness 
analysis is becoming increasingly essential as a health technology assessment exercise. The 
assessment presented here shows this approach can be a useful tool for both healthcare 
delivery professionals and healthcare technology innovators to compare costs and patient 
benefit for a new therapeutic versus standard care with an incumbent device or other 
alternatives. To be broadly comparable across treatments, standard quality-adjusted life-year 
(QALY) measure of clinical outcome has been employed which also strengthens the case 
from a health economics perspective. Therefore, this analysis forms a model that can be 
applied in other therapeutic areas. 
This economic assessment exercise suggests that the proposed therapeutic for SNHL is a 
good business proposition, as indicated by sufficient headroom together with a promising 
revenue and favourable rate of adoption. Moreover, analysis of costs related to other 
commercial RM based products showed that this putative hearing therapeutic was no more 
expensive. Together, the experimental demonstrator and the economic exercise suggest that 
this putative therapy holds the potential to treat SNHL at a reasonable cost and therefore can 
be considered a cost-effective treatment. However, as the results come from an exercise that 
is based on a series of estimates and assumptions, confirmation of these findings in a 
prospective study are encouraged. For this, not only the cost-effectiveness but also the 
clinical-effectiveness of these novel products deserves further research. 
 
Economic outcomes described must be viewed with caution given the assumptions made in 
the study which have not been statistically tested. The costs analyzed in the current study 
were limited to those directly related to product development. There exists a large indirect 
cost component with SNHL, such as medical care utilisation, wages and work time lost. 
Thus, it is likely that the use of a cellular product will result in even greater overall savings 
for patients with SNHL when such indirect costs are considered. Despite the limitations of 
the exercise, it is evident that health care providers and coverage decision makers should take 
not only the initial high cost of such novel therapeutics but the overall cost of care into 
account when deciding about the appropriate allocation of their financial resources.  
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This is the first instance where an extensive economic analysis for a stem cell based 
therapeutic has been undertaken and presented in the public domain (Singh and Williams 
2009). These calculations focussing on supply side issues arm both developers and investors 
with tools which allow them to channel their funds when exploring new potential RM 
technologies. While the growth of the overall RM landscape is significant, it brings with it a 
new set of challenges related to the uncertainty encompassing the RM value chain. The 
headroom method appears to be a simple and precise way to make a preliminary conclusion 
regarding the cost-effectiveness of a novel therapeutic, even though few parameters are 
particularly uncertain, without having to put together a complex model with wide parameter 
uncertainties. Such a model, generating a reasonable estimate of the headroom and the 
corresponding ROI, may allow investors a fast fail approach i.e. immediate termination and 
channelling the investment elsewhere, thereby decreasing late and expensive failures. While 
the results of this simplified analysis is not expected to be definitive, the reasoning also 
assists stakeholders, enabling innovators to articulate the benefits of their innovations and 
highlight the evidence required to take the innovation forward. Therefore, testing investment 
decisions in this manner before embarking on product development may assist generation of 
cost-effective clinically relevant therapies.  
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8.1 Introduction 
This chapter summarises the key research findings and contributions of this thesis, discusses 
the limitations of the research outcomes and suggests areas for further work. Because this 
research is exploratory in nature, its main contributions are new insights with explanatory 
power, rather than a statistically tested hypothesis. 
Over recent years, translation has come to be recognised as a core issue for RM. This is 
primarily due to the technically challenging, high-risk and capital-intensive processes 
required to get regenerative therapies into the clinic. There is little coverage in the 
management and commercialisation literature of issues concerned with translation of RM 
products. As the underlying science expands, translation issues need to be resolved and firms 
within the sector will have to actively extend their scope to focus on such issues to build a 
successful venture. 
The research reported in this thesis was designed to address a research gap in understanding 
the necessary mechanisms to facilitate translation of scientific knowledge into commercially 
viable clinical RM products. The following issues have been addressed: 
 The emergence of RM industry and the characteristics of product development. 
 The characteristics of industry investment readiness by which new therapies can be 
first taken into clinical markets. 
 The mechanisms of knowledge translation between science and business in the RM 
domain, the importance of regulatory oversight and economic assessments. 
 
8.2 Key Research Findings 
Initial literature review led to the following research question: What are the mechanisms 
required to enable translation of emerging scientific knowledge into commercially viable 
clinical RM products? To answer the research question, the following sub-questions were 
formulated to guide data collection:  
 
  Conclusion 
223 
 
 What are the key scientific, translational and commercialisation challenges facing 
successful realisation of RM products? 
 What are the principal indicators affecting commercialisation of RM products and 
how can they be considered in an integrated manner? 
 How can economic assessment of potential technologies help RM businesses? 
Through analysis, conceptualisation and deductive reasoning a new reference model, 
“Industry Investment Readiness”, in the form of a parallel timeline of key indicators affecting 
RM translation, is proposed.  
The key findings are discussed below chapter by chapter: 
1. The literature review clearly suggested that the overall RM industry is an 
amalgamation of research, innovation and development pursuing the invention of 
technologies that may not only lead to dramatic improvements in medical 
therapeutics, but also fundamentally reshape the healthcare landscape. Unlike 
pharmaceutical and medical device R&D, RM R&D is predominantly carried out 
through entrepreneurial entrants, university laboratories and their collaborative 
arrangements. A significant number of private firms are essentially conducting blue-
sky research in basic science showing a convergence of science and business. The 
translational requirements to realise clinical cell-based treatment regimes for three key 
disease application areas have been reviewed. However, out of the three principle 
disease opportunities identified, the level and maturity of incumbent intellectual 
property in diabetes is sufficiently strong to not let a cellular product take its place in 
the near future. Similarly, recent disruptive innovations, such as coronary artery 
bypass grafting (CABG) have brought a step change in invasive cardiac intervention 
lately that the medical community may not be ready for another therapeutic revolution 
in a short span of time. The life expectancy for the global population is increasing, 
larger portions of the population will be afflicted with conditions poorly served by 
conventional therapeutics such as neurodegenerative and myelin disorders, and stroke; 
as the single most important risk factor for these conditions is age. This increase in the 
number of patients will step up the demand for novel and improved treatments. 
Consequently, the focus of this research was narrowed down to a key unmet clinical 
need within the neuroscience space: sensori-neural hearing loss. SNHL has become a 
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significant health problem with wide psychosocial and economic implications, and the 
present technology based treatment options neither replicate the complex native 
biological system within the inner ear nor furnish a full, permanent therapeutic 
solution. Further, there is increased ongoing scientific activity working towards 
describing the regenerative biology of the auditory system together with functional 
studies to ascertain the potential of stem cells in treating inner ear related hearing 
disorders. Moreover, importantly such a cell-based treatment application clinically 
will be localised due to the presence of blood–labyrinth barrier and therefore will not 
affect complex multifunction structures, i.e. brain or spinal cord, present in the 
vicinity.  
 
2. Evidence from the qualitative systematic review, using SNHL as a detailed case 
exemplar of emerging product concepts, suggests that scientific, translational and 
commercial challenges remain to be integrated and consequently have to be addressed 
simultaneously. Evidence on the different challenges and issues faced by RM was 
obtained from past publications and reviews supplemented by data from selected 
observational studies and clinical trials. Due to the lack of long-term results of an RM 
application only illustrative data was used using a range of assumptions that seemed 
reasonable, such conclusions can not yet be evidence based. The product development 
starts at the scientific level and considers both scientific as well as technological 
feasibility. The application of the products on the demand side needs to be taken into 
account together with critically assessing the market potential. The manufacturing of 
autologous products is labour intensive with inter-patient variability and limited 
possibilities for pre-planning as products are manufactured on demand. The 
production of allogeneic products can eliminate some of the problems while offering 
increased market size. The requirement for delivery on demand poses logistical 
challenges of long-term storage and distribution which necessitate coordination with 
the specific user-needs, for instance surgery procedure schedules. Marketing could be 
implemented directly or via licensing. Partnering might be beneficial for firms with 
limited resources. Therefore, appropriate choices between pharmaceutical or medical 
device industry and large or small organisations are required. Due to the complexity 
of the products, innovative marketing strategies together with educated marketing 
staff are required to educate patients as well as surgeons. In this regard, the fit of a 
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cell based therapy for hearing loss into mainstream clinical practice is validated by 
integrating it within the Porter’s healthcare delivery value chain. 
 
3. The RM industry emergence map was based on analysis of products and applications 
of major RM companies together with their underlying enabling technologies and 
corresponding value, regulatory strategies, applied business models and commercial 
markets. The emergence maps revealed that the RM sector is not structured in a way 
that enables it to deal satisfactorily with science led fundamental business problems. 
Further, Gartner’s hype cycle established that heightened expectations together with 
media hype led to overflow of capital and proliferation of new firms without 
comprehensively analysing the true potential of the applied technologies. The firms 
indiscriminately borrowed business models and organisational strategies from other 
high-technology industries under the premise that they would also work within this 
sector. Both these high level strategic tools for mapping RM emergence, assisted in 
identifying specific indicators of investment readiness. Together, they were used as a 
strategic technology management tool to highlight the differences and understand the 
corresponding implications for business strategies by integrating into a reference 
model in the form of an investment readiness parallel timeline. The proposed 
reference model takes into consideration the enabling technology, value and supply 
chain structures to further describe the key indicators of RM industry readiness. The 
“investment readiness” reference model highlights the fact that translational capability 
across key indicators can play a significant role in organisations through delivering 
the required performance to meet the objectives of the overall business models. The 
business model of the company determines the business plan adopted for a particular 
product under development. Technology and investment readiness drive the 
development objectives. Regulatory strategies provide development and lifecycle 
management together with validation of pre- and post-market requirements and 
quality systems to mitigate risk while simultaneously increasing safety and efficacy. 
The primary objective at the beginning of a project, typically, is to achieve proof of 
concept despite the fact that firms operate with various business models. This 
objective then switches to achieving a process to deliver a commercially- and 
clinically-viable application. The most efficient way to complete the development 
project is to consider the six key indicators identified in the reference model in 
conjunction to consolidate the overall commercial venture/process, and use this to 
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manage the reduction of uncertainty and the increase of value. It must be recognised 
that some uncertainties are external to business, particularly regulation and 
reimbursement. 
 
4. Regulatory framework is another fundamental issue shaping the RM business 
landscape by influencing product and process development. A favourable regulatory 
environment is essential to realise the potential of an emerging industry. This is 
because private start ups with limited resources are undertaking basic science research 
projects, which in other industries generally come under the auspices of university 
research laboratories or large business units. The recent regulations for advanced 
therapy medicinal products (ATMPs) in the European Union impact the product 
developers by significantly influencing RM product definition, product and process 
design, and ultimately business risk. The proactive engagement of concerned 
authorities at the front-end by engaging with developers throughout the product 
lifecycle will help alignment with the emerging framework and enable better 
decisions by both developers and regulators. The regulatory strategy for product 
developers presented is inductively derived from extensive analysis of European 
Union’s ATMP policy-related documents. It provides a new perspective on firm level 
process and product development activities, and the inherent gaps and uncertainties 
present in the draft framework. The ATMP regulations, due to the complexity of the 
products, are in some respect different from other related sectors and certain issues 
have still not been addressed. This new perspective together with the regulatory 
strategy is particularly important for the RM domain, where the product failure rates 
are high and regulatory frameworks are constantly evolving over time. It further 
addresses the role of regulatory frameworks in enabling translation in firms and how 
they are linked to process development, enriching current knowledge in the literature. 
 
5. A stem cell culture system appropriate for commercial applications and developing 
cellular products was established in order to demonstrate a scalable novel stem cell 
expansion and differentiation protocol, and evaluate manufacturing costs. Human 
embryonic stem cell (hESC) lines, after directed differentiation, hold the maximum 
potential for cell transplantation treatment in various severe diseases. Defined scalable 
culture conditions, amenable to GMP grade production, are a requirement for 
producing clinical-grade cells that offer optimal defined quality and safety in cell 
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transplantation. In the novel experiment undertaken with serum-free defined culture 
media, cells were expanded and maintained without feeder cells on an automated cell 
culture platform. This is advantageous for the large scale cultivation of hESC required 
in clinical applications. The cells continued to express hESC markers, characteristic 
of undifferentiation, Oct-4, stage specific embryonic antigens 3 and 4 (SSEA-3 and 4) 
and Tra-1-81. In addition, these cells spontaneously differentiated to form embryoid 
bodies, which represent the three germ layers, and also maintained a normal 
karyotype over ten passages. A novel scalable method was further employed to 
differentiate the above cell population into otic progenitor cells using a scalable, 
translational friendly and serum-free cell-culture protocol. The protocol yielded 
differentiated cells expressing the characteristic otic progenitor marker, Pax-2, which 
indicates the potential of these cells to be used as a cellular replacement in treating 
SNHL. This demonstrator experimental programme further allowed the determination 
of key experimental costs to evaluate approximate cost of goods for input into the 
economic assessment exercise. 
 
6. The economic assessment of a novel cell-based therapeutic enables the evaluation of 
potential business performance i.e. productivity and profitability. The key cost 
components of this assessment exercise were derived from the experimental 
demonstrator i.e. a scalable novel stem cell expansion and differentiation protocol. 
The economic position of the cellular therapeutic was explored in terms of net present 
value and financial analysis was carried out by estimating available headroom, cost of 
goods (CoGs) and exploring return on investment (ROI). The headroom furnished 
insight into the financial impact of introducing a new intervention. This further allows 
affordability issues to be addressed from the perspectives of supplier, user and payer 
especially the capital required by the supply side. It thus informs both R&D as well as 
investment decisions because in the research intensive RM industry such decisions 
can have long-term ramifications. Such assessment exercises assist the balancing of 
both short- and long-term challenges of product developers and other potential 
stakeholders to ultimately create value. 
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8.3 Research Contribution 
A significant contribution of this research is the development of a new reference model, the 
“Investment Readiness” reference model. It offers a new perspective on the nature and 
characteristics of the overall RM domain in the form of parallel trajectories representing key 
indicators which are necessary for the successful translation of novel RM based therapeutics 
and achieving business objectives. It links technological capability and business models for 
firms in the domain. The reference model also identifies the roles and implications of 
technology readiness, investment readiness, business models, organisational development, 
regulation, and reimbursement practices at various points in a development project. These are 
specifically linked to the consequences of the ultimate application(s) and value development.  
An investigative experimental programme for a representative putative therapeutic and the 
corresponding financial assessment exercise suggests how cost of goods can be used to 
evaluate available headroom and return on investment for potential stake holders so that they 
can make well informed decisions before channelling their resources towards a new product. 
The exercise also identifies key parameters effecting economic positioning and rate of 
adoption.  
The key contributions of this thesis are therefore: 
1. New insights into the key challenges involved in realising the commercial 
potential of cell based therapeutics. 
The work confirms the importance of identifying and working towards the solution of 
key challenges faced by RM industry, especially those related to commercialisation of 
cellular products. In this regard 
 A qualitative systematic review exercise has been undertaken to explore 
challenges facing RM product development. 
 Key scientific, translational and commercialisation challenges and 
complexities have been identified and discussed in the process of overall 
translation. 
 
2. Technology roadmapping to link fundamental enabling technological capability 
for developing RM products with robust business plans integrating strategy, 
technology development, and the regulatory and reimbursement framework. 
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This research provides further understanding of how the industry emergence mapping 
can be useful in achieving present business goals. It provides new perspectives, 
enriching current knowledge in the literature in the following ways by 
 Providing an understanding of the past business models employed by RM 
firms, and industry practices. 
 Identifying lessons for present developers at various points during the 
development of underlying technologies of potential products, and their 
implications for different business models. 
3. A generic investment readiness reference model generated from the enabling 
technology, value and supply chain structures to identify key indicators and 
characteristics of industry readiness. 
The reference model developed in this research provides a new understanding of the 
nature and characteristics of investment readiness in the RM domain which is 
inherently different in character from other sectors and has not been sufficiently 
addressed in the scientific/management literature. The “Investment Readiness” 
reference model generated in this research specifically 
 Integrates key RM business issues, particularly investment and technology 
readiness, policy making for regulation and reimbursement, together with the 
coupling of business models and investment strategy. 
 It will consequentially assist research-based technology-intensive RM firms as 
they move closer to market. 
 The performance of RM start ups and SMEs ultimately hinges upon the 
successful clinical application of their developed products, the key step for 
creating and realising value, and their ability to deal with the fundamental 
business issues specific to the area. 
 From the various potential opportunities for products and their developers in 
the later stages of clinical development, the research identifies six key factors 
that must be in place for high growth potential. 
 Two key indicators dominated by public policy, regulation and reimbursement, 
play an important role in the overall process of translation. 
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4. A novel experimental programme demonstrating expansion, maintenance and 
differentiation of human embryonic stem cells by both manual and automated 
methods. 
A novel experimental programme demonstrating the development of hESC culture 
systems appropriate for commercial application in the development of a hearing 
therapy 
 Demonstrated an automated, single cell, serum-free culture protocol in the 
absence of feeder-cell layers for large scale manufacture of hESC populations 
for therapeutic and pharmacological applications 
 Demonstrated directed differentiation of hESCs towards an important 
therapeutic lineage (hearing), i.e. otic progenitor cells, by employing a 
scalable guided differentiation protocol. 
 
5. New insights into economic positioning by mapping net present value, and 
financial analysis by estimating available headroom, cost of goods and return on 
investment. 
The analytical approach demonstrated, together with the “Investment Readiness” 
reference model, can be used as a guide for companies in the following ways, It 
 Provides a guide to represent various investment options and the link to a 
firm’s business strategies. 
 Provides a systematic approach for quantifying the financial implications of 
process development by calculating the return on investment for the supplier. 
 Uses the concept of net present value to identify key parameters affecting the 
rate of adoption for a novel product which will ultimately affect the 
probability of business success. 
 
8.4 Limitations of Research Outcome and Suggestions for Further Work 
The mechanisms required to enable translation of underlying scientific knowledge into 
commercially viable clinical RM products is a relatively unexplored area. Although new 
understanding of the research topic is generated through this research, there are limitations to 
the outcomes of the research. 
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8.4.1 Practicability of the Research Findings 
As outlined in Chapter two, this research is prompted by the need in the industry for a deeper 
understanding of the mechanisms required to enable translation of scientific knowledge into 
commercially- and clinically-effective products. Although the key features of the business 
model and the reference model taking into account the key indicators for overall investment 
readiness have been developed, and initial concepts for the involved financial implications of 
a process development exercise are suggested, there are still gaps between the research 
outcome and an approach is required that links firm-specific capabilities and the details of 
their business models with success. A next step for this research is to conduct case studies 
together with “action research” in companies to further develop the reference model into a 
strategic tool, supported by a database of information which can be further customised for a 
firm’s specific use. This should include detailed calculation of key components of the 
business model, for instance, return on investment and its sensitivity to the key parameters. 
This can only take place in the context of a business where complete data is available. 
Further work in the economic assessment exercise requires prospective studies to corroborate 
its results. This necessitates research to be carried out to obtain better estimates of the clinical 
benefits, since the rate of adoption is dependant on it. Investigations into the clinical-
effectiveness of the putative hearing therapy in routine clinical practice and patient-related 
outcomes (such as health related quality of life) are needed to complement the exercise on 
cost-effectiveness and help reimbursement agencies make well-informed coverage decisions. 
 
From a commercial standpoint, such cost-effectiveness analysis at early stages of product 
development would incentivise the development of start-ups, increase the portfolio of 
products at the proof-of-concept level and make the industry pipeline solid. It also defines in 
a clear and precise way the added value of the product to the health of the society and to 
efficient resource allocation. However, in the current form, its suitability for use by 
commercial enterprise is limited given the lack of pharmaco-economic data from industrial 
sources. Further, from the perspective of a decision-maker faced with scarce resources and 
operating under tight budgets, evidence provided by an economic analysis represents only a 
single input to the overall decision-making process. Apart from the cost-effectiveness which 
assists in prioritization of the intervention, overall policy-making depends upon the budgetary 
impact of the therapeutic on the annual national health care costs. Nevertheless, the ultimate 
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aim of this cost-effectiveness analysis still holds true i.e. maximise the health effects from a 
given amount of resources. This thesis has sought to link the key features of the investment 
readiness framework with those of the business model and ultimately to the build up of cost 
of goods, this being critical to realising living regenerative medicine products. 
The impact of the economic assessment exercise on the overall business model of a 
commercial venture clearly indicates reassessment of the reference model to build further 
corporate strategy. As a result, manufactures will be able to reassess the trajectories of the 
reference model and place the development of therapeutics that offer cost- and clinically-
effective solutions as a mission-critical enterprise goal. This reassessment will also assist 
realignment of current capabilities, assets and investment portfolio towards value creation for 
stakeholders and build opportunities for sustainable competitive advantage and 
differentiation. However, the grand strategic direction upon which ventures embark will also 
have to address issues posed by the ultimate product application on the following fronts: first, 
the standards applied by both the regulator and the payer for therapeutic evaluation in terms 
of pharmaco-economic analysis and/or overall healthcare value, apart from basic safety and 
efficacy studies; second, integration of economic considerations into treatment selection by 
payers; and third prioritisation of clinical need is the primary driver for development of novel 
innovative therapeutics and not the marginal advances offered over conventional therapeutic 
regimes. Therefore, product developers need to enter with caution and base assessments on 
what the overall market is and where its future lies. 
8.4.2 Limitations of the Research Findings 
This research is focused on translational requirements in the RM domain which is a relatively 
unexplored area. Therefore, the research is exploratory and explanatory in nature, adopting a 
qualitative methodology.  
Although the research has resulted in a reference model that explains the nature and 
characteristics of underlying mechanisms to enable translation in the RM domain, together 
with economic analysis for the supply side to determine the overall business model and 
decisions of potential stakeholders, the assumptions underpinning the constructs of the 
reference model and the economic exercise have not been statistically tested.  
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Similarly, the economic assessment exercise is a valid fit within the sub-components of both 
the investment proposition and reimbursement trajectories of the reference model. This is 
because it reduces uncertainty in terms of defining a firm’s business model and assists 
identification of both the payers and the purchasers of a particular therapy by demonstrating 
cost-effectiveness for fair resource allocation. However, further work is recommended to test 
both the reference model and economic analysis using a quantitative approach on a 
representative sample. 
8.4.3 Further experiments to increase efficiency of cell culture systems and test 
cell functionality  
This study demonstrated scalable and translation friendly cell culture systems together with a 
protocol for hESC differentiation towards otic progenitors. Variation in cell population, in 
terms of cell damage, is most likely to be caused by cryopreservation and recovery of cells 
from cryopreservation. Optimisation of these processes to minimise cell damage would 
improve cell viability and potentially improve the suitability of the cells for their stepwise 
differentiation towards otic progenitors. These processes could be optimised using a design of 
experiments methodology to analyse the interaction between key parameters of each process 
together with individual parameters. For cryopreservation and the corresponding recovery 
process, the key parameters include cell density and volume together with rate of freezing 
and rate of thawing while recovering cells from cryopreservation. 
The stepwise guidance protocol can be improved further to increase the percentage of 
differentiated otic progenitor cells. Culture media for differentiation is composed of a number 
of supplements. The stability and effectiveness of these supplements with respect to 
maximising the percentage of differentiated cells should be investigated together with 
methods to reduce process variation and cost of goods through either removal or decreasing 
the concentration of less effective supplements. It is suggested that a design of experiments 
approach should be undertaken to investigate the effectiveness of media supplements as 
described for cryopreservation and recovery process. Such reductions in cost can form the 
basis of preliminary evidence for a business case. 
A further experimental programme is required to conduct in vivo tests to demonstrate 
functionality of the derived otic progenitor cell population. For this, mechanisms will be 
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required to sort and purify potential therapeutic cell populations before testing in relevant 
animal models. 
 
8.5 Conclusion  
Over recent years, translation has come to be recognised as a core issue for RM and the task 
of getting regenerative therapies into the clinic is presently challenging, high-risk and capital-
intensive. The demands from potential investors and stakeholders to predict behaviour, 
optimise performance, reduce risk and accelerate time to market constrain a firm’s pursuit of 
economic goals. This is largely due to the longer time associated with ultimate product 
performance and value-creation together with consolidating share in existing markets or new 
market creation with whole-life costs modelled and understood. Adopting a potential 
practice-driven solution to the research question, a reference model in the form of a parallel 
timeline of key indicators effecting translation of emerging and established science was 
developed to characterise and conceptualise investment readiness in the RM domain. 
Building on current knowledge in the literature and evidence from the work undertaken, the 
contributions of this research are 
 New insights into the key challenges involved in realising the commercial potential of 
cell based therapeutics 
 Technology roadmapping to link fundamental enabling technological capability for 
developing RM products with robust business plans integrating strategy, technology 
development and the regulatory and reimbursement framework. 
 A generic investment readiness reference model generated from the enabling 
technology, value and supply chain structures to identify key indicators and 
characteristics of industry readiness 
 A novel experimental programme demonstrating expansion, maintenance and 
differentiation of human embryonic stem cells to otic progenitors by both manual and 
automated methods 
 New insights into economic positioning by mapping net present value, and financial 
analysis by estimating available headroom, cost of goods and return on investment for 
a putative hearing therapeutic 
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To integrate RM into the overall healthcare system and thus invigorate it, will necessitate 
new levels of accountability and collaborative effort on the part of all stakeholders. 
Specifically: 
Researchers, developers and suppliers must identify unmet clinical needs and channel 
resources towards investigating, exploring and developing corresponding therapeutics while 
keeping in mind the later translational and commercial challenges inherent in manufacturing 
such therapeutics. Work in partnership with care delivery organizations and clinicians to 
develop products that improve therapeutic prognosis or offer equivalent effect at reduced 
costs. 
Regulators must address the pitfalls of the current regulatory framework by engaging in 
dialogue with suppliers and also, where applicable, provide expert advice throughout the 
product life-cycle thereby assisting to eliminate obstacles, encourage innovation, and direct 
developers to compliant sustainable solutions. 
Healthcare providers and clinicians must expand their present focus on episodic, acute care 
to include enhanced and integrated management of chronic diseases and the overall 
prevention of illness. 
Payers must provide more value to the patients from the healthcare system and assist care 
delivery organizations and clinicians in dispensing superior healthcare, thereby, helping 
consumers maximising the value they receive through life and ultimately lead healthier and 
more productive lives. 
Such increased accountability spanning the overall system with adequate healthcare 
financing, regulators framing rational policy, healthcare professionals adhering to clinical 
standards and dispensing quality care, payers providing incentives for preventive and 
proactive chronic care, will assist novel and long term cost-effective RM based therapeutics 
to enter mainstream clinical practice and maintain an important role in improving the quality 
of life for many. 
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1. PURPOSE 
 
To establish a Standard Operating Procedure for the routine isolation, automated growth, 
cryopreservation and automated sub-culture of human embryonic stem cells (hESCs). 
 
2. SCOPE  
 
To describe an experimental protocol for the automated sub culture of hES cells, including aseptic 
technique, pipetting, swabbing, handling flasks, cleaning and Quality Control. 
 
3. SPECIAL NOTES – HEALTH & SAFETY 
 
 Biological risk is low as work involves cells from a reputable, leading academic group. Cells are 
not known to be carrying human pathogens. 
 
HOWEVER, ALL WORK WITH HUMAN DERIVED CELLS MUST BE CARRIED OUT 
UNDER THE ASSUMPTION THAT THE SPECIMEN MAY CARRY AN INFECTIOUS 
AGENT. 
 
 Most gases used in cell culture (CO2, O2, N2,) are not harmful in small amounts but can be 
dangerous if handled improperly. When a major leak occurs, there is a risk of asphyxiation from 
CO2, and N2, and a fire hazard from O2. Evacuation and maximum ventilation are necessary in 
each case. 
 
4. REFERENCES 
 
SOP 037 Use of PPE in T208B 
 SOP 038 Biological spill response 
SOP 009 Use and Maintenance of the BSC-G2000 Vertical Laminar Airflow Cabinet 
SOP 020 Use and Maintenance of Water Bath 
SOP 015 Use and Maintenance of the BOECO U032R Centrifuge 
SOP 017 Use and Maintenance of the CO2 Incubator 
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SOP 022 Use and Maintenance of the Microscope 
SOP 003 Disposal and Disinfection of Biological Waste 
SOP 013 Use and Maintenance of the Liquid Nitrogen Store 
SOP 032 Resuscitation of Cryopreserved Cultured Cells 
SOP 045 Use and Maintenance of the Planar Controlled Rate Freezer 
SOP 031 Cryo-Preservation of Cultured Cells 
SOP 034 Cell Counting and Viability Assessment 
SOP 036 Mycoplasma Testing 
 
Guidance Note 1: Work with Cell Cultures 
Good Cell Culture Practice: ECVAM Good Cell Culture Practice Task Force Report 1, Hartung, T et al, 
ATLA, 30, pp407-414, 2002.  
Good Cell Culture Practice: ECVAM Good Cell Culture Practice Task Force Report 2, Coecke, S et al, 
ATLA, 33, pp261-287, 2005.  
 
5. RESPONSIBILITIES 
 
 Good laboratory practice should be observed for handling potentially infectious material. 
 
 All work involving the handling of potential pathogens should be performed in a Class II 
biological safety cabinet appropriate for the organism involved. 
 
 Keep work surfaces free of clutter. Clean working areas with a suitable disinfectant (70% IMS, 
1% Virkon) between operations and allow 15 minutes between handling different cell types. 
 
 Use personal protective equipment (PPE) - Wear gloves and a laboratory coat throughout 
procedure. 
 
 Maintain separate bottles of media and separate pipette tips for each cell type cultivated 
 
 Do not allow stored media to go out of date 
 
 Handle limited numbers of cell vessels at one time to reduce the risk of contamination and 
spread of bacteria or mycoplasma. 
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 Check that equipment (incubators, centrifuges, BSC, micropipettes etc) is cleaned, serviced and 
calibrated as appropriate. 
 
 All disposable contaminated items and spent media must be disinfected and autoclaved in 
accordance with SOP 003. 
 
 Any contaminated sharps must be disposed of in a sharps bin. 
 
 Correctly label reagents including flasks, medium and ampoules. 
 
 When work is finished, uncontaminated and autoclaved waste should be disposed of through the 
waste management system. 
 
6. EQUIPMENT AND MATERIALS 
 
6.1 Reagents: 
 
i. mTeSR basal medium, defined and quality-controlled maintenance medium for hESCs 
(Stem Cell Technologies, 05850, ~£200/400ml) 
ii. mTeSR 5X Supplement (Stem Cell Technologies , 05852, 100 mL) 
iii. BD Matrigel, hESC-qualified Matrix for feeder-free conditions (BD Biosciences, 354277, 
~£247/5ml) 
iv. mFreSR,  defined, serum-free cryopreservation medium designed specifically for hESCs 
(Stem Cell Technologies, 05854, ~£165/10 x 5ml) 
v. DMEM/F-12 (Stem Cell Technologies, 36254, ~£10/500ml) 
vi. Dispase (Stem Cell Technologies, 5 mg/mL) 
vii. 70% Ethanol or Isopropanol 
viii. Phosphate Buffered Saline Solution (PBS) (w/o Ca or mg) sterile, cell culture tested 
(Lonza) 
ix. 0.25% Trypsin-5mM EDTA solution, 2.5 g porcine trypsin and 0.2 g EDTA•4Na per liter 
of Hanks' Balanced Salt Solution with phenol red, sterile-filtered, cell culture tested (Sigma, 
E5134) 
x. 0.4% Trypan Blue solution, liquid, sterile-filtered, cell culture tested  (Sigma-Aldrich, 
T8154) 
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6.2 Equipment: 
 
i. Class II Biological Safety Cabinet 
ii. Compact SelecT 
iii. Microscope 
iv. Centrifuge 
v. Centrifuge tubes: Corning plug seal cap, sterile, polypropylene, non-pyrogenic, 
RCF:9400xg, max 50mL (Fisher, CFT-643-021J) 
vi. Medium aspiration pump 
vii. CO2 incubator (37˚C, 5% CO2) 
viii. Disposable Pipettes (sterile) and pipettes aids 
ix. Disposable plastic tubes (~15ml)(sterile) 
x. Haemocytometer 
xi. T175 Flasks: Nunc EasY Flask, tissue culture, angled neck, polystyrene radiation sterilised, 
filter cap, 175cm
2
 growth area (Fisher, TKT-130-210T) 
xii. Water bath (37˚C) 
xiii. Planer controlled rate freezer 
xiv. Cryostorage tank 
xv. Vials containing ~40 Sterile 3mm diameter soda-lime glass beads 
 
7. PROCEDURE 
 
All manipulations with open culture vessels or media must be performed in a biological safety cabinet using 
sterile techniques. Refer to SOP 009. 
 
7.1 Preparation  
All solutions, glassware, culture flasks etc should be sterile and all procedures carried out under aseptic 
conditions and in the sterile environment of the Class II BSC.   
 
7.1.1 Prepare working solutions: 
 hES media: mTeSR basal medium (400 ml) supplemented with mTeSR 5X supplement (100 ml) 
 Run a pre-clean cycle on the Cedex cell counter 
 If cryopreserving cells defrost mFreSR 
 Prepare cryopreservation chamber – adjust to start temperature. 
 
7.1.2 Inspect Disposables (e.g. culture vessels, pipettes) for cracks or damage. 
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7.1.3 Open the BSC and clean working area with 1% Virkon followed by 70% IMS  
 
7.1.4 Decontaminate the outside of the culture vessels with 70% IMS. 
 
7.1.5 Assess Culture Vessel(s) for Contamination before any process: Examine all culture(s) using 
an inverted microscope to confirm the absence of bacterial or fungal contamination and the 
absence of signs of distress (floating cells, excessive debris). Cultures contaminated or exhibiting 
signs of distress should be discarded. 
 
7.2 Coating Plates with BD Matrigel™ hESC-qualified Matrix  
 
7.2.1 Dispense 25 mL of dilution medium (DMEM/F-12) into a 50 mL tube and keep on ice. 
7.2.2 Remove an aliquot of frozen matrigel from -80°C. Thaw on ice until liquid, then add to the cold 
dilution medium (1:25 dilution) and mix well. Wash the vial with cold medium if desired. 
7.2.3 For a 6-well plate, use 1 mL of diluted matrigel per well (0.8ml / cm2 of a 1:25 dilution). Swirl the 
plate to spread the matrigel solution evenly across the surface 
7.2.4 Leave the coated plate(s) at room temperature (15 - 25ºC) for 1 hour before use, allowing 
polymerisation to occur. 
7.2.5 Gently tilt the plate(s) onto one corner and allow the excess matrigel solution to collect in that 
corner. Remove the solution by aspiration and do not scratch the coated surface. 
7.2.6 Immediately add the cell suspension of mTeSR medium and the cells. 
 
7.3 Thawing Cryopreserved hESCs 
 
7.3.1 Quickly thaw the hESCs in a 37°C water bath by gently shaking the cryovial continuously until 
only a small frozen pellet remains. Remove the cryovial from the water bath and wipe with 70% 
ethanol to sterilize. 
7.3.2 Transfer the contents of the cryovial to a 15 mL conical tube using a 2 mL pipette. 
7.3.3  Add 5-7mL of warm mTeSR drop wise to the tube and mix gently as the medium is added. 
7.3.4 Centrifuge cells at 300 x g for 5 minutes at room temperature (15 - 25°C). 
7.3.5  Aspirate the medium, leaving the cell pellet intact. Re-suspend the pellet in 1 - 2 mL of mTeSR. 
7.3.6 Remove the matrigel solution from a coated culture plate. 
7.3.7 Transfer 2ml of medium in the culture plate containing the cell aggregates. 
7.3.8  Place the plate into the 37°C incubator with 5% CO2 and 95% humidity. 
7.3.9 Change the medium daily.  
 
7.4 Subculture of hESCs 
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7.4.1 Warm mTeSR, Trypsin, DMEM/F-12 to passage cells 
7.4.2 Take a confluent culture plate of hES cells from the incubator (i.e. a flask with minimal cell 
culture plastic exposed) and transfer to the BSC. Aspirate the entire medium to the biological 
waste bottle using a sterile glass pipette. 
7.4.3  Add 1 mL trypsin (0.25%) per well. Place at 37°C for 7 minutes  
7.4.4 Transfer the detached cells to a 15 mL conical tube and rinse the well with an additional 2 mL of 
mTeSR to collect any remaining aggregates.  
7.4.5 Centrifuge the 15 mL tube containing the cells at 300 x g for 5 minutes at room temperature (15 - 
25°C). 
7.4.6 Aspirate the supernatant. For each well of hESC, add 1 - 2 mL of mTeSR and re-suspend the 
pellet by gently pipetting 
7.4.7 Plate the hESCs with mTeSR onto a new matrigel coated plate  
 
 Record the morphology of cells, number of cells, and rate of growth of cells in each plate/flask. 
Keep a photographic record of cell growth. Keep cells out of the incubator for a set time for 
monitoring (4 minutes per day). 
 
7.2 Automated maintenance and subculture of hESCs 
7.3.1 Seed at 1.5 x 106 cells in a T175 flask in 40 ml of mTeSR. Do this by calculating the volume 
containing 1.5 x 10
6
 cells, subtracting this from 40 ml, adding this volume of bulk media to the 
flask first , then adding the appropriate volume of cell suspension. Import into the compact SelecT 
incubator (37 ºC/5% CO2, humidified)  
7.3.2 Use the SelecT daily to change the media by adding fresh mTeSR (40 ml) to the flask (SelecT 
Protocol 2). 
7.3.3 On the 3rd day after seeding use the SelecT to passage the cells (SelecT Protocol 1). 
7.3.4 Use the SelecT daily to change the media by adding fresh mTeSR (40 ml) to the flask (SelecT 
Protocol 2). 
7.3.5 On the 3rd day after first passage carry out a second passage protocol (Select Protocol 1). Use the 
SelecT daily to change the media by adding fresh mTeSR (40 ml) to the flask (SelecT Protocol 2). 
7.3.6  Continue this pattern of feeding and passaging as long as required. 
 
 Record all cell counts. Keep a photographic record of cell growth. Keep cells out of the 
incubator for a limited time for monitoring (less than 4 minutes). 
 
 Record the size of colonies, number of colonies, and rate of growth of colonies in each flask. 
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Keep a photographic record of cell growth. Keep cells out of the incubator for a minimum time 
for monitoring (less than 4 minutes per day). 
 Record osmolality and pH of culture media. 
 
7.4 Cryopreservation of hESC 
 
7.4.1 Label cryovials with a lot number and record cell type, lot number, passage number, date, media 
and lot number, and operator in a lab book along with references to lab book information relating 
to the pre-culture of the cells.  
7.4.2 Bring required amount of mFreSR to room temperature (15 - 25°C). 
7.4.3 Aspirate mTeSR from culture plates/tissue flasks  
7.4.4 Rinse wells with 2 mL of DMEM/F-12 and aspirate.  
7.4.5 Add 1 mL per well of trypsin (0.25%). Place at 37°C for 8-10 minutes. 
7.4.6 Transfer the detached cells into a 15 mL conical tube and rinse the wells with additional 2 mL 
mTeSR to collect any remaining cells. Add the rinse to the 15 mL tube with the cells. 
7.4.7 Centrifuge the 15mL tube containing the cells at 300xg for 5 min at room temperature (15-25°C). 
7.4.8 Ensure the controlled rate freezer is prepared and ready to run at 4ºC. 
7.4.9 Gently aspirate the supernatant taking care to keep the pellet intact. 
7.4.10 Re-suspend the pellet in mFreSR medium,1 mL of mFreSR per well (10 sq. mm) of a 6-well plate 
7.4.11 Transfer 1 mL of cell suspension in mFreSR each labelled cryovial. Mix gently before taking each 
aliquot.  
7.4.12 Rapidly transfer the cryovials to the controlled rate freezer (no more than 5 minutes after cells 
first exposed to freezing medium) and reduce the temperature from 4ºC at 1ºC per minute to -80 
ºC (SOP 031). Once this temperature is reached transfer to the liquid nitrogen freezer.  
 
 7.6 Clean Up Cell Culture Waste 
 
 Discard all unused spent media and unused cells according to SOP 003. 
 Discard all plasticware in a biohazard bag and discard sharps in a biohazard sharps container. 
 Reusable items must be soaked with 1% Virkon solution for a minimum of 1hr prior to 
washing and autoclaving.  
 All apparatus (e.g. BSC, incubator) used in the Cell Culture should be cleaned regularly. 
Refer to equipment SOPs. 
7.7 Quality Control - Signs of Instability or Deterioration in Cell Cultures 
 Screen for the presence of Mycoplasma (refer to SOP 036) and other organisms (by macro 
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or microscopic examination). 
 Cell cultures should be routinely examined for changes in pH (optimal pH range for cell 
culture is 7.0 - 7.4). Phenol red is commonly used as an indicator. It is purple at pH 7.8, 
reddish-pink at pH 7.6, red at pH 7.4, becoming orange at pH 7.0, yellow at pH 6.5, and 
lemon yellow below pH 6.5. If phenol red is not present in the media, pH readings may be 
obtained by using pH paper or a pH meter. 
 Cell cultures should be routinely examined for changes in characteristic cell morphology. 
Observe for excessive rounding of attachment dependent cells (cells will round during cell 
division), sloughing (shedding of cells off the culture vessel), increased cytoplasmic 
vacuolization, increased granularity around the nucleus, crenated (serrated) outer membrane 
edge, and retracted (shrunken) cells.  
 Changes in cell growth may be attributed to cell damage during splitting (poor technique), 
aging of cells, changes in media or media components, contamination, and incubator 
temperature and/or gas flow changes. 
 
 8 DOCUMENTATION 
 
8.1 Record changes to the protocol in a laboratory notebook 
 
8.2 Record starting vial or culture vessel information. 
 
 8.3 Record and retain all suppliers’ data on primary cells supplied. 
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Protocol 1: Automated CompacT SelecT Program for Cell Harvesting 
This program detaches adherent cells from the flask using trypsin and generates a cell 
suspension. Three individual flasks with the requisite concentration of 1,500,000 cells per ml 
are generated and placed in the incubator. 
 
<SelecT_Protocol>  
  
  <properties>  
    <description> Primary culture passage </description>  
    <flaskingtime units="s">0</flaskingtime>  
    <platingtime units="s">0</platingtime>  
  </properties>  
  
  <steps>  
  
  
    <fetch>  
    <dump pause = "4s"/>  
  
<dispense liquid = " PBS"  
          volume = "20ml"/>  
    <swirl repeat = "1" speed = "100%" pause = "0s" capped = "no"/>  
    <dump pause = "4s"/>  
 
    <putdown name = "output"/>  
    <pipette     fromliquid = "static"  
          toname = "output"  
          volume = "8ml"  
          fromheight = "2mm"  
          toheight = "50mm"  
          aspiratespeed = "5ml/s"  
          dispensespeed = "5ml/s"  
          pause = "2s" 
 newtip = "yes"/> 
 
    <pickup name = "output"/>  
    <swirl repeat = "3" speed = "100%" pause = "1s" capped = "no"/>  
    <dump pause = "4s"/>  
  
    <incubate period = "10m"/>  
    <shake repeat = "40" speed = "100%" pause = "0s" capped = "yes"/>  
    <dispense liquid = "mTeSR"  
          volume = "15ml"/>  
    <shake repeat = "4" speed = "100%" pause = "1s" capped = "yes"/>  
     
<putdown name = "pool"/>  
    <mix     name = "pool"  
  Appendix 
275 
 
          volume = "10ml"  
          repeat = "5"  
          fromheight = "2mm"  
          toheight = "5mm" 
          mixspeed = "10ml/s"  
          finaldispensespeed = "10ml/s" 
  newtip = "yes"/> 
 
 
    <count     name = "pool"  
          fromheight = "2mm"  
          aspiratespeed = "5ml/s"  
          dispensespeed = "1ml/s"  
          pause = "2s"/>  
  
    <pickup name = "pool"/>  
    <dispense liquid = "mTeSR"  
          volume = "10ml"  
          cellconc = "1500000"  
          minvolume = "0ml"  
          maxvolume = "40ml"/>  
    <putdown name = "pool"/>  
     
<new repeat = "2"  
          flasktypegroup = "Single">  
<dump pause = "4s"/> 
    <dispense liquid = " mTeSR "  
          volume = "15ml"/>  
    <putdown name = "output"/>  
 <mix     name = "pool"  
          volume = "10ml"  
          repeat = "2"  
          fromheight = "2mm"  
          toheight = "50mm"  
          mixspeed = "10ml/s"  
          finaldispensespeed = "5ml/s"/> 
      
    <pipette     fromname = "pool"  
          toname = "output"  
          volume = "10ml"  
          fromheight = "2mm"  
          toheight = "20mm"  
          aspiratespeed = "1ml/s"  
          dispensespeed = "1ml/s"  
          pause = "2s"/>  
    <pickup name = "output"/>  
     
    <store passage = "yes"/>  
    </new>  
    <pickup name = "pool"/>  
    <dispose/>  
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  </fetch>    
  
  
  </steps>  
  
</SelecT_Protocol> 
 
 
 
 
Protocol 2: Automated CompacT SelecT Program for Media Change 
This program disposes of the culture media in the flasks and adds fresh culture media. 
 
 
<SelecT_Protocol>  
  
  <properties>  
    <description> Feed </description>  
    <flaskingtime units="s">0</flaskingtime>  
    <platingtime units="s">0</platingtime>  
  </properties>  
  
  <steps>  
  
    <fetch>  
    <dump pause = "4s"/>  
    <dispense liquid = "mTeSR"  
          volume = "40ml"/>  
      
    <store passage = "no"/>  
  
    </fetch>    
  </steps>  
  
</SelecT_Protocol>  
 
 
 
 
 
 
